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Abstract 
 
Oxidative stress is a contributing factor to many neurodegenerative diseases. In 
particular, mitochondria are a key source of oxidative stress due to electron leakage at the 
level of the electron transport chain. To combat the endogenous production of reactive 
oxygen and reactive nitrogen species mitochondria are equipped with several redox-
cycling systems, such as glutathione (GSH). Mitochondrial GSH has been shown to be a 
critical reservoir of this antioxidant, where selective depletion of mitochondrial GSH can 
induce apoptosis in several systems. Many studies have intricately linked Bcl-2 to 
cellular GSH status and it has been previously shown that Bcl-2 is a GSH binding 
protein. Therefore, we hypothesize that Bcl-2 may play an important role in regulating 
mitochondrial GSH transport.  
Here, we show that inhibition of Bcl-2 in primary cerebellar granule neurons 
(CGNs) induced apoptosis, mitochondrial oxidative stress, selective depletion of the 
mitochondrial GSH pool, and led to inhibition of mitochondrial GSH transport.  
Furthermore, we found that Bcl-2 is an interacting partner with a previously identified 
mitochondrial GSH transporter, the 2-oxoglutarate carrier (OGC), and this interaction is 
modulated by GSH. To further support a role for Bcl-2 in regulating mitochondrial GSH 
transport, we show that Bcl-2 requires OGC for protection against apoptosis induced by 
oxidative stress and to increase the mitochondrial GSH pool. These data suggest that Bcl-
2 plays a key role in regulating mitochondrial GSH transport and that the enhancement of 
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the interaction between Bcl-2 and OGC by GSH may increase mitochondrial GSH 
transport.   
The mechanisms of mitochondrial GSH transport thus far have only been 
extensively studied in liver and kidney, where the OGC and the dicarboxylate (DIC) 
carrier have been identified as inner membrane mitochondrial GSH transporters. Most 
studies examining mitochondrial GSH transport mechanisms in brain have not allowed 
for the distinction between neuronal and glial cell mitochondrial GSH transport 
mechanisms. Therefore, we employed primary cerebellar astrocytes and primary CGNs 
as a system to study mitochondrial GSH transport mechanisms and differences between 
neuronal and glial cells. It was found that cerebellar astrocytes use both the OGC and 
DIC to transport GSH into mitochondria, while CGNs preferentially use the DIC. In 
addition, discrete inhibition of one mitochondrial GSH transporter (DIC) using chemical 
inhibition and genetic knockdown, in CGNs, led to increased susceptibility to both 
oxidative and nitrosative stress. Overall, this suggests that inhibition of a single 
mitochondrial GSH transporter is sufficient to predispose neurons to oxidative stress, 
such as the conditions observed in neurodegenerative diseases.  
Finally, the consequences of overexpressing a mitochondrial GSH transporter 
were examined. Stable NSC34 motor neuron- like cell lines were produced which 
overexpress OGC. The stable OGC cell lines had significantly increased mitochondrial 
GSH levels and were markedly resistant to both oxidative and nitrosative stress. More 
importantly, the stable OGC cell lines up-regulated Bcl-2 expression (a protein we have 
shown previously to interact with OGC) and this phenomenon was due to increased 
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mitochondrial GSH levels. The up-regulation of Bcl-2 was required to sustain increased 
mitochondrial GSH levels and resistance to oxidative stress. Overall, this study 
implicates the importance of not only the mitochondrial GSH pool, but mitochondrial 
GSH transport for neuronal survival. These findings suggest that modulation of  
mitochondrial GSH transport could be a novel therapeutic approach for neuro-
degenerative diseases. 
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1 
 
CHAPTER ONE: INTRODUCTION 
 
Mitochondrial dysfunction, oxidative stress, and subsequent apoptosis are major 
unifying themes in the pathology of neurodegenerative diseases. Particularly, oxidative 
stress at the level of the mitochondria induces mitochondrial dysfunction and downstream 
apoptosis. Glutathione (GSH) is a key endogenous antioxidant compartmentalized into 
mitochondria, where it functions to combat reactive oxygen species (ROS) which are 
produced by the electron transport chain (ETC) as a byproduct of aerobic energy 
production. The mitochondrial GSH pool has been shown to be critical for cell survival in 
numerous systems. However, the precise role that mitochondrial GSH transport plays in 
the maintenance of cell viability remains to be understood. The mechanism of GSH 
compartmentalization into mitochondria has been extensively studied in kidney and liver, 
while limited studies have been completed regarding the same mechanisms within the 
central nervous system (CNS). Furthermore there is a lack of focus on the regulation of 
mitochondrial GSH transport. Prevalent evidence suggests a role for Bcl-2 in GSH 
trafficking and metabolism, and it has been previously shown that Bcl-2 is a GSH 
binding protein (Voehringer et al., 1998; Zimmermann et al., 2007). A major focus of this 
thesis is to examine the possible role of Bcl-2 in the regulation of mitochondrial GSH 
transport while also elucidating the importance of mitochondrial GSH transport in 
neuronal survival.  
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1.1 Overview of Apoptotic Pathways and their Involvement in Neurodegenerative 
Diseases 
 
Apoptosis, or programmed cell death, plays important physiological roles in the 
development and maintenance of an organism; however, aberrant signaling to or from 
apoptotic pathways contributes to the pathogenesis of diverse diseases. An 
overabundance of apoptosis for example, leads to neurodegenerative diseases while a 
lack of apoptosis is observed in many types of cancer. Currently, it is understood that two 
distinct apoptotic pathways exist, the extrinsic and intrinsic apoptotic pathways; both are 
discussed below and reviewed in Figure 1.1. 
1.1.1 The Extrinsic Apoptotic Pathway 
 The extrinsic apoptotic pathway initiates with an extracellular signal, such as 
that from cytotoxic T cells of the immune system. This extracellular signal leads to the 
recruitment and dimerization of death receptors (i.e. TNF or Fas receptors) which are 
specific for the extracellular signal received (Elmore, 2007; Ow et al., 2008). The 
oligomerization of the death receptors initiates the intracellular formation of the death 
inducing signaling complex (DISC) which, subsequently recruits procaspase-8 and 
activates it through a cleavage event (Chang et al., 2003; Donepudi et al., 2003; Cordeiro 
and Bidere, 2013). Other procaspases are cleaved downstream and activated by caspase-
8, including caspase-3 and -9. In addition, caspase-8 cleaves the BH3-only protein, Bid, 
producing its activated form, truncated-Bid (t-Bid) (Li et al., 1998). This mechanism is 
considered a convergence point for the extrinsic and intrinsic apoptotic pathways, as t-
Bid also translocates to the outer mitochondrial membrane, initiating the intrinsic or 
mitochondrial apoptotic cascade, as discussed in detail below.  
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1.1.2 The Intrinsic Apoptotic Pathway 
Intrinsic apoptosis, or the mitochondrial apoptotic pathway, is initiated by an 
intracellular signal such as DNA damage, accumulation of misfolded proteins, or 
oxidative stress. The exact mechanisms of this pathway are highly debated; here some of 
the major hypotheses will be reviewed.  The Bcl-2 family of proteins, both pro-survival 
(Bcl-2, Bcl-XL, Bcl-w) and pro-apoptotic, (Bax and Bak multi-domain proteins; and 
BH3-only proteins such as Bim, Bad, Hrk) have been shown to regulate the 
mitochondrial apoptotic pathway (Figure 1.2; Burlacu, 2003). This pathway involves the 
activation of BH3-only proteins, such as the dephosphorylation of Bad, which causes its 
release from 14-3-3 plasma membrane anchoring proteins, thus allowing its translocation 
to mitochondria (Masters et al., 2001; Yang et al., 2008). There are two main hypotheses 
regarding the mechanism by which BH3-only proteins promote apoptosis at 
mitochondria. BH3-only proteins are thought to either inhibit pro-survival Bcl-2 family 
proteins (such as Bcl-2 and Bcl-XL) thus “sensitizing” mitochondria to the effects of Bax 
and Bak (indirect model); or to directly activate Bax and Bak (direct model) (Cheng et 
al., 2001; Vela et al., 2013).  However, evidence has been provided which unifies both 
hypotheses suggesting that certain BH3-only proteins may act as suppressors of pro-
survival proteins while others may act as direct activators of Bax and Bak (Kuwana et al., 
2005; Kim et al., 2006). Following the activation of BH3-only proteins, the mitochondrial 
outer membrane becomes permeabilized, leading to the release of pro-apoptotic proteins 
such as cytochrome c and the apoptosis inducing factor (AIF) (Green and Reed, 1998; 
Martinour and Green, 2001). Two main hypotheses dominate the mechanism by which 
mitochondrial outer membrane permeabilization (MOMP) occurs. First, is direct pore 
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formation by the pro-apoptotic proteins Bax and Bak, where previous studies have shown 
the ability of Bax to form pores in membranes and induce MOMP in isolated 
mitochondria (Antonsson et al., 2000; von Ahsen et al., 2000; Desagher and Martinou, 
2000; Suzuki et al., 2000). Second, in the mitochondrial permeability transition pore 
(mPTP) model, matrix swelling is caused by the loss of mitochondrial membrane 
potential and inward flow of ions, such as Ca
2+
. The mPTP is thought to be responsible 
for the loss of mitochondrial membrane potential and is hypothesized to consist of 
voltage dependent anion channel (VDAC), adenine nucleotide translocase (ANT), and 
cyclophilin D (Crompton et al., 1998; Crompton et al., 1999). Finally, these two 
hypotheses are linked by studies showing that Bax and Bak interact with components of 
the proposed mPTP, VDAC and ANT, thus suggesting there is cooperation between pro-
apoptotic Bcl-2 family proteins and the mPTP in the permeabilization of the outer 
mitochondrial membrane and release of mitochondrially sequestered pro-apoptotic 
proteins (Marzo, 1998; Shimizu et al., 1999; Tsujimoto and Shimizu, 2002). In addition 
to the two hypotheses regarding MOMP mechanisms, the release of cytochrome c from 
cardiolipin (the lipid which tethers cytochrome c to the inner mitochondrial membrane) 
can also occur through several mechanisms. First, is the direct oxidation of cardiolipin by 
enhanced ROS production or the cardiolipin-cytochrome c complex (Ott et al., 2002; 
Orrenius and Zhivotovsky, 2005). Second, increased mitochondrial Ca
2+
 can weaken the 
electrostatic interaction between cardiolipin and cytochrome c and lastly, hydrolysis of 
cardiolipin by phospholipase A2 can lead to the release of cytochrome c from 
mitochondria (Sedlack and Robinson, 1999; Ott et al., 2007).  Overall, cytochrome c 
discharge results in electron transport deficits, further production of ROS, and even 
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greater release of cytochrome c into the cytosol (Orrenius et al., 2007).  Once released, 
cytochrome c associates with the apoptotic protease-activating factor (Apaf-1), which 
induces the cleavage and activation of procaspase-9, forming the apoptosome complex, 
and downstream activation of other caspases and caspase activated DNAses (CADs) (Zou 
et al., 1999; Adrain and Martin, 2001; Jiang and Wang, 2000; Kim et al., 2005; Riedl and 
Salvesen, 2007). The apoptotic pathway culminates in membrane blebbing, degradation 
of intracellular proteins and DNA, presentation of extracellular apoptotic markers 
(phosphatidylserine) and phagocytosis of the apoptotic cell, thus preventing damage to 
other neighboring cells and creating a “silent” death lacking significant inflammation 
(Fadok et al., 1992; Lauber et al., 2004). 
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Figure 1.1 Overview of Apoptotic Pathways The extrinsic and intrinsic pathways are 
depicted, showing the binding of the death receptor (Fas) by the death ligand (FasL), 
intracellular signaling through the DISC complex, activation of caspases (Pro-Cas to 
Cas), inhibition of inhibitor of caspase activated DNAses (ICAD) and thus activation of 
caspase activated DNAses (CADs), leading to the degradation of DNA. Cleavage of Bid 
into t-Bid represents a convergence point between the extrinsic and intrinsic pathways 
where BH3-only proteins are activated leading to inhibition of pro-survival proteins (Bcl-
2/Bcl-XL) and activation of Bax/Bak. MOMP is induced either directly by Bax/Bak or 
through the formation of the mPTP (VDAC, ANT, CyD). Cytochrome c (Cyt C) is 
released from the mitochondria; the apoptosome (Cyt C, Apaf-1, caspase-9) is formed, 
leading to the activation of caspases, CADs, and the degradation of DNA. PM=plasma 
membrane. I acknowledge Aimee Winter for drawing the double helix DNA shown in the 
nucleus.  
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Figure 1.2 Bcl-2 family members Pro-survival Bcl-2 family members are depicted in 
blue, with transmembrane domain (TM) and Bcl-2 like homology domains (BH) 1-4. 
Pro-apoptotic family members with multiple domains are depicted in red (BH1-3 and 
TM), while BH3-only domain members are depicted in orange.  
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1.1.3 Apoptosis in Neurodegeneration 
The means by which particular subsets of neurons degenerate in 
neurodegenerative diseases has been shown to rely upon apoptotic pathways. The 
pathology of Parkinson’s disease (PD) is due to the degeneration of dopamine neurons 
found in the substantia nigra located in the midbrain, where signs of apoptotic DNA 
damage have been observed in PD patients (Mochizuki et al., 1996). Substantia nigra 
samples from postmortem PD patients also display increased caspase-3, Bax, and 
apoptotic nuclei compared to age-matched control subjects (Hartmann et al., 2000; Tatton 
2000). Furthermore, in PD models both in vitro and in vivo, inhibition of apoptotic 
proteins affords protection to degenerating dopamine neurons (Eberhardt et al., 2000).  
Indices of apoptosis have also been shown in amyotrophic lateral sclerosis (ALS), a 
disease in which the alpha motor neurons in the lumbar spinal cord degenerate. Motor 
neurons from spinal cord sections of ALS patients show decreased Bcl-2 mRNA but 
increased Bax mRNA levels compared to control subjects and non-neuronal tissue 
sections (Mu et al., 1996). An additional study showed an increase in pro-apoptotic 
protein levels (such as Bax) and a decrease in Bcl-2 protein levels at the mitochondria 
resulting in an increase in cytosolic Bcl-2 expression levels. Increased caspase-3 
activation and apoptotic DNA damage were also observed (Martin 1999). Overall, the 
underlying mechanism of apoptosis induced during neuronal degeneration is 
hypothesized to be a consequence of mitochondrial dysfunction and oxidative stress, for 
which substantial evidence has been observed in these neurodegenerative diseases.  
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1.2 Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases 
 
The high energy demands of the central nervous system (CNS) induce the 
dependence of neurons and glial cells on mitochondrial energy production. Mitochondria 
produce ATP from molecular oxygen using oxidative phosphorylation, a process that is 
driven by the ETC. Unfortunately; electron leakage from the ETC causes the formation of 
highly reactive species, such as superoxide. In order to combat the endogenous ROS 
produced at mitochondria, several free radical scavenging systems exist, including 
superoxide dismutase, thioredoxin, and glutathione (GSH). However, if  ROS production 
exceeds the availability of the endogenous free radical scavengers, then indices of 
mitochondrial oxidative stress (MOS) accumulate, leading to the damage of 
mitochondrial lipids, DNA and proteins (Lin and Beal, 2006). It has been demonstrated in 
cardiac myocytes that ROS accumulation leads to mitochondrial membrane 
depolarization, a consequence dependent on cellular GSH concentrations. Furthermore, 
ROS stimulated mitochondrial membrane depolarization leads to ROS stimulated ROS 
release, inducing damage to surrounding mitochondria, propagating MOS signals, and 
enhancing cellular injury (Zorov et al., 2000; Zorov et al., 2006).  
Mitochondrial dysfunction and subsequent oxidative stress are major 
contributing factors to many neurodegenerative diseases, such as ALS and PD. In 
particular, increased oxidative stress has been demonstrated through the depletion of 
GSH levels in postmortem studies of the substantia nigra of PD patients (Perry and 
Young, 1986). Furthermore, in an ALS mouse model, depleted levels of GSH within 
lumbar spinal cord tissue were correlated to the onset and progression of the ALS disease 
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phenotype (Chi et al., 2007). Other indices of oxidative stress, such as damage to DNA, 
lipids and proteins are also prevalent in these neurodegenerative diseases. For example, 
sporadic ALS and PD patients have increases in oxidized Coenzyme Q10 and 8-hydroxy-
2’-deoxyguanosine (8-OHdG; oxidative modification to DNA) in cerebral spinal fluid 
(CSF) samples (Murata et al., 2008; Isobe et al., 2010). Mitochondrial dysfunction is 
shown through decreased protein levels of complex II, III, and V in mitochondria from 
postmortem sporadic PD brain (Arthur et al., 2009). It is also well established that PD 
patients have decreased complex I activity, within postmortem samples of the substantia 
nigra (Schapira et al, 1990). The G93A mutant SOD1 mouse model of ALS displays 
aggregation of mitochondria and reduced activity of complexes I, II and IV in spinal cord 
tissues (Jung et al., 2002; Sotelo-Silveira et al., 2009). Furthermore, ALS patients also 
have mitochondrial aggregates in spinal cord anterior horn sections, and decreased 
cytochrome c oxidase activity (Sasaki and Iwata, 1996; Borthwick et al., 1999). The 
involvement of oxidative stress and mitochondrial dysfunction within neurodegeneration 
has been reviewed extensively (Lin and Beal, 2006; Federico et al., 2012).   
 
1.3 Glutathione synthesis, functions and metabolism 
 
Glutathione (GSH) is the most prominent cellular thiol with numerous functions 
and a distinct synthesis pathway. This tri-peptide consisting of glutamate, cysteine and 
glycine is present at higher concentrations than all other known free radical scavenging 
systems. As discussed above, depletion of GSH has been observed in several 
neurodegenerative diseases, and therefore its significance in neuronal survival is of 
interest. Here, its synthesis, functions, regulation and metabolism are reviewed.   
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1.3.1 Glutathione synthesis 
The synthesis of GSH is limited to the cytosol and occurs in two ATP- dependent 
reactions (Griffith and Meister, 1985). The first step in GSH synthesis requires L-
glutamate to react with ATP, leading to the formation of L-glutamylphosphate, a reaction 
intermediate, which then combines with L-cysteine to form γ-L-glutamyl-L-cysteine, 
ADP, and phosphate (Griffith, 1999; Forman et al., 2009; Figure 1.3). This first step in 
GSH synthesis is catalyzed by glutamate cysteine ligase (GCL; also known as γ-glutamyl 
cysteine ligase) and occurs through the γ-carboxyl group of glutamate leading to the 
formation of a γ-peptidic linkage with the amino group of cysteine (Griffith, 1999; Wu et 
al., 2004). This γ-carboxyl linkage renders GSH uncleavable by all cellular proteases, 
except for γ-glutamyltranspeptidase (Wu et al., 2004; Lu, 2009). The second step in GSH 
synthesis is catalyzed by glutathione synthetase (GS), and begins with γ-L-glutamyl-L-
cysteine reacting with ATP, to form the reaction intermediate γ-L-glutamyl-L-
cysteinylphosphate, which then combines with L-glycine to form γ-L-glutamyl-L-
cysteinyl-L-glycine or GSH, ADP and phosphate (Griffith, 1999; Forman et al., 2009). 
GCL is considered the rate limiting enzyme in GSH synthesis based on data showing that 
its overexpression, but not that of glutathione synthetase (GS), leads to an increase in 
cellular GSH content (Forman et al., 2009). The bioavailability of cysteine is also a rate 
limiting determinant for GSH synthesis (Griffith, 1999; Lu, 2009).  
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Figure 1.3 Glutathione Synthesis L-glutamate and L-cysteine are substrates for γ-
glutamate cysteine ligase (GCL) in the formation of L-γ-glutamylcysteine. Next, L-
glycine and L-γ-glutamylcysteine are substrates for glutathione synthetase (GS) in the 
formation of γ-glutamyl-cysteine-glycine, or GSH. The hydrolysis of ATP into ADP and 
phosphate is a requirement for each enzymatic step in GSH synthesis.  
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1.3.2 Regulation of glutathione synthesis 
The regulation of GSH synthesis is modulated by several factors including; 
feedback inhibition, the availability of amino acid precursors, and post-translational 
modifications. The GCL holoenzyme has two subunits, GCLC (catalytic) and GCLM 
(modulatory). GCLC contains all of the enzymatic activity for the holoenzyme while 
GCLM regulates the holoenzyme (Huang et al., 1993). The GCL holoenzyme forms an 
intermolecular disulfide bond between the GCLC and GCLM subunits which increases 
the affinity of GCLC for glutamate under oxidizing conditions (Soltaninassab et al., 
2000; Filomeni et al., 2002). However, when cellular GSH levels are increased, GSH 
reduces the intermolecular disulfide bond, decreasing the affinity of GCLC for glutamate, 
thus allowing for feedback inhibition of GCLC by GSH (Soltaninassab et al., 2000; 
Filomeni et al., 2002).  
Second, the availability of amino acid precursors, particularly cysteine, affects 
the rate of GSH synthesis, and therefore, contributes to its regulation. Amino acid 
availability and preference for use in GSH synthesis is dependent on cellular activities 
and cell type. For example, the availability of specific precursors in the liver is dependent 
on several factors such as diet, amino acid transport, and the transsulfuration pathway. In 
liver, the major sources of cysteine are either provided from the metabolism of 
methionine, in which transsulfuration converts homocysteine to cysteine or through 
protein degradation (i.e. diet) (Griffith, 1999; Wu et al., 2004; Lu, 2009). Previous studies 
do not provide support for the use of the transsulfuration pathway within the brain, based 
on low levels of enzymatic activity and RNA expression of its constituents, and the 
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inability of methionine to increase GSH levels (Dringen and Hamprecht, 1999; Ishii et al, 
2004). Overall, most tissues receive the precursors L-cysteine or L-cystine (disulfide 
form of cysteine) from GSH excreted into the plasma from the liver; and amino acid 
transport systems are important for maintaining cellular GSH in tissues other than liver 
(Griffith, 1999). In particular, the Na
+
 independent Xc
- 
amino acid transporter normally 
exchanges intracellular glutamate for extracellular cystine such that elevated extracellular 
glutamate concentrations can reduce the availability of cystine by inhibiting its transport 
through this system (Griffith, 1999; Lu, 2009). In the brain, high extracellular 
concentrations of glutamate and glycine are not present because these molecules function 
as neurotransmitters. Therefore, GSH precursors are effectively transported into neurons 
after their release from astrocytes (Dringen and Hirrlinger, 2003). Astrocytes export 
approximately 10% of their total intracellular GSH within one hour, and the GSH 
exported is broken down by γ-glutamyltranspeptidase and aminopeptidase N in order to 
provide precursors to neurons for de novo GSH synthesis (Dringen et al., 1997; Dringen 
et al., 1999; Dringen et al., 2001). Furthermore, differences in the precursors used 
between astrocytes and neurons have been documented. Astrocytes use cystine and 
glutamate as precursors transported through the Xc
- 
amino acid transporter, while neurons 
use cysteine and glutamine for GSH precursors transported by excitatory amino acid 
transporters (EAAT) XAG-, these differences have been hypothesized to prevent 
competition for precursors between neighboring cells (Kranich et al., 1996; Dringen et 
al., 1999; Shanker et al., 2001; Dringen and Hirrlinger, 2003).  
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Finally, post-transcriptional and post-translational modifications of GCLC and 
GCLM also contribute to the regulation of GSH synthesis; however these effects have not 
been elucidated for GS (Lu, 2009). For both subunits of the holoenzyme, GCL, mRNA 
stabilization has been reported under oxidative conditions (Liu et al., 1998).  GCLC 
phosphorylation and S-nitrosylation (at the active site thiol) has been shown to decrease 
its activity (Sekhar and Freeman, 1999; Griffith, 1999). During apoptosis, caspase-3 
dependent cleavage of GCLC results in decreased activity (Franklin et al., 2003). Overall, 
the post-transcriptional and post-translational modifications of GCLC are the best 
characterized.   
GCLC contains binding sites for the transcription factors AP-1, AP-2, NF-κB, 
SP-1 and ARE/EpRE (antioxidant response element/ electrophile response element); 
GCLM transcriptional binding sites have been less studied, but include AP-1 and 
ARE/EpRE (Moinova and Mulcahy, 1998; Griffith 1999). In addition, Nrf1 and Nrf2 can 
increase the transcription of GCLC by modulating AP-1 and NF-κB (Yang et al., 2005).  
NF-κB can regulate the transcription of GCLM through AP-1 (Yang et al., 2005). Finally, 
numerous oxidative stress inducers have been shown to increase either the transcription 
of GCLC or GCLM and in some cases both, however this appears to be tissue specific, 
and differences have been found between in vitro and in vivo studies (reviewed in 
Griffith, 1999 and Lu, 2009). GS transcription is regulated by NF-κB, AP-1, Nrf1 and 
Nrf2 (Yang et al., 2002; Yang et al., 2005; Lu, 2009).  
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1.3.3 Functions of glutathione 
The functions of GSH are as diverse as its cellular compartmentalization; it has 
been shown to be present in the mitochondria, endoplasmic reticulum (ER), peroxisomes, 
nucleus and cytosol.  Therefore, GSH functions as more than an antioxidant; it has been 
implicated in the control of the cell cycle, cell signaling, a store of cysteine, protein 
folding, the detoxification of xenobiotics in addition to other functions, all of which are 
reviewed below (Lu, 2009).   
Within the mitochondrial matrix, GSH serves as an antioxidant, a function which 
is linked to other enzymatic systems of the mitochondria. GSH functions in conjunction 
with superoxide dismutase (SOD) to scavenge superoxide, where SOD converts 
superoxide into water and hydrogen peroxide (H2O2) while GSH works to detoxify the 
H2O2 produced. The reaction between H2O2 and GSH can occur both enzymatically and 
non-enzymatically. Glutathione peroxidase (GPx) is a selenoenzyme which facilitates the 
reduction of H2O2 into water, using GSH as an electron donor, forming glutathione 
disulfide (GSSG) (Meister and Anderson 1983; Dringen et al., 2000; Lu 2009). Next, 
glutathione reductase (GR) recycles GSSG at the expense of NADPH, into two GSH 
molecules (Meister and Anderson 1983; Dringen et al., 2000; Lu 2009; Figure 1.4). GSH 
can also scavenge the hydroxyl radical, peroxynitrite, and nitric oxide (Sjöberg et al., 
1982; Koppal et al., 1999; Yadav and Mishra 2013). Other antioxidant functions of GSH 
include the reduction of lipid hydroperoxides and prevention of the fenton reaction from 
occurring between metals (copper and iron) and oxygen (Filomeni et al., 2002). The 
mechanism by which GSH prevents the fenton reaction has been hypothesized to rely 
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upon its role in the detoxification of copper and cellular trafficking of copper (Ferreira et 
al., 1993; Maryon et al., 2013). 
Beyond its capacity as an antioxidant, GSH serves to detoxify certain cellular 
components and by-products. Glutathione-S-transferase (GST) facilitates the conjugation 
of GSH with proteins such as xenobiotics (quinones) and HNE (lipid radicals) (Meister, 
1988). The addition of GSH to these toxic compounds induces their export to the 
extracellular matrix, where they are then metabolized by γ-glutamyltranspeptidase 
leading to the formation mercapturic acids and thus detoxifying these components 
(Boyland and Chasseaud, 1969; Dickinson and Forman, 2002; Lu, 2009). Post-
translational modifications and protein conjugation are relevant to the cell signaling 
function of GSH. For example, GSH will conjugate with NO to form S-nitrosoglutathione 
(GSNO), which can participate in S-nitrosylation, form glutathione adducts with cysteine 
residues of proteins, or serve as a cellular NO reservoir and targeting (Ji et al., 1999; 
Andre and Felley-Bosco, 2003). In particular, GSNO has been shown to act as a 
neuroprotective agent during oxidative stress conditions (Rauhala et al., 1998). In 
addition, GST assisted GSH conjugation to proteins can either lead to the activation or 
loss of function of proteins due to structural changes (Filomeni et al., 2002).   
In the ER, GSH is present in its oxidized form, GSSG, where it is necessary for 
protein folding and the formation of disulfide bonds within nascent proteins (Hwang et 
al., 1992; Mari et al., 2009). GSH is also important for the regulation of intracellular Ca
2+
 
levels, in which the inhibition of GSH synthesis and thus depleting cellular GSH levels 
caused an increase in intracellular Ca
2+
 levels and a decrease in PC12 cell viability 
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(Jurma et al., 1997). GSH has also been shown to protect the protein sulfhydryl groups on 
Ca
2+
 transporters from oxidation (Rimpler et al., 1999).  
Nuclear localized GSH has a role in DNA synthesis and cell cycle control. 
Glutaredoxin is an enzyme which utilizes GSH as a reducing mechanism for 
ribonucleotide reductase (the rate limiting enzyme in DNA synthesis) which converts 
nucleotide diphosphates to deoxyribonucleotide disphosphates, an essential step in DNA 
synthesis (Holmgren, 1981; Pallardό et al., 2009). When GSH is depleted, it has been 
shown to inhibit DNA synthesis further implicating the requirement for GSH in this 
process (Dethlefsen et al., 1988; Pallardό et al., 2009). Inhibition of GSH synthesis and 
subsequent reductions in cellular GSH content induces a decrease in telomerase activity, 
as well as, decreased expression of the cell cycle regulatory proteins Id2 and E2F4 
(Borrás et al., 2004). In addition, inhibition of GSH synthesis leads to cell cycle arrest, 
consistent with several studies that have shown GSH is required for cell cycle entry into 
the S phase (Shaw and Chou 1986; Messina and Lawrence 1989; Poot et al., 1995; Lu, 
2009).  
GSH also has CNS specific functions as shown in recent studies which have 
provided evidence that GSH may play a role in synaptic transmission, through an 
interaction with the glutamatergic receptors, NMDA and AMPA (Varga et al., 1997). The 
consequences of GSH binding to NMDA receptors in neurons is dependent on the 
concentration of GSH. For example, low concentrations of GSH (μM) prevent the 
binding of excitatory agonists, while high concentrations of GSH (mM) modulate redox 
sites of the NMDA receptor, increasing its currents (Janáky et al., 1999). In addition, 
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GSH appears to bind currently non-identified receptors, a phenomenon linked to sodium. 
However, the importance of these findings is limited due to the variability of findings and 
relatively few published studies (Janáky et al., 1999; Oja et al., 2000). 
Finally, GSH affords protection from apoptotic stimuli. This function could be a 
culmination of its numerous other actions discussed above. It has been proposed that one 
of the earliest events in the induction of apoptosis is GSH depletion (Esteve et al., 1999; 
Franco et al., 2007). GSH depletion in the nucleus has been shown to increase cell 
susceptibility to DNA alkylating agents (Britten et al., 1991).  Furthermore, GSH 
depletion in the cytosol and more specifically in the mitochondria has been shown to play 
a role in the apoptotic pathway, at the level of mitochondrial permeability transition 
(Armstrong and Jones, 2002).  Mitochondrial DNA oxidation has been shown to correlate 
with a decrease in GSH and an increase in oxidized GSH levels, while total cellular GSH 
depletion is an event which occurs prior to DNA fragmentation (Esteve et al., 1999). 
These studies indicate that mitochondrial GSH plays an important role in cell survival, 
which is discussed in the next section. 
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Figure 1.4 Glutathione detoxification of H2O2 Superoxide (O2-) is dismutated into 
hydrogen peroxide (H2O2) and water (H2O) via superoxide dismutase (SOD). H2O2 is 
broken down into H2O at the expense of two GSH molecules using the enzyme GSH 
peroxidase (GPx), forming oxidized GSH, or GSH disulfide (GSSG). GSH reductase 
(GR) uses NADPH as an electron donor to form two GSH molecules from GSGG, 
leading to the formation of NADP
+
. Glucose-6-phosphate dehydrogenase (G6PD) then 
cycles NADP
+
 back into NADPH. 
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1.4 The discrete mitochondrial glutathione pool is critical for cell survival 
Although the mitochondrial GSH pool only constitutes 10-30% of total cellular 
GSH (percentage is specific to cell type); the concentration of GSH in the mitochondria is 
comparable to the cytosolic concentration of GSH which is ~1-10 mM (Smith et al., 
1996; Filomeni et al., 2002; Circu et al., 2008). Mitochondria contain several antioxidant 
enzyme scavenging systems; however, GSH is present at a concentration that is 500-1000 
times that of other antioxidant systems (Schafer and Buettner, 2001; Filomeni et al., 
2002). Furthermore, mitochondria from brain rely upon GSH detoxification of matrix-
generated H2O2, because catalase has only been found to be present on the outer 
mitochondrial membrane (Vitorica et al., 1984; Mari et al., 2009). The specific depletion 
of mitochondrial GSH in cerebellar granule neurons (CGNs), led to increased ROS 
production, mPTP induction, and cell death. In the same system, depletion of the 
cytosolic GSH pool did not recapitulate these effects (Wüllner et al., 1999). Furthermore, 
specific depletion of mitochondrial GSH in astrocytes sensitized these glial cells to cell 
death induced by either oxidative stress (H2O2) or nitrosative stress (SIN-1 or SNAP) 
(Muyderman et al., 2007). The importance of mitochondrial GSH has not just been 
demonstrated in the brain, but also in hepatocytes. For example, depletion of total cellular 
GSH (both mitochondrial and cytosolic) led to an increase in cell death and lipid 
peroxidation which was greater than when only the cytosolic pool of GSH was depleted 
(Meredith and Reed, 1982; Meredith and Reed, 1983). Several models of cell death lead 
to a specific decrease of mitochondrial GSH; and thus depletion and oxidation of this 
reservoir has been hypothesized to be the mode of cell toxicity. These studies include 
22 
 
toxicity induced by aromatic hydrocarbons in rat adrenal cells, hypoxia in hepatocytes, 
cisplatin treated renal cells and cardiomyocyte apoptosis in streptozotocin induced 
diabetes in rats and mice (Hallberg and Rydström 1989; Santos et al., 2003; Lluis et al., 
2005; Ghosh et al., 2005; and Santos et al., 2007). Studies on the exact contribution of the 
mitochondrial GSH pool to cell survival have been relatively limited because the 
understanding of how to discretely manipulate this pool of GSH was not previously 
available. The recent identification of specific mitochondrial GSH transporters (discussed 
below) will now allow for more specific depletion of mitochondrial GSH pools and thus a 
better understanding of the involvement that this specific pool of GSH plays in cell 
survival can be elucidated. Nonetheless, current evidence suggests that the mitochondrial 
GSH pool is key to cell survival and resistance to apoptosis in numerous models.  
1.5 Deciphering the mechanism by which glutathione is 
compartmentalized into mitochondria 
The transport of GSH into mitochondria first became of interest to researchers in 
the late 1980s. At that time liver and kidney tissues were used primarily due to their high 
mitochondrial content. The first study completed by Griffith in 1985 demonstrated that 
mitochondria lack the enzymes required for the synthesis of GSH (Griffith and Meister, 
1985). Moreover, the charge of GSH at physiological pH (-1 to -2), the relative negative 
charge of the mitochondrial membrane space in relation to the cytoplasm, and the similar 
mitochondrial and cytoplasmic GSH concentrations, do not allow for simple diffusion to 
account for the observed mitochondrial GSH levels (Lash, 2006). These studies 
suggested that either an active and/or facilitated process contributed to the movement of 
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GSH into mitochondria, and two inner membrane anion carriers, dicarboxylate (DIC, 
Slc25a10) and 2-oxoglutarate (OGC, Slc25a11)  carriers, were subsequently identified as 
mitochondrial GSH transporters in both liver and kidney. These carriers belong to a 
mitochondrial super family, the solute carrier family that exhibit similar predicted 3D 
structure, namely, this family is characterized by containing three transmembrane 
domains and are believed to exist as homodimers (Lash, 2006). OGC is known to 
transport 2-oxoglutarate in exchange for dicarboxylates, while DIC exchanges 
dicarboxylates in exchange for phosphate. OGC functions to provide substrates for 
several metabolic processes including the citric acid cycle, malate/aspartate shuttle, 2-
OG/isocitrate shuttle, nitrogen metabolism, and gluconeogensis from lactate (Lash, 
2006).  DIC supplies dicarboxylates to the citric acid cycle, while also transporting 
thiosulfates into the cytoplasm for the enzymes rhodanese and thiosulfate reductase 
(Lash, 2006). The early studies and identification of these carriers as mitochondrial GSH 
transporters are reviewed below.   
In the early studies regarding mitochondrial GSH transport, it was shown that 
there were two components, high-affinity and low-affinity in rat liver mitochondria, and 
both were inhibited by protonophores, glutamate, and the GSH analog, ophthalmic acid 
(Mårtensson et al., 1990). Respiratory rates of mitochondria were also shown to affect 
mitochondrial GSH transport in liver, while protonophores and antimycin A reduced 
uptake of GSH (Kurosawa et al., 1990). Collectively, these early studies allowed for the 
prediction that mitochondrial GSH transport may be determined by mitochondrial energy 
dependency. 
24 
 
 Lash and colleagues were the first group to examine the potential contributions 
of previously identified electro-neutral anion carriers to mitochondrial GSH transport. 
Several molecules were found to inhibit GSH transport into isolated rat kidney 
mitochondria, including glutamate, malate/butylmalonate, succinate/phenylsuccinate, and 
phosphoenylpyruvate. In addition, GSH transport was also shown to be dependent on 
phosphate and ATP production (Chen and Lash, 1998). These studies confirmed that both 
the DIC and OGC were able to transport GSH into mitochondria (Chen and Lash, 1998). 
The tricarboxylate carrier was ruled out, because its inhibitor, phosphoenylpyruvate 
induced mitochondrial permeability transition, and thus decreased mitochondrial GSH 
transport via a non-specific mechanism (Chen and Lash, 1998).  Further investigation of 
the effect glutamate exhibited on GSH transport into isolated mitochondria, ruled out the 
involvement of the glutamate and glutamate/aspartate transporters in this process. It was 
shown that GSH did not inhibit glutamate transport, that GSH transport was independent 
of pH, and aspartame did not affect GSH transport. Therefore, it was concluded that the 
glutamyl residue was important for GSH transport, thus elucidating the effect of 
glutamate on GSH transport (Chen and Lash, 1998).  
In a separate study, fractions enriched from rabbit kidney mitochondria were 
reconstituted into proteoliposomes to study GSH transport mechanisms. One study 
reported that, DIC and OGC were responsible for approximately 70-80% of 
mitochondrial GSH transport in kidney (Chen et al., 2000). Finally, overexpression of 
OGC or DIC in NRK-52E rat kidney cells, led to an increase in mitochondrial GSH 
transport rates and increased resistance to apoptosis (Lash et al., 2002; Xu et al., 2006). 
25 
 
Identification of DIC and OGC mediated GSH transport in kidney made a profound 
impact on this field of research, and stimulated interest of mitochondrial GSH transport 
mechanisms in other tissue types. Studies completed in isolated rat liver mitochondria 
showed that GSH transport was only partially inhibited by phenylsuccinate and 
butylmalonate, and was independent of ATP hydrolysis (Zhong et al., 2008). 
Furthermore, overexpression of OGC in H4IIE rat hepatoma cells, led to a significant 
increase in mitochondrial GSH uptake, and resistance to several apoptotic stimuli (Zhong 
et al., 2008). Overall, mitochondrial GSH transport in liver may only be partially 
dependent on OGC and DIC (approx. 45-50%), and therefore similar to kidney, other 
carriers could play a role in this process (Lash, 2006).  
Mitochondrial GSH transport mechanisms may vary among tissues and cell types 
for several reasons. For example, although DIC has been found to have consistent 
expression and amino acid sequence homology among various tissues and species, OGC 
does not display the same consistency (Lash, 2006). Specifically, there are six amino acid 
differences between kidney and brain OGC constructs, two of which are different in 
charge or polarity, and three of which are in close proximity to transmembrane domains 
(Lash, 2006). OGC mRNA levels are highest in heart, skeletal muscle, brain, liver and 
kidney, but low in lung and pancreas. Consistent with this finding, expression of 
mitochondrial carriers is dependent on the energy demand of the cell type (Lash, 2006). 
Therefore, mitochondrial GSH transport mechanisms appear to be tissue and cell type 
specific.  
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More recent studies have emerged examining mitochondrial GSH transport in the 
brain. Mitochondrial GSH transport in isolated mitochondria from whole rat brain was 
shown to be inhibited by the substrates citrate, isocitrate, malate, and 2-oxoglutarate. In 
the same system, the inhibitors of specific transporters, butylmalonate (DIC), 
phenylsuccinate (OGC), and benzene 1,2,3-tricarboxylate (tricarboxylate carrier, TCC) 
significantly prevented the  uptake of GSH into isolated mitochondria (Wadey et al., 
2009).  The authors of this particular study concluded that isolated rat brain mitochondria 
were dependent on TCC for mitochondrial GSH transport, as butylmalonate (specific 
DIC inhibitor) and phenylsuccinate (specific OGC inhibitor) had previously been shown 
to have a weak inhibitory effect on TCC. However, the authors failed to explain the 
effects of the substrates malate (DIC substrate) and 2-oxoglutarate (OGC substrate) on 
mitochondrial GSH uptake within this study (Wadey et al., 2009). While cortical neurons 
and astrocytes express both OGC and DIC, it appears that isolated mitochondria from the 
cortex depend primarily on DIC for GSH transport (Kamga et al., 2010). Interestingly, 
inhibition of DIC- mediated GSH transport in isolated mitochondria led to an increase in 
ROS and H2O2 production, impaired complex I activity, and decreased mitochondrial 
membrane potential (Kamga et al., 2010). Finally, PC12 cells (rat adrenal 
pheochromocytoma cell line) were also found to be dependent on DIC, but not OGC, for 
mitochondrial GSH transport (Kamga et al., 2010). Overall, studies examining 
mitochondrial GSH transport mechanisms and mitochondrial GSH transport regulation in 
brain are limited and warrant further investigation.  
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1.6 Past studies linking Bcl-2 overexpression to cellular glutathione metabolism 
1.6.1 The diverse functions of Bcl-2 
Beyond its functions in inhibiting pro-apoptotic proteins, Bcl-2 is also involved 
in the regulation of the cell cycle and Ca
2+
 homeostasis. These additional functions of 
Bcl-2 in promoting cell survival were discovered as a consequence of numerous studies 
examining Bcl-2-dependent protection from a variety of toxic insults (Table 1.1). Bcl-2 
was found to protect from both free radical generators and toxic insults which lead to cell 
death independent of free radicals or reactive intermediates (Table 1.1).  However, the 
protection Bcl-2 afforded from agents which act through Ca
2+
 mediated cell stress, was 
found to rely upon the targeting of Bcl-2 to the endoplasmic reticulum (ER) and the 
interaction between Bcl-2 and the inositol 1, 4, 5-trisphosphate (IP3) receptor. Previous 
work indicated that the BH4 domain of Bcl-2 was responsible for interacting with and 
inhibiting Ca
2+
 release from the endoplasmic reticulum (ER) via the IP3 receptor (Rong 
et al., 2009). Overexpression of Bcl-2 was found to maintain ER Ca
2+
 uptake and inhibit 
Ca
2+
 efflux, thus potentiating apoptosis induced by thapsgargin, an inhibitor of the ER 
Ca
2+
 ATPase (He et al., 1997). Furthermore, Bcl-2 was also shown to regulate 
mitochondrial Ca
2+
 uptake in a GT1-7 neuronal cell line, thus preventing mitochondrial 
Ca
2+
 overload, mitochondrial permeability transition, and apoptosis (Murphy et al., 
1996). Bcl-2 also functions as a repressor of the cell cycle transition between G1 to S 
phase, a phenomenon that is hypothesized to be dependent on the regulation of ROS by 
Bcl-2 (Deng et al., 2003). The mechanism by which Bcl-2 suppresses cell cycle transition 
was found to be dependent on increased expression of p27 and p130; both of which are 
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repressors of the E2 family of transcription factors (E2F4; E2F1) which control the 
expression of critical cell cycle proteins (Vairo et al., 2000). Interestingly, the functions 
that Bcl-2 contributes to cell survival are similar to the previously identified functions of 
GSH discussed above (i.e. cell-cycle, prevention of apoptosis, and Ca
2+
 signaling). Thus, 
it is not surprising that Bcl-2 expression and GSH have been related in several ways, as 
discussed below.  
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Table 1.1 Bcl-2 protects from a variety of insults in diverse systems 
Cell Type Insult Citation 
PC12  Growth factor withdrawal, A23187, 
Dopamine, Serum Withdrawal, 
H2O2, Aβ25-35, FeSO4,HNE, 
AMVN, Cycloheximide, 
Actinomycin D, colchicine,EGTA, 
Enediyne-5, cisplatin 
 
Mah et al., 1993 
Sato et al., 1994 
Lindenboim et al. 1995 
Cortazzo and Schor 1996 
Ellerby et al., 1996 
Offen et al., 1997 
Kruman et al., 1997 
Tyurina et al., 1997 
Bruce-Keller et al., 1998 
Jang and Surh et al., 2004 
GT1-7 Potassium cyanide with glucose 
deprivation, BSO, Diethyl maleate, 
Ethacrynic acid, Serum Withdrawal 
Myers et al. 1995 
Kane et al., 1993/1995 
Ellerby et al., 1996 
Hippocampal 
neurons 
Adriamycin,Glutamate,Glucose 
deprivation 
Lawrence et al. 1996 
L929 cells TNF Hennet et al., 1993 
Hematopoietic IL-3 withdrawal Baffy et al., 1993 
CSM14.1 
 
Serum withdrawal, A23187, 
Glucose deprivation, menadione, t-
BOOH, BSO 
Zhong et al., 1993 
Thymocytes 
in vivo 
Dexamethasone, radiation, anti-
CD3 
Sentman et al., 1991 
Sympathetic 
neurons 
NGF withdrawal-delay in apoptosis Garcia et al., 1992 
LY-ar Gamma-radiation Mirkovic et al., 1997 
Transgenic 
mice 
 
BSO-unweaned pups, adriamycin, 
focal ischemia, 3-nitropropionic 
acid, permanent ischemia induced 
by middle cerebral artery 
occlusion, natural occurring cell 
death 
Martinou et al. 1994 
Lawrence et al. 1996 
Merad-Saïdoune et al., 
1999 
Bogdanov et al., 1999 
Astrocytes Glucose deprivation, H2O2 Papadopoulos et al., 1998 
FL15.12 IL-3 withdrawal, H2O2, menadione Nunez et al., 1990 
Hockenbery et al., 1990 
Hockenbery et al., 1993 
FDC-P1, 32D IL-4, GM-CSF, IL-3 Withdrawal Nunez et al., 1990 
HL-60 CCCF, STS Armstrong and Jones, 2002 
Fibroblasts H2O2, glucose withdrawal Rimpler et al., 1999 
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1.6.2 Bcl-2 expression influences glutathione 
 The first evidence presenting an influence of Bcl-2 on GSH metabolism 
developed from early studies showing that its overexpression not only protected from 
oxidative stress but also increased cellular GSH levels. These studies, originally 
conducted to determine if the apoptotic pathway was conserved among various toxic 
insults, found that enhanced Bcl-2 expression provided protection from oxidative stress 
independent of inhibiting free radical generation (Hockenbery et al., 1993).  A separate 
study determined that Bcl-2 overexpression afforded protection from apoptosis induced 
by GSH depleting agents such as, BSO, diethyl maleate, and ethacrynic acid, in a GT1-7 
hypothalamic neural cell line (Kane et al., 1993). Finally, Bcl-2 overexpression in a 
variety of cell types leads to an increase in cellular GSH concentration (reviewed in Table 
1.2).  One particular study aimed to evaluate the cell type specific involvement of Bcl-2 
expression on GSH metabolism (Schor et al., 2000). However, upon close examination of 
their data both cell types (PC12 and MCF-7) displayed increased basal cellular GSH 
content, but no differences in antioxidant enzyme activities were observed (Schor et al., 
2000). After review of the literature regarding Bcl-2 overexpression and cellular GSH 
status, it was found that only one cell type out of nine, HL-60 (Human promyelocytic 
leukemia cells), did not show increased cellular GSH levels in the presence of increased 
Bcl-2 (Table 1.2., Armstrong and Jones, 2002). In addition, two separate studies 
examining HeLa cells showed a variation in the effects of Bcl-2 on cellular GSH levels; 
Voehringer et al. only showed increased GSH in the nuclear compartment where as 
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Meredith et al., showed a total cellular GSH increase (Meredith et al., 1998; Voehringer 
et al., 1998). These differences may be due to the different techniques used to 
overexpress Bcl-2, such as retroviral gene transfer (in HL-60 cells) and two distinct 
vectors used for stable transfection in the separate HeLa cell studies. Furthermore, the 
strength of the promoter used to drive expression could cause variation in results in the 
same cell line (Table 1.2). The most evident variable effect induced by the 
overexpression of Bcl-2 in different cell types, is its effect on antioxidant enzymes, as 
shown in Table 1.2. In vivo studies observed that knockout of Bcl-2 in mice led to a 
decrease in the activities of several antioxidant enzyme systems, suggesting that Bcl-2 
may have multiple effects regarding cellular antioxidant status (Hochman et al., 1998). 
Overall, most studies which have examined the effects of Bcl-2 overexpression have 
correlated it with an increase in cellular GSH content (Table 1.2). A few possible 
mechanisms have been suggested in regards to how enhanced Bcl-2 expression leads to 
increased cellular GSH content. First, Bcl-2 overexpression in PC12 cells led to 
constitutive activation and enhanced transcriptional activity of NF-κB which led to 
downstream increases in GCLC levels (Jang and Surh, 2004). Therefore, Bcl-2 
overexpression in this system appeared to induce an increase in de novo GSH synthesis. 
Second, enhanced Bcl-2 expression in HeLa cells did not alter the levels of GSH 
synthesizing enzymes, but inhibited methionine dependent GSH extrusion from cells at 
the plasma membrane, which correlated with an increase in cellular GSH, levels 
(Meredith et al., 1998). Finally, Bcl-2 overexpression in PC12 and GT1-7 cells led to an 
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increase in NADPH and decrease in NAD
+
 levels, as well as a decrease in the ratio of 
ATP/ADP (Ellerby et al., 1996). If Bcl-2 overexpression induced an increase in NADPH  
production, this could lead to an increase in cellular GSH by the reduction of GSSG (see 
Figure 1.4). However, after examining flux through the pentose-phosphate pathway, it 
was concluded that Bcl-2 overexpression did not exert an effect on the production of 
NADPH (Ellerby et al., 1996).  
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Table 1.2 Effects of Bcl-2 overexpression on glutathione levels and antioxidant enzymes 
in various systems 
 
 
 
Cell Type Effect on antioxidant  
enzymes  
Effect on 
GSH 
Mechanism of  
Bcl-2  
expression 
Citation 
PC12  Increase in Cu/Zn 
SOD1  
and GPx 
Increase Retroviral  Bruce-Keller  
et al., 1998 
PC12  
 
MCF-7  
No change in GR, 
GSH  
synthesis 
ND 
Increase 
 
Increase 
Plasmid/Stable  Schor et al., 
2000 
 
 
GT1-7 ND Increase Retroviral Kane et al., 
1993 
PC12  
 
GT1-7 
Increase in SOD and 
CAT 
Increase in SOD and 
GR 
Increase 
 
Increase 
Retroviral  Ellerby et al.,  
1996 
 
HeLa  ND 
 
ND 
Increase  
 
Increase 
Tet-repressible 
promoter/Stable 
Plasmid/Stable  
Voehringer et 
al., 1998 
Meredith et al., 
1998 
LY-ar 
 
ND Increase Endogenous  Mirkovic et al., 
1997 
HL60  ND Decreased Retroviral  Armstrong and  
Jones, 2002 
Astrocytes Increase in SOD and 
GSH Px 
Increase Retroviral Papadopoulos  
et al., 1998 
NT-2/D1 
SK-N-MC 
Increase in Cu/Zn 
SOD  
Increase in Cu/Zn 
SOD,  
CAT, GPx 
Increase 
Increase 
Plasmid, stable  Lee et al., 2001 
HeLa ND Increase Stable 
transfection 
Meredith et al., 
1998 
Fibroblast ND Increase Retroviral Rimpler et al.,  
1999 
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The next major finding correlating an effect of Bcl-2 expression on GSH showed 
that cellular trafficking of Bcl-2 influences the cellular localization of GSH. Voehringer 
and colleagues observed that overexpression of Bcl-2 in HeLa cells caused a significant 
increase in nuclear Bcl-2 levels and a subsequent relocalization of GSH to the nucleus. In 
addition, the increased nuclear localization of Bcl-2 led to enhanced nuclear GSH 
transport (Voehringer et al., 1998). Therefore, the trafficking of Bcl-2 appears to 
influence the cellular compartmentalization of GSH. The major effects of Bcl-2 on 
cellular GSH are reviewed in Figure 1.5.  
Further evidence linking Bcl-2 expression with GSH metabolism derived from 
cancer studies. It was found that cancer cells which overexpressed Bcl-2 (LY-ar; mouse 
lymphoma cells and HeLa cells) were highly resistant to gamma radiation-induced 
apoptosis. However, upon culturing these cells in cysteine/methionine free media or 
treatment with diethyl maleate which reduces GSH levels, resensitization of these cells to 
gamma-radiation induced apoptosis occurred (Mirkovic et al., 1997; Voehringer et al., 
1998). In contrast, Bcl-2 overexpression in PC12 cells caused the chemotherapeutic drug, 
neocarzinostatin (NCS) to significantly increase apoptosis.  NCS requires reduction by 
thiols in order to be activated and the increased GSH due to Bcl-2 overexpression could 
therefore account for the increased toxicity of NCS in these cells. Indeed, BSO pre-
treatment prevented Bcl-2 from rendering the PC12 cells more susceptible to NCS and 
Bcl-2 conferred protection from both enedicine-5 and cisplatin, which are insensitive to 
cellular redox status (Cortazzo and Schor, 1996). Upon depletion of GSH in HL-60 cells 
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overexpressing Bcl-2, both the mitochondrial membrane potential and the ratio of 
GSH/GSSG were significantly decreased while ROS species production and apoptosis 
were increased compared to control cells (Armstrong and Jones, 2002).   
More recently, it has been shown that the use of BH3 mimetics, which inhibit the 
pro-survival functions of Bcl-2, affect mitochondrial function and GSH. For example, in 
HeLa cells overexpressing Bcl-2, ABT-737 BH3-mimetic treatment leads to an increase 
in caspase-dependent apoptosis and ROS production, with a decrease in cellular GSH 
content (Howard et al., 2009). Furthermore, our lab has shown that inhibition of Bcl-2 
using two distinct BH3 mimetics leads to mitochondrial oxidative stress, disruption of 
mitochondrial membrane potential, and displacement of GSH from mitochondria. Finally, 
Bcl-2 was shown to be a GSH binding protein, providing a unifying hypothesis for the 
antioxidant function of Bcl-2 and its effect on GSH metabolism in various systems 
(Zimmermann et al., 2007). 
Based on the lack of studies examining the regulation of mitochondrial GSH 
transport and its involvement in neuronal survival, the major aims of this thesis are to 
provide novel data in these areas. Here it is shown that Bcl-2 is a novel interacting 
partner for OGC and this interaction is dependent on GSH.  Furthermore, discrete 
inhibition of a mitochondrial GSH transporter (DIC) in primary neurons induces 
significant sensitization to both oxidative and nitrosative stress conditions. Conversely, 
stable overexpression of OGC induces specific increases in mitochondrial GSH and, 
strikingly, increased resistance to oxidative and nitrosative stress. Finally, increased 
mitochondrial GSH leads to an upregulation of Bcl-2 in stable OGC overexpressing cell 
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lines while knockdown of Bcl-2 decreases mitochondrial GSH levels and resensitizes 
these cells to oxidative stress. Therefore, Bcl-2 and OGC work in a synergistic manner in 
the transport of mitochondrial GSH in order to promote neuronal survival.    
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Figure 1.5 Overview of the effects of Bcl-2 on cellular GSH At the plasma membrane 
(PM) Bcl-2 inhibits methionine-dependent GSH efflux. Inhibition of Bcl-2 with HA14-1 
leads to mitochondrial GSH extrusion, while also inhibiting the binding of Bcl-2 to GSH. 
Bcl-2 redistribution to the nucleus increases nuclear GSH content. Bcl-2 constitutively 
activates NF-κB causing an increase in GCLC levels and thus de novo GSH synthesis.  
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CHAPTER TWO: BCL-2 IS A NOVEL INTERACTING PARTNER FOR THE 2-
OXOGLUTARATE CARRIER AND A KEY REGULATOR OF 
MITOCHONDRIAL GLUTATHIONE 
2.1 Abstract 
Despite making up only a minor fraction of the total cellular glutathione, recent 
studies indicate that the mitochondrial glutathione pool is essential for cell survival. 
Selective depletion of mitochondrial glutathione is sufficient to sensitize cells to 
mitochondrial oxidative stress (MOS) and intrinsic apoptosis. Glutathione is synthesized 
exclusively in the cytoplasm and must be actively transported into mitochondria. 
Therefore, regulation of mitochondrial glutathione transport is a key factor in maintaining 
the antioxidant status of mitochondria. Bcl-2 resides in the outer mitochondrial 
membrane where it acts as a central regulator of the intrinsic apoptotic cascade. In 
addition, Bcl-2 displays an antioxidant-like function that has been linked experimentally 
to the regulation of cellular glutathione content. We have previously demonstrated a 
novel interaction between recombinant Bcl-2 and reduced glutathione (GSH), which was 
antagonized by either Bcl-2 homology-3 domain (BH3) mimetics or a BH3-only protein, 
recombinant Bim. These previous findings prompted us to investigate if this novel Bcl-
2/GSH interaction might play a role in regulating mitochondrial glutathione transport. 
Incubation of primary cultures of cerebellar granule neurons (CGNs) with the BH3 
mimetic HA14-1 induced MOS and caused specific depletion of the mitochondrial 
glutathione pool. Bcl-2 was co-immunoprecipitated with GSH after chemical cross-
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linking in CGNs and this Bcl-2/GSH interaction was antagonized by preincubation with 
HA14-1. Moreover, both HA14-1 and recombinant Bim inhibited GSH transport into 
isolated rat brain mitochondria. To further investigate a possible link between Bcl-2 
function and mitochondrial glutathione transport, we next examined if Bcl-2 associated 
with the 2-oxoglutarate carrier (OGC), an inner mitochondrial membrane protein known 
to transport glutathione in liver and kidney. After co-transfection of CHO cells, Bcl-2 
was co-immunoprecipitated with OGC and this novel interaction was significantly 
enhanced by glutathione monoethyl ester. Similarly, recombinant Bcl-2 interacted with 
recombinant OGC in the presence of GSH. Bcl-2 and OGC co-transfection in CHO cells 
significantly increased the mitochondrial glutathione pool. Finally, the ability of Bcl-2 to 
protect CHO cells from apoptosis induced by hydrogen peroxide was significantly 
attenuated by the OGC inhibitor phenylsuccinate. These data suggest that GSH binding 
by Bcl-2 enhances its affinity for the OGC. Bcl-2 and OGC appear to act in a coordinated 
manner to increase the mitochondrial glutathione pool and enhance resistance of cells to 
oxidative stress. We conclude that regulation of mitochondrial glutathione transport is a 
principal mechanism by which Bcl-2 suppresses MOS. 
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2.2 Introduction 
 
Mitochondrial oxidative stress (MOS) plays a key role in the pathology 
underlying several neurodegenerative diseases, including amyotrophic lateral sclerosis 
(ALS), Parkinson’s disease, and Alzheimers disease (Lin and Beal, 2006). Accordingly, 
elucidating the pathways that regulate the mitochondrial oxidant/antioxidant balance is 
essential to develop novel therapeutics for neurodegeneration. Glutathione is an 
endogenous tripeptide antioxidant and a key player in averting MOS and evading 
apoptosis (reviewed in Franco and Cidlowski, 2009). It has been previously shown that 
selective depletion of mitochondrial glutathione sensitizes cells to oxidative or nitrosative 
stress (Muyderman et al., 2004; Muyderman et al., 2007). Moreover, glutathione 
depletion can induce apoptosis directly through opening of the mitochondrial 
permeability transition pore (Armstrong and Jones, 2002). In addition, γ-glutamylcysteine 
synthetase knockout mice, in which glutathione synthesis is inhibited and glutathione is 
depleted, display significant 
apoptotic cell death in multiple tissues (Dalton et al., 2004). These findings demonstrate 
that maintenance of cellular glutathione and, in particular, the mitochondrial glutathione 
pool is crucial for cell survival (Sims et al., 2004; Mari et al., 2009). Glutathione 
synthesis occurs exclusively in the cytosol because the enzymes required for its synthesis 
are absent within mitochondria (Griffith and Meister, 1985). Furthermore, glutathione has 
an overall negative charge at physiological pH and mitochondria exhibit a large negative 
membrane potential; consequently, glutathione transport into mitochondria cannot be 
explained by simple diffusion (Griffith and Meister, 1985; Lash 2006). Previously, two 
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inner mitochondrial membrane (IMM) anion carriers were identified in kidney and liver 
as glutathione transporters, the 2-oxoglutarate carrier (OGC; Slc25a11) and the 
dicarboxylate carrier (DIC; Slc25a10) (Chen and Lash, 1998; Chen et al., 2000; Coll et 
al., 2003; Zhong et al., 2008). Overexpression of either OGC or DIC in a rat renal 
proximal tubular cell line (NRK-52E cells) significantly enhanced mitochondrial 
glutathione transport and protected these cells from chemically induced apoptosis, such 
as that induced by tert-butylhydroperoxide (Lash et al., 2002; Xu et al., 2006). In the 
context of the CNS, few studies have examined the mechanisms responsible for 
mitochondrial glutathione transport. In one study, glutathione transport into isolated rat 
brain mitochondria seemed to be influenced most by inhibitors of the tricarboxylate 
carrier rather than OGC or DIC (Wadey et al., 2009). However, another study showed 
that an inhibitor of DIC, butylmalonate, significantly decreased the glutathione content of 
isolated mouse brain mitochondria, suggesting that DIC may be the major glutathione 
transporter in mouse cerebral cortical mitochondria (Kamga et al., 2010). The authors of 
this study also showed that both OGC and DIC are expressed in cortical neurons and 
astrocytes. These studies suggest that multiple IMM anion transporters might be involved 
in mitochondrial glutathione transport in the CNS. Yet, essentially nothing is known 
about how the function of these IMM glutathione transporters is regulated. Previous 
studies have shown that the antiapoptotic protein Bcl-2 displays an antioxidant-like effect 
in response to either exogenous oxidative stress or glutathione depletion (Hockenbery et 
al., 1993; Kane et al., 1993). Overexpression of Bcl-2 leads to an increase in the cellular 
content of glutathione (Ellerby et al., 1996; Voehringer and Meyn, 2000). In contrast, 
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Bcl-2 knockout mice show reduced glutathione levels and glutathione peroxidase activity 
in brain tissue and demonstrate enhanced susceptibility to MOS-induced neuronal cell 
death (Hochman et al., 1998). Thus, the antioxidant-like function of Bcl-2 depends, in 
large part, on its potential to regulate the cellular glutathione status. In this context, we 
have previously shown that recombinant Bcl-2 is capable of directly binding to GSH in 
vitro, an interaction that is antagonized by the Bcl-2 homology-3 domain (BH3) mimetics 
HA14-1 and compound 6, as well as the BH3-only protein, Bim (Zimmermann et al., 
2007). Interestingly, several BH3-only proteins are known to induce a pro-oxidant state at 
mitochondria, suggesting that disruption of this Bcl-2/GSH interaction might be an 
underlying factor in this effect (Ding et al., 2004; Liu et al., 2005). Collectively, these 
findings prompted us to hypothesize that Bcl-2 might be a key regulator of the 
mitochondrial glutathione pool. Here, we show that Bcl-2 interacts with GSH in intact 
primary cerebellar granule neurons (CGNs). As we have shown previously using 
recombinant proteins, this Bcl-2/GSH interaction is disrupted by the BH3 mimetic HA14-
1. Consistent with a central role for Bcl-2 in maintenance of the mitochondrial 
glutathione pool, both HA14-1 and Bim inhibited mitochondrial GSH transport. Most 
significantly, in cotransfected CHO cells, Bcl-2 coimmunoprecipitates with OGC and this 
novel interaction is markedly enhanced by glutathione monoethylester (GSH-MEE). 
Moreover, Bcl-2 and OGC coexpression significantly increases the mitochondrial 
glutathione pool. Finally, we show that the ability of Bcl-2 to protect cells from apoptosis 
induced by hydrogen peroxide depends on OGC activity. We conclude that Bcl-2 is a 
novel interacting partner for OGC and a central regulator of the mitochondrial glutathione 
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pool. This newly discovered property of Bcl-2 suggests a molecular mechanism by which 
Bcl-2 protects cells from oxidative injury. 
2.3 Materials and Methods 
2.3.1 Materials 
Ethacrynic Acid, Triton X-100, DTT, anti-tubulin antibody, DAPI, and 
phenylsuccinic acid were received from Sigma Aldrich (St. Louis, MO). HA14-1 was 
purchased from Alexis Biochemicals (Enzo Life Sciences, Plymouth Meeting, PA). 
Glutathione assay kit was obtained from Oxford Biomedical (Rochester Hills, MI). 
Mitochondrial Cytosolic fractionation kit was purchased from Biovision (Mountain 
View, CA). MDA assay kit was obtained from OxisResearch (Percipio Bioscience, Foster 
City, CA). Anti-Cox-IV was purchased from Cell Signalling (Beverly, MA). Glutathione 
monoethylester and rotenone were received from Calbiochem (San Diego, CA). Anti-V5 
antibody was purchased from Abcam (Cambridge, MA). Recombinant BimL was 
obtained from R&D systems (Minneapolis, MN). The anti-GSH antibody and protein 
A/G beads were received from Santa Cruz Biotechnology (Santa Cruz, CA). 
Disuccinimyidyl suberate (DSS) was purchased from Pierce Chemical (Rockford, IL). 
Lipofectamine 2000 was purchased from Invitrogen (Carlsbad, CA). Anti-Bcl-2 antibody 
was from BD Pharmigen (Franklin Lakes, NJ). Mouse TrueBlot® ULTRA Anti-Mouse 
Ig HRP secondary antibody was obtained from eBioscience (San Diego, CA). GST 
tagged Slc25a11 (GST-OGC) recombinant protein and Slc25a11 (OGC) antibody were 
purchased from Novus Biologicals (Littleton, CO). Recombinant Bcl-2 protein was 
obtained from Calbiochem (Darmstadt, Germany). Optimem media was purchased from 
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Gibco (Carlsbad, CA). Maxiprep Kit was obtained from Qiagen (Valencia, CA). Anti-
active caspase-3 was purchased from Promega (Madison, WI). Fitc secondary antibody 
for immunohistochemistry was from Jackson ImmunoResearch Inc (West Grove, PA). 
ECL, Percoll, and secondary antibodies for immunoblotting were purchased from GE 
Life Sciences (Piscataway, NJ). V5-OGC plasmid was a generous gift from Dr. Lash, 
Wayne State University (Detriot, MI). The Bcl-2 plasmid was a generous gift from Dr. 
Hardwick, Johns Hopkins University (Baltimore, MD). 
2.3.2 Cerebellar Granule Neuron (CGN) Culture 
CGNs were isolated from P7 Sprague Dawley rat pups and cultured as previously 
described (Zimmerman et al., 2007). All animal manipulations were performed in 
accordance with and under approval of the University of Denver Institutional Animal 
Care and Use Committee. 
2.3.3 Immunohistochemistry 
CGNs or CHOs were transfected and/or treated as described under the Figure 
Legends section and fixed with 4% paraformaldehyde. Next, cells were blocked and 
permeabilized in PBS, pH 7.4 with 5% BSA and 0.2% Triton X-100 for 1 h, followed by 
incubation with the primary antibody overnight at 4°C diluted in 0.2% Triton X-100 and 
2% BSA in PBS. After which, the primary antibody was removed and cells were washed 
5X with PBS over 30 min. Next, the cells were incubated with secondary antibody and 
DAPI for 1 h at room temperature, diluted in 0.2% Triton X-100 and 2% BSA in PBS. 
Cells were washed 5X with PBS over 30 min, and placed in anti-quench. Images were 
captured using a Zeiss Axioplan 2 fluorescence microscope equipped with a Cooke 
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Sensicam CCD camera and Slidebook Image analysis software (Intelligent Imaging 
Innovations, Inc Denver, CO). 
2.3.4 CHO cell culture 
K1-CHO (Chinese Hamster Ovary) cells were plated on 35-mm diameter plastic 
dishes in Ham’s F12 media containing 10% fetal bovine serum, 2 mM L-glutamine and 
(100 U/mL/100 μg/mL) penicillin/streptomycin. Cells were cultured overnight at 37°C in 
10% CO2. The following day cells were prepared for transfection or treatment, at which 
point cultures were 60–80% confluent. 
2.3.5 Plasmid Preparation 
DsRed2, Bcl-2, and V5-OGC plasmids were transformed using 50 ng of plasmid 
in JM109 Escherichia coli (E. Coli) cells, and grown on LB agar plates containing 35 
μg/mL kanamycin sulfate or 100 μg/mL ampilicillin sodium salt at 37°C overnight. 
Starter cultures were grown in LB broth with 35 μg/mL kanamycin sulfate or 100 μg/mL 
ampilicillin sodium salt for 8 h at 37°C, and diluted 1:250 into overnight cultures, for 
plasmid purification using the Qiagen Maxi Prep Kit (Valencia, CA). DNA 
concentrations were determined using a ThermoScientific NanoDrop 2000. 
2.3.6 Transfection 
DsRed2 (Con), Bcl-2, or V5-OGC were used at a concentration of 5 μg/mL. 
Plasmids were transfected using a standard Lipofectamine 2000 protocol. CHO cells 
cultures were incubated with the plasmid/Lipofectamine 2000 mixture in Opti-MEM, for 
6 h at 37°C and 10% CO2. Transfection media was removed and cell cultures were placed 
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in 1 mL of Ham’s F12 media and incubated overnight at 37°C and 10% CO2. Indicated 
treatments were administered 24 h post-transfection. 
2.3.7 Mitochondrial/Cytosolic Fractionation 
Cells were treated as indicated in the “Results” or “Figure Legend” sections after 
which the media was aspirated and cells were washed 1X in ice cold PBS, pH 7.4. 200 
μL of cytosolic buffer (provided in the kit, diluted 1:5 in ddH2O, with added protease 
inhibitor cocktail and 1mM DTT as per the manufacturer’s recommendations) was added 
to the cells and allowed to incubate on ice for 20 min. Cells were scraped and harvested, 
then homogenized with 40 passes of a dounce homogenizer. Samples were spun down at 
720 rcf for 10 min at 4°C. The supernatant from each sample was transferred to a new 
tube labeled mitochondrial fraction and spun at 10,000 rcf for 30 min at 4°C. The 
supernatant was then transferred to a new tube labeled cytosolic fraction and the pellet in 
the mitochondrial fraction tube was resuspended in 150 μL mitochondrial buffer 
(provided in the kit, with added protease inhibitor cocktail and 1mM DTT as per the 
manufacturer’s recommendations). Samples were measured for glutathione content as 
described below. 
2.3.8 Glutathione Assay 
Total Glutathione (GSH+GSSG) was measured using an assay kit (DTNB) from 
Oxford Biomedical, following the manufacturer’s protocol. All glutathione measurements 
were normalized to protein concentration. 
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2.3.9 MDA Assay 
MDA was measured using an MDA assay kit from OxisResearch, following the 
manufacturer’s protocol. All MDA measurements were normalized to protein 
concentration. 
2.3.10 Immunoblot analysis 
Immunoblot analysis was completed as previously described in (Zimmermann et 
al., 2007). 
2.3.11 GSH Transport Assay 
GSH transport into isolated mitochondria was measured as previously published 
(Zimmermann et al., 2007). 20 μL of rat brain mitochondria were added to 230 μL of 
GSH transport buffer (5 mM HEPES, pH 7.2, 220 mM mannitol, 70 mM sucrose, 0.1 
mM EDTA, 0.1% BSA (fatty acid-free), 5 mM succinate, and 1 mM potassium 
phosphate) at room temperature. The isolated mitochondria were then preincubated for 20 
min with either 0.5 μL Me2SO (vehicle, Con), 20 μM HA14-1 (HA14), or 2 μM 
recombinant Bim (Bim). A trace amount (0.5 μCi) of radiolabeled [3H]GSH in buffer 
containing unlabeled (cold) GSH at a final concentration of 50 μM was then added to the 
isolated mitochondria, vortexed and incubated for 15 sec at room temperature. 1 mL 
volume of ice-cold transport buffer was then added to each tube, and the samples were 
pelleted and washed 2X with 500 μL ice-cold buffer, and then 100 μL of 1N NaOH was 
added to dissolve the final pellets. [
3
H]GSH uptake into the isolated mitochondria was 
counted by liquid scintillation. The data were calculated as percentages of [
3
H]GSH 
uptake relative to Con. 
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2.3.12 Isolation and treatment of rat brain mitochondria 
Mitochondria were isolated as previously described in (Zimmermann et al., 2007). 
Mitochondria were treated as follows; for 4 h GSH-MEE Co-incubation, mitochondria 
were incubated with 2 mM GSH-MEE in combination with either vehicle (Con), 20 μM 
HA14-1, or 10 μM rotenone for 4 h 37°C, 300 rpm. For the 2 h GSH-MEE pre-load/2 h 
wash out, mitochondria were pre-incubated with 2 mM GSH-MEE for 2 h, 37°C, 300 
rpm, washed 2X with mitochondrial isolation buffer, and then incubated with either 
vehicle (Con), 20 μM HA14-1, or 10 μM rotenone for 2 h, 37°C, 300 rpm. All described 
treatments were completed in mitochondrial isolation buffer; 0.64 M sucrose, 2mM 
EDTA, and 20mM Tris-HCl, pH 7.4. The isolated mitochondria were then washed 3X in 
mitochondrial isolation buffer and assayed for glutathione content (described above). 
2.3.13 Immunoprecipitation 
CHO cells transfected with Bcl-2 and V5-OGC (5 μg each) were treated with 
either vehicle or 2 mM GSH-MEE for 4 h, 37°C, 10% CO2 and lysed with 0.1% Triton 
X-100/Wahl buffer as described previously (Zimmermann et al., 2007), containing either 
1 mM DTT or 2 mM GSH-MEE. Lysates were then immunoprecipitated using a 
monoclonal V5 antibody in 0.1% Triton X-100/Wahl buffer containing either 1 mM DTT 
or 2 mM GSH-MEE overnight, 4°C, mixing by inversion. Next, 50 μL or protein A/G 
agarose beads were incubated with the samples for 4 h, 4°C, mixing by inversion. 
Immune complexes were washed 3X and resolved by SDS-PAGE as previously 
described (Zimmermann et al., 2007). Whole cell lysates contained 200 μg of protein. 
Immunoblot analysis was completed for Bcl-2 (using Mouse TrueBlot® ULTRA Anti-
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Mouse Ig HRP secondary antibody to eliminate the light chain) and V5. Primary CGNs 
were pre-incubated with 20 μM HA14-1 or vehicle (0.4%DMSO) for 2 h, 37°C, 10% 
CO2 and samples were cross-linked with 500 μM DSS for 30 min, 37°C, 10% CO2. 
CGNs were lysed in 1% Triton X-100/Wahl buffer with 50 mM glycine (to quench the 
cross-link), after which lysates were immunoprecipitated using a monoclonal GSH 
antibody and Protein A/G agarose beads as described above, and subjected to SDS-PAGE 
as described previously (Zimmermann et al., 2007). Recombinant immunoprecipitation 
experiments were performed using 50 ng of both recombinant Bcl-2 and recombinant 
GST-OGC, incubated in 0.1% Triton/Wahl buffer with 10 μM GSH overnight in the 
presence of either a monoclonal Bcl-2 antibody or a monoclonal Slc25a11 (OGC) 
antibody. Samples were immunoprecipitated as described above and subjected to SDS-
PAGE as described previously (Zimmermann et al., 2007). Total samples contained 50 
ng of both Bcl-2 and GST-OGC recombinant proteins. 
2.4 Results 
2.4.1 The BH3 mimetic, HA14-1, induces MOS and apoptosis of CGNs 
Consistent with our previous observations (Zimmermann et al., 2005; 
Zimmermann et al., 2007), incubation of CGNs with the BH3 mimetic, HA14-1, induced 
an increase in active caspase-3, degradation of the microtubule network, and nuclear 
fragmentation indicative of apoptosis (Figure 2.1.A). Exposure of CGNs to HA14-1 
significantly increased the concentration of malondialdehyde (MDA) in mitochondrial 
fractions, demonstrating an induction of MOS (Figure 2.1.B). 
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Figure 2.1 The BH3 mimetic, HA14-1, induces mitochondrial oxidative stress and 
apoptosis of CGNs A. CGNs were treated for 24 h with either HA14-1 (HA14; 15 μM) or 
vehicle, control (Con, 0.3% DMSO). Top panels: Fitc, tubulin; DAPI, nuclei; Cy3, active 
caspase-3. Arrows indicate apoptotic cells with either condensed/fragmented nuclei, or 
immunoreactivity for active caspse-3. Bottom panels: decolorized DAPI images to show 
nuclear morphology. B. CGNs were treated with either vehicle (Con) or HA14-1 (HA14; 
20 μM) for 4 h and then fractionated into cytosolic and mitochondrial fractions. 
Mitochondrial fractions were then measured for MDA concentration, or lipid 
peroxidation levels. Data are shown as μ moles of MDA present per μg of protein and 
analyzed using a Student’s T-test, ***p<0.001, n=4. 
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2.4.2 HA14-1 selectively depletes the mitochondrial glutathione pool in CGNs 
We have previously shown that CGN apoptosis induced by HA14-1 is prevented 
by glutathione (Zimmermann et al., 2005; Zimmermann et al., 2007). Therefore, we 
measured mitochondrial and cytosolic pools of total glutathione in CGNs incubated in the 
absence and presence of HA14-1. CGNs treated with HA14-1 for 4 h displayed selective 
depletion of total mitochondrial glutathione to approximately 50% of the control level 
(Figure 2.2.A). In contrast, CGNs incubated with ethacrynic acid, a compound that forms 
nonfunctional adducts with GSH, showed significant depletion of both the mitochondrial 
and cytosolic pools of glutathione (Figure 2.2.A). Cox-IV blots were performed to 
demonstrate pure fractionation of mitochondria and cytoplasm (Figure 2.2.B). The 
fraction of total cellular glutathione made up by mitochondrial (~10%) versus cytosolic 
(~90%) pools were consistent with previous studies (Figure 2.2.C). In addition, control 
levels of total mitochondrial glutathione were an average of 6.78 +/− 0.33 nmoles/mg of 
protein (n=4) and these results are consistent with previous studies (Ravindranath et al., 
1989; Sagara et al., 1993; Huang and Philbert, 1995). 
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Figure 2.2 HA14-1 selectively depletes mitochondrial glutathione in CGNs A. CGNs 
treated with either vehicle (Con), HA14-1 (HA14; 20 μM), or ethacrynic acid (EA; 100 
μM) for 4 h and then separated into mitochondrial and cytosolic fractions. Total 
glutathione content of each fraction was measured using a DTNB colorimetric assay. 
Data are shown as percent of control glutathione (GSH+GSSG) and analyzed using one-
way ANOVA with a post-hoc Tukey’s analysis. *p<0.05, **p<0.01 vs Con, n=4. Control 
levels of total mitochondrial glutathione were an average of 6.78 +/− 0.33 nmoles per mg 
of protein. B. Immunoblot shown is for Cox-IV to demonstrate the purity of the 
mitochondrial and cytosolic fractions in (A). C. Graph showing the representative pools 
of cellular glutathione between mitochondrial and cytosolic fractions, n=4. 
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2.4.3 Bcl-2 co-immunoprecipitates with GSH following chemical cross-linking in 
CGNs; an interaction antagonized by the BH3 mimetic, HA14-1 
We have previously shown that recombinant Bcl-2 directly interacts with GSH in 
vitro (Zimmermann et al., 2007). To determine if Bcl-2 interacts with GSH in intact cells 
we utilized a chemical cross-linking approach and measured the co-immunoprecipitation 
of Bcl-2 with GSH from CGNs. Cultured CGNs were cross-linked using DSS 
(disuccinimidyl suberate; a cell permeable, homobifunctional cross-linker possessing two 
amine-reactive N-hydroxysuccinimide esters), and upon quenching the cross-link with 
excess glycine, Bcl-2 was co-immunoprecipitated with GSH using a GSH antibody 
(Figure 2.3). In CGNs pre-incubated with DMSO vehicle and then cross-linked and 
immunoprecipitated with a GSH antibody, both monomeric and dimeric forms of Bcl-2 
were co-immunoprecipitated with GSH. However, pre-treatment of the CGNs, prior to 
cross-linking, with HA14-1 significantly decreased the amount of both the monomeric 
and dimeric forms of Bcl-2 co-immunoprecipitated with GSH. These data strongly 
suggest that Bcl-2 and GSH interact in intact CGNs, and this interaction can be 
antagonized by the BH3 mimetic, HA14-1. Furthermore, we completed similar 
experiments in isolated rat brain mitochondria and found that HA14-1 also antagonized 
the interaction between Bcl-2 and GSH (data not shown). These findings are consistent 
with our previously published data in which we showed that recombinant Bcl-2 and GSH 
interact in a direct manner. Moreover, this interaction shows specificity between Bcl-2 
and GSH, since other Bcl-2 family proteins, such as Bcl-xL and Bcl-w, did not interact 
directly with GSH (Zimmermann et al., 2007). 
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Figure 2.3 Bcl-2 co-immunoprecipitates with GSH following chemical cross-linking in 
CGNs, an interaction antagonized by the BH3 mimetic HA14-1 CGNs were pre-incubated 
with either vehicle (0.4% DMSO) or 20 μM HA14-1 for 2 h, after which they were cross-
linked (x-link) with DSS, which was quenched upon lysing (see materials and methods). 
Lysates were immunoprecipitated (IP) with a monoclonal antibody to GSH. Immune 
complexes were resolved by SDS-PAGE and immunoblotted (IB) for Bcl-2. 
Mono=monomeric, dimer=dimeric, WCL=whole cell lysate. 
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2.4.4 HA14-1 depletes glutathione from isolated mitochondria. HA14-1 and Bim 
inhibit mitochondrial GSH transport in vitro 
We examined the effects of HA14-1 on glutathione pools in isolated rat brain 
mitochondria. Incubation of isolated mitochondria with HA14-1 induced a significant 
depletion of total glutathione (GSH+GSSG) when mitochondria were co-incubated in the 
presence of GSH-MEE (Figure 2.4.A, n=3, **p<0.01 vs. Con) for 4h. HA14-1 has 
previously been shown to have some uncoupling and inhibitory effects on mitochondrial 
respiration at high concentrations (Milanesi et al., 2006). To exclude the possibility that 
HA14-1 (used at 20 μM) was depleting glutathione in isolated rat brain mitochondria by 
inhibiting mitochondrial respiration, and in turn inducing oxidative stress, we compared 
its effects to those of the complex I inhibitor, rotenone, which we used at a concentration 
significantly higher than its previously shown IC50 value for complex I (Chen et al., 2006; 
Janssen et al., 2007). While HA14-1 (20 μM) significantly depleted total mitochondrial 
glutathione content, rotenone (10 μM) had no such effect (Figure 2.4.A). In another series 
of experiments, we pre-loaded isolated mitochondria with 2 mM GSH-MEE for 2 h and 
then washed the mitochondria prior to adding HA14-1 or rotenone for an additional 2 h. 
Following the 2 h pre-incubation with GSH-MEE, mitochondrial glutathione content was 
increased by approximately 250% over non-loaded controls (data not shown). Incubation 
with HA14-1 induced a marked reduction of total glutathione in the pre-loaded 
mitochondria, suggesting that the Bcl-2 inhibitor actually stimulated glutathione efflux 
(Figure 2.4.B, n=6, *p<0.05 vs. Con). In contrast, incubation with rotenone had no effect 
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on mitochondria pre-loaded with GSH-MEE. We compared the amount of total 
glutathione in freshly isolated mitochondria versus the Con samples in the treatment 
paradigms of Figures 2.4.A and 2.4.B; no differences in the levels of total glutathione 
were observed (an average of 17.84 +/− 1.69 nmoles/mg, n=3, data not shown). Finally, 
we assessed the effects of HA14-1 or recombinant Bim on the transport of [
3
H]GSH into 
isolated mitochondria. Both Bcl-2 inhibitors, HA14-1 (20μM) or Bim (2μM), 
significantly inhibited GSH uptake into mitochondria (Figure 2.4.C, #p<0.01 vs Con and 
*p<0.05 vs Con, n=3). These data show that HA14-1 and Bim suppress mitochondrial 
GSH transport and that HA14-1 is capable of inducing efflux of glutathione from isolated 
mitochondria. 
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Figure 2.4 HA14-1 depletes glutathione from isolated rat brain mitochondria, in addition 
HA14-1 and Bim inhibit mitochondrial GSH transport A. Isolated rat brain mitochondria 
were incubated in mitochondrial buffer with a combination of 2 mM GSH-MEE and 
either vehicle (Con), HA14-1 (20 μM), or rotenone (10 μM) for 4 h. Samples were then 
washed 3X in mitochondrial buffer and assayed for glutathione (GSH+GSSG) content. 
Data are shown as percent of control glutathione (GSH+GSSG) and analyzed using a 
one-way ANOVA with a post-hoc Tukey’s analysis. ** p<0.01 vs Con, n=3. B. Isolated 
rat brain mitochondria were incubated in mitochondrial buffer with GSH-MEE (2 mM) 
for 2 h at 37°C, washed 2X, and then incubated in mitochondrial buffer with either Con, 
HA14-1 (HA14; 20 μM), or rotenone (10 μM) for 2h at 37°C. After which samples were 
washed 3X with mitochondrial buffer and assayed for glutathione (GSH+GSSG) content 
using a DTNB colorimetric assay, data are normalized to protein concentration. Two 
controls are shown because some of the experiments performed with HA14-1 were 
carried out separately from several of the experiments performed with rotenone. Data are 
represented as percent of the respective control glutathione (GSH/GSSG) and analyzed 
using a Student’s T-test. *p<0.05 vs Con, n=6. Control total mitochondrial glutathione 
levels for the isolated rat brain mitochondria experiments were an average of 17.84 +/− 
1.69 nmoles/mg of protein. C. Isolated rat brain mitochondria were incubated with either 
vehicle (Con; 0.4%DMSO), HA14-1 (HA14; 20 μM) or Bim (2 μM) for 20 min and then 
0.5μ Ci of [3H]GSH for 15 sec at room temperature. [3H]GSH was measured as described 
under Materials and Methods. Data are represented as percent of Con (CPM values) and 
analyzed using a one-way ANOVA with post-hoc Tukey’s analysis. **p<0.01 vs Con, 
*p<0.05 vs Con, n=3 experiments completed in triplicate. I acknowledge Kristin 
Marquardt for assistance in generating the data for this figure.  
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2.4.5 Bcl-2 co-immunoprecipitates with OGC and this interaction is enhanced by 
GSH-MEE 
HA14-1, a BH3 mimetic that binds Bcl-2 within the hydrophobic groove, 
selectively depletes mitochondrial glutathione and antagonizes the interaction between 
Bcl-2 and GSH in CGNs, and inhibits GSH uptake/stimulates glutathione efflux in 
isolated brain mitochondria. These data suggest a possible role for Bcl-2 in regulating 
mitochondrial glutathione transport. It has been previously shown that the IMM anion 
transporters OGC and DIC are responsible for glutathione transport across the inner 
mitochondrial membrane into the matrix in liver and kidney (Chen and Lash, 1998; Chen 
et al., 2000). Therefore, we next examined the potential of Bcl-2 to interact with the OGC 
in a transient co-transfection system. CHO cells overexpressing Bcl-2 and a V5-tagged 
OGC were lysed in 0.1% Triton X-100 with 1 mM DTT, and immunoprecipitated with or 
without a V5 antibody. Bcl-2 co-immunoprecipitated with V5-OGC upon addition of the 
V5 antibody but did not precipitate in the presence of protein A/G agarose beads alone 
(Figure 2.5.A). Next, we determined the effects of GSH-MEE on the interaction of Bcl-2 
with OGC. CHO cells overexpressing Bcl-2 and V5-OGC were treated with 2 mM GSH-
MEE for 4 h, and cells were lysed and immunoprecipitated in buffer also containing 2 
mM GSH-MEE. In control conditions, CHO cells overexpressing Bcl-2 and V5-OGC 
were untreated, lysed, and immunoprecipitated in buffer containing 1 mM DTT. The 
relative amount of Bcl-2 co-immunoprecipitated with V5-OGC was appreciably 
increased in the presence of GSH-MEE versus DTT (Figure 2.5.B). Densitometric 
analysis using normalization of the Bcl-2 band intensity to the V5-OGC band intensity 
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revealed a significant increase (approximately five-fold) in Bcl-2 co-immunoprecipitation 
with V5-OGC in the presence of GSH-MEE versus DTT (Figure 2.5.C, n=9, p<0.05 vs. 
DTT). GSH-MEE enhanced the interaction between Bcl-2 and OGC irrespective of the 
time in which it was added into the experiment, such as treating the cells only or simply 
adding GSH-MEE to the immunoprecipitation buffer (data not shown). Moreover, in a 
cell free system, recombinant Bcl-2 also interacted directly with recombinant GST-
tagged OGC in the presence of GSH (Figure 2.5.D). Both recombinant Bcl-2 and 
recombinant GST-OGC co-immunoprecipitated with a Bcl-2 antibody and a Slc25a11 
(OGC) antibody (Figure 2.5.D). Finally, upon the addition of ethacrynic acid to the 
immunoprecipitation buffer (which already contained GSH therefore ethacrynic acid was 
used to deplete the GSH), the interaction between recombinant OGC and recombinant 
Bcl-2 was antagonized (Figure 2.5.E). These results indicate that Bcl-2 is an interacting 
partner for OGC and this novel protein-protein interaction is enhanced by GSH. 
 
 
 
 
 
 
 
 
 
 60 
 
 
 
Figure 2.5 Bcl-2 co-immunoprecipitates with V5-OGC from co-transfected CHO cells, 
GSH-MEE enhances the interaction A. CHO cells were co-transfected with Bcl-2 and 
V5-OGC (5μg each) lysed in Wahl buffer containing 0.1% TritonX-100 and 1 mM DTT, 
and immunoprecipitated (IP) with a monoclonal V5 antibody. Immune complexes were 
then resolved by SDS-PAGE, immunoblotted for V5 and Bcl-2. WCL= Whole cell 
lysate, IP =immunoprecipitate, −V5 antibody=Protein A/G agarose alone was used in the 
IP. B. Same as in (A), except at 24 h post-transfection cells were treated with 2 mM 
GSH-MEE for 4 h (and GSH-MEE was added to the IP buffer). Alternatively, 1 mM 
DTT was added to the IP buffer. C. Densitometry comparing pixel density of co-
immunoprecipitated Bcl-2 with V5-OGC in the presence of either 1 mM DTT (Con) or 2 
mM GSH-MEE. Data are normalized to the amount of V5 immunoprecipitated and are 
expressed as a percent of Bcl-2 immunoprecipitated in the presence of DTT (Con). Data 
was analyzed using a Student’s T-test, *p<0.05, n=9. D. Recombinant Bcl-2 and 
recombinant GST-OGC were co-immunoprecipitated with either anti-Bcl-2 (Bcl-2 IP) or 
anti-Slc25a11 (OGC IP) in 0.1% Triton X-100/Wahl buffer with 11.1 μM GSH. Immune 
complexes were resolved by SDS-PAGE, immunoblotted for Bcl-2 and Slc25a11 (OGC). 
E. Recombinant Bcl-2 and recombinant GST-OGC were co-immunoprecipitated with 
anti-Bcl-2 in either 0.1% Triton X-100/Wahl buffer with 10 μM GSH (−EA) or 0.1% 
Triton X-100/Wahl buffer with 10 μM GSH and 100 μM ethacrynic acid (+EA). Immune 
complexes were resolved by SDS-PAGE, immunblotted for Bcl-2 and Slc25a11 (OGC). 
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2.4.6 Co-expression of Bcl-2 and OGC increases mitochondrial glutathione 
We next examined the effects of Bcl-2 and OGC expression on mitochondrial 
glutathione content. Here, we utilized CHO cells expressing DsRed-2 (Con), Bcl-2, V5-
OGC, or a combination of Bcl-2 and V5-OGC. At 24 h post-transfection, cells were lysed 
and mitochondrial and cytosolic fractions were obtained by differential centrifugation and 
measured for total glutathione content. Control, Bcl-2, and OGC expressing CHO cells 
showed similar mitochondrial glutathione content (Figure 2.6.A). However, with the co-
expression of both Bcl-2 and OGC, total mitochondrial glutathione was significantly 
increased compared to Bcl-2 expression alone (Figure 2.6.A, n=3, *p<0.05 vs. Bcl-
2/OGC). Immunoblot analysis confirmed the expression of Bcl-2 and OGC in the 
appropriate mitochondrial fractions (Figure 2.6.B), and a Cox-IV blot demonstrated the 
relative purity of the mitochondrial fractions (Figure 2.6.C). Control levels of total 
mitochondrial glutathione were an average of 12.69 +/− 1.81 nmoles/mg of protein. 
These data suggest that Bcl-2 and OGC work in a concerted manner to increase the 
mitochondrial glutathione pool. 
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Figure 2.6 Co-transfection with Bcl-2 and V5-OGC significantly increases mitochondrial 
glutathione content A. CHO cells were transfected with control (DsRed), Bcl-2, V5-
OGC, or a combination of Bcl-2 and V5-OGC (5μg each). After 24 h, cells were 
fractionated and mitochondrial glutathione (GSH+GSSG) content was measured using 
DTNB, and normalized to protein concentration. Data are expressed as percent of control 
glutathione and analyzed using a one-way ANOVA with a post-hoc Tukey’s analysis 
*p<0.05 vs Bcl-2/OGC, n=3. Control levels of total mitochondrial GSH were at an 
average of 12.69 +/− 1.81 nmoles/mg of protein. B. Immunoblots of mitochondrial 
fractions indicating expression of Bcl-2, V5-OGC, or a combination of both in 
transfected CHO cells. C. Immunoblot for Cox-IV indicating purity of mitochondrial and 
cytosolic fractions. 
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2.4.7 Bcl-2 protection from hydrogen peroxide toxicity is dependent on the 
function of OGC 
Finally, we examined the consequences of increasing the mitochondrial 
glutathione pool via co-expression of Bcl-2 and OGC in transiently transfected CHO 
cells. In agreement with many previous studies (Hockenbery et al., 1993; Satoh et al., 
1996; Papdopoulous et al., 1998), overexpression of Bcl-2 alone significantly protected 
CHO cells from hydrogen peroxide-induced apoptosis as assessed by measuring the 
percentage of adherent cells expressing active caspase-3 (Figure 2.7.A, n=4, *p<0.05 vs 
Con+H2O2, **p<0.01 vs Con+H2O2). In a similar manner, expression of either OGC 
alone or OGC in combination with Bcl-2 also significantly protected cells from hydrogen 
peroxide. Interestingly, co-incubation of CHO cells with the OGC inhibitor, 
phenylsuccinate (PhS), at a concentration (500 μM) which was titrated down to a 
maximally non-cytotoxic level, did not significantly enhance the active caspase-3 
staining either on its own or in combination with the hydrogen peroxide exposure (Figure 
2.7.B). Overexpression of OGC, in either the absence or presence of Bcl-2, maintained its 
protective effect against hydrogen peroxide even in the presence of this low dose of PhS 
(Figure 2.7.C, n=4, *p<0.05 vs Con+PhS and H2O2, #p<0.01 vs Bcl-2+PhS and H2O2). 
These results are consistent with the low dose of PhS being sufficient to only inhibit the 
transport capabilities of the endogenous OGC within CHO cells. In marked contrast to 
the effects observed with OGC, Bcl-2 appeared to lose its protective effect against 
hydrogen peroxide when the endogenous levels of OGC within CHO cells were 
simultaneously inhibited by PhS. This point is demonstrated by the findings that Bcl-2 
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alone was ineffective at attenuating caspase-3 activation in CHO cells treated 
concomitantly with PhS and hydrogen peroxide (Figure 2.7.C). These results suggest that 
Bcl-2 protects cells from hydrogen peroxide-induced apoptosis via an OGC-dependent 
mechanism (i.e., via an increase in mitochondrial glutathione transport resulting in an 
enhancement of the mitochondrial glutathione pool). 
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Figure 2.7 Bcl-2 protection against H2O2-induced apoptosis is OGC-dependent A. CHO 
cells transfected with DsRed, Bcl-2, V5-OGC, or a combination of Bcl-2 and V5-OGC 
were treated with 100 μM H2O2 for 24 h and stained for active caspase-3. Data are 
represented as mean +/− SEM. Data were analyzed using a one-way ANOVA with a 
post-hoc Tukey’s analysis. *p<0.05 vs Con+H2O2, **p<0.01 vs Con+H2O2, *** p<0.001 
vs Con+H2O2, and #p<0.001 vs Con, n=4. B. CHO cells transfected as in (A) and treated 
with either vehicle, 100 μM H2O2 for 24 h alone or in combination with 500 μM 
phenylsuccinate (PhS), or 500 μM phenylsuccinate (PhS) alone for 24 h and stained for 
active caspase- 3. NS=not significant, data are represented as mean +/− SEM and 
analyzed using a Student’s T-test. C. CHO cells transfected as in (A), treated with a 
combination of 100 μM H2O2 and 500 μM phenylsuccinate (PhS) for 24 h and stained for 
active caspase- 3. Data are represented as mean +/− SEM. Data were analyzed using a 
one-way ANOVA with a post-hoc Tukey’s analysis. *p<0.05 vs Con+PhS and H2O2 and 
**p<0.01 vs Con+PhS and H2O2, n=4. 
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2.5 Discussion 
Bcl-2 is a key sentinel of the mitochondria that acts to suppress the intrinsic 
apoptotic cascade via its inhibitory interactions with pro-apoptotic family members 
(Chipuk et al., 2008). Beyond its classical anti-apoptotic role, Bcl-2 is also known to have 
a critical antioxidant-like function (Hockenbery et al., 1993). This antioxidant-like 
property has been linked experimentally to the regulation of cellular glutathione content 
(reviewed in Voehringer, 1999). For example, overexpression of Bcl-2 increases cellular 
glutathione via an enhancement of glutathione synthesis and a diminution of cellular 
glutathione efflux (Ellerby et al., 1996, Meredith et al., 1998; Jang et al., 2004). 
Accordingly, overexpression of Bcl-2 protects cells from oxidative stress induced by 
glutathione depleting agents (Kane et al., 1993; Merad-Saïdoune et al., 1999; Rimpler et 
al., 1999). Furthermore, the protective effects of Bcl-2 against oxidative damage are 
significantly diminished by depriving cells of glutathione precursors, for instance through 
incubation in cysteine/methionine-deficient media (Mirkovic et al., 1997). Finally, Bcl-2 
null mice show altered antioxidant enzyme activities in brain, such as decreased 
glutathione peroxidase activity, and demonstrate increased sensitivity to neural oxidative 
injury (Hochman et al., 1998). Many studies have provided evidence of a connection 
between cellular glutathione status and the antioxidant-like action of Bcl-2. However, the 
specific molecular mechanism(s) underlying this relationship between Bcl-2 and 
glutathione has not yet been elucidated. 
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Previously, a novel interaction between recombinant Bcl-2 and GSH in a cell-free 
assay was demonstrated (Zimmermann et al., 2007). We showed that two dissimilarly 
structured BH3 mimetics predicted to bind in the hydrophobic surface groove (i.e., the 
BH3 groove) of Bcl-2, HA14-1 and compound 6, each antagonized this novel Bcl-2/GSH 
interaction, as did recombinant Bim (Zimmermann et al., 2007) . From these previous 
data, we concluded that Bcl-2 is a de facto GSH-binding protein and we hypothesized 
that this newly discovered property of Bcl-2 might play a central role in its antioxidant-
like function at mitochondria. Consistent with our hypothesis, we report here that HA14-
1 induces a specific depletion of the mitochondrial glutathione pool in CGNs and this 
BH3 mimetic inhibits the Bcl-2/GSH interaction in intact CGNs. In addition, HA14-1 and 
Bim inhibit the mitochondrial uptake of [
3
H]GSH and HA14-1 induces glutathione efflux 
in isolated rat brain mitochondria. Importantly none of these results are observed in 
isolated mitochondria incubated with the complex I inhibitor, rotenone, demonstrating 
that the effects of HA14-1 on mitochondrial glutathione transport are independent of any 
inhibitory actions on the mitochondrial respiratory machinery. 
To further establish a link between Bcl-2 function and mitochondrial glutathione 
transport, we used a transient co-transfection system in CHO cells to demonstrate a novel 
interaction between Bcl-2 and the IMM glutathione transporter, OGC. Significantly, this 
unique protein-protein interaction is markedly enhanced by GSH-MEE. We also show the 
interaction between OGC and Bcl-2 is direct through the use of recombinant proteins in 
an immunoprecipitation and this interaction is dependent on glutathione because the 
 68 
 
addition of ethacrynic acid (which binds to GSH and forms non-functional adducts) 
significantly abolished the ability of OGC and Bcl-2 to bind. Additional experiments 
using co-transfected CHO cells reveal that Bcl-2 and OGC work in conjunction to 
significantly increase the mitochondrial glutathione pool. Finally, we demonstrate that the 
ability of Bcl-2 to protect cells from oxidative stress is largely dependent on an intact 
transporter function of OGC because phenylsuccinate (an OGC inhibitor) abolishes the 
protective effect of Bcl-2 against hydrogen peroxide-induced apoptosis in CHO cells. 
Based on our current and previously published data, we propose the following 
model to explain how Bcl-2 acts as a central regulator of the mitochondrial glutathione 
pool. Under normal circumstances, OGC functions as an IMM glutathione transporter 
that helps to maintain an adequate mitochondrial glutathione pool. We suggest that Bcl-2 
localized to the outer mitochondrial membrane acts as a “sensor” of cytoplasmic 
glutathione content, and upon GSH-binding, a conformational change is induced within 
Bcl-2 that increases its affinity for OGC. The Bcl-2/OGC interaction in turn, enhances 
the mitochondrial glutathione transporter function of OGC to increase the mitochondrial 
glutathione pool. In this manner, an increase in cytoplasmic glutathione content, which 
may occur via either enhanced synthesis or reduced efflux (Meredith et al., 1998; Jang et 
al., 2004), may be transduced into the mitochondria to induce a corresponding elevation 
in mitochondrial glutathione content. However, when HA14-1 or Bim binds to Bcl-2 
within the BH3 groove, this antagonizes (either directly or allosterically) the interaction 
between GSH and Bcl-2, and as a consequence lowers the affinity of Bcl-2 for OGC. 
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Thus, BH3 mimetics and BH3-only proteins inhibit the capacity of Bcl-2 to regulate 
mitochondrial glutathione transport through OGC, leading to a selective depletion of 
mitochondrial glutathione, an increase in MOS, and activation of the intrinsic apoptotic 
cascade. 
Our proposed model is supported by several previously published observations. 
First, in addition to our results showing that the BH3 mimetic, HA14-1, depletes 
mitochondrial glutathione in CGNs, other BH3 mimetics have been shown to have 
similar effects in different cell types. The highly selective Bcl-2 inhibitor, ABT-737, has 
been shown to deplete cellular glutathione in Jurkat cells and HeLa cells, although 
mitochondrial glutathione content was not explicitly measured in this study (Howard et 
al., 2009). These findings, along with our data showing that Bim directly inhibits GSH 
uptake into isolated mitochondria, strongly suggest that inhibition of Bcl-2 is a common 
mechanism of depleting mitochondrial glutathione. Second, there is a precedent for Bcl-2 
to interact with and modulate the activity of IMM transporters. For instance, Bcl-2 has 
been shown to enhance the ADP/ATP exchange activity of the IMM adenine nucleotide 
translocase in proteoliposomes, isolated mitochondria, and intact cells (Belzacq et al., 
2003). Interestingly, Bax displaces Bcl-2 from the translocase and acts to inhibit the 
ADP/ATP exchange activity. Third, a previous study demonstrated a positive correlation 
between an accumulation of Bcl-2 in the nuclear membrane and a redistribution of 
glutathione into the nucleus, adding further support to a central role for Bcl-2 in the 
regulation of glutathione transport that is not restricted to mitochondria (Voehringer et 
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al., 1998). Finally, the ability of BH3 mimetics and BH3-only proteins (e.g., Bim) to 
disrupt the Bcl-2/GSH interaction is entirely consistent with the pro-oxidant state induced 
at mitochondria by pro-apoptotic Bcl-2 family members (Kirkland et al., 2002; Starkov et 
al., 2002; Ding et al., 2004). 
Collectively, the results described above suggest that Bcl-2 plays a central role in 
the regulation of mitochondrial glutathione transport and maintenance of the 
mitochondrial glutathione pool. Moreover, this key antioxidant-like function of Bcl-2 
likely involves direct GSH-binding and a GSH-stimulated interaction with the IMM GSH 
transporter, OGC. Gallo et al. found a similar interaction between the C. elegans 
homolog of OGC (MISC-1) and the Bcl-2 homolog (Ced-9), further providing evidence 
for an interaction between Bcl-2 and OGC (Gallo et al., 2011). 
Given the substantial roles of glutathione depletion and MOS in 
neurodegeneration, one could postulate how negatively impacting this novel function of 
Bcl-2 might contribute to the pathophysiology of various neurodegenerative diseases. For 
example, GSH depletion in the spinal cord of mice harboring a familial ALS mutation 
(G93A) in the SOD1 gene has been shown to correlate with motor neuron degeneration 
during disease progression (Chi et al., 2007). In transgenic mice and rats, as well as 
human familial ALS patients, various mutant forms of SOD1 are apparently recruited to 
spinal cord mitochondria (Liu et al., 2004). In general, these mutant forms of SOD1 are 
observed as misfolded aggregates that have been localized to essentially every 
compartment of the mitochondria; however, mutant SOD1 has also been shown to 
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aggregate with Bcl-2 at mitochondria (Pasinelli et al., 2004). Most significantly, this 
interaction of mutant SOD1 with Bcl-2 has been shown to induce a conformational 
change in Bcl-2 that exposes its BH3 domain and converts Bcl-2 into a “toxic” protein at 
mitochondria (Pedrini et al., 2010). Although the authors of this elegant study support a 
direct toxic function of the conformationally altered form of Bcl-2 at mitochondria, it is 
tempting to speculate that the interactions of Bcl-2 with mutant SOD1 may also interfere 
with the novel role that Bcl-2 plays in regulating mitochondrial glutathione transport. For 
instance, if only a fraction of Bcl-2 is actually altered in conformation by its interaction 
with mutant SOD1, then this “toxic” form of Bcl-2 may in fact act like a BH3-only 
protein and disrupt the ability of adjacent unaltered Bcl-2 molecules to bind GSH and 
stimulate OGC-dependent glutathione transport into the mitochondria. In fact, this model 
is consistent with findings in NSC34 motor neuronal cells stably expressing G93A 
mutant SOD1. These cells demonstrate a significant depletion of the mitochondrial 
glutathione pool with no effect on cytosolic glutathione content (Muyderman et al., 
2009). Moreover, these mutant SOD1-expressing cells demonstrate a more pronounced 
depletion of mitochondrial glutathione and display an enhanced sensitivity to apoptosis in 
response to ethacrynic acid when compared to non-transfected or wild type SOD1-
expressing NSC34 cells (Rizzardini et al., 2005; Muyderman et al., 2009). Thus, motor 
neuron toxicity induced by mutant SOD1 likely involves the interaction of this protein 
with Bcl-2 in the outer mitochondrial membrane. The precise consequences of this 
interaction, if any, on the capacity of Bcl-2 to regulate mitochondrial glutathione 
transport requires further study. 
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In conclusion, we identify the regulation of mitochondrial glutathione transport 
and maintenance of the mitochondrial glutathione pool as essential and novel functions of 
Bcl-2. We establish Bcl-2 as a direct GSH-binding protein and a novel interacting partner 
for the IMM glutathione transporter, OGC. Either BH3 mimetics or BH3-only proteins 
(e.g., Bim) interfere with the Bcl-2/GSH interaction and result in inhibition of 
mitochondrial glutathione transport. Bcl-2 and OGC appear to work in a concerted 
manner to significantly increase the mitochondrial glutathione pool. Accordingly, the 
ability of Bcl-2 to protect cells from oxidative stress is largely dependent on an intact 
transporter function of OGC. These findings suggest a molecular mechanism for the well 
established antioxidant-like function of Bcl-2, particularly at the level of the 
mitochondria. Finally, this novel function of Bcl-2 may be a target of pathogenic 
proteins, such as mutant SOD1, which result in devastating neurodegenerative disorders 
like ALS. 
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CHAPTER THREE: MITOCHONDRIAL GLUTATHIONE TRANSPORT IS A 
KEY DETERMINANT OF NEURONAL SUSCEPTIBILITY TO OXIDATIVE 
AND NITROSATIVE STRESS 
 
3.1 Abstract  
 
Mitochondrial oxidative stress significantly contributes to the underlying pathology of 
several devastating neurodegenerative disorders. Mitochondria are highly sensitive to the 
damaging effects of reactive oxygen and nitrogen species; therefore, these organelles are 
equipped with a number of free radical scavenging systems. In particular, the 
mitochondrial glutathione (GSH) pool is a critical antioxidant reserve that is derived 
entirely from the larger cytosolic pool via facilitated transport. The mechanism of 
mitochondrial GSH transport has not been extensively studied in the brain. However, the 
dicarboxylate (DIC) and 2-oxoglutarate (OGC) carriers localized to the inner 
mitochondrial membrane have been established as GSH transporters in liver and kidney. 
Here, we investigated the role of these carriers in protecting neurons from oxidative and 
nitrosative stress. Immunoblot analysis of DIC and OGC in primary cultures of rat 
cerebellar granule neurons (CGNs) and cerebellar astrocytes showed differential 
expression of these carriers, with CGNs expressing only DIC and astrocytes expressing 
both DIC and OGC. Consistent with these findings, butylmalonate specifically 
reduced mitochondrial GSH in CGNs, whereas both butylmalonate and phenylsuccinate 
diminished mitochondrial GSH in astrocytes. Moreover, preincubation with 
butylmalonate but not phenylsuccinate significantly enhanced susceptibility of 
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CGNs to oxidative and nitrosative stressors. This increased vulnerability was largely 
prevented by incubation with cell-permeable GSH monoethylester but not malate. 
Finally, knockdown of DIC with adenoviral siRNA also rendered CGNs more susceptible 
to oxidative stress. These findings demonstrate that maintenance of the mitochondrial 
GSH pool via sustained mitochondrial GSH transport is essential to protect neurons from 
oxidative and nitrosative stress. 
 
3.2 Introduction 
 
Mitochondrial oxidative stress and mitochondrial dysfunction are convergence points in 
the underlying pathologies of several devastating neurodegenerative disorders (Lin and 
Beal, 2006). For instance, previous studies have provided significant evidence for 
increased mitochondrial oxidative damage and organelle dysfunction in Parkinson 
disease (PD) and amyotrophic lateral sclerosis (ALS) (Murata et al., 2008; Arthur et al., 
2009; Isobe et al., 2010). Overall, mitochondrial dysfunction leads to an increase in 
reactive oxygen species (ROS), which damage mitochondrial DNA, lipids, and proteins 
(Lin and Beal, 2006). Moreover, ROS induced alterations in mitochondrial membrane 
potential and permeability can trigger a positive feedback mechanism known as ROS-
induced ROS release, which has the potential to propagate oxidative stress signals from 
mitochondria to mitochondria, thus exacerbating cellular injury (Zorov et al., 2006). 
These findings indicate that mitochondrial free radical scavenging systems, such as the 
essential antioxidant glutathione (GSH), are critical to protect neuronal cells from 
mitochondrial oxidative stress. GSH exists as a discrete mitochondrial pool and a much 
 75 
 
larger cytosolic store. The mitochondrial GSH pool is considered to be an indispensable 
antioxidant reservoir. For example, selective depletion of the mitochondrial GSH pool 
within cerebellar granule neurons (CGNs) induced opening of the mitochondrial 
permeability transition pore, increased ROS production, and caused significant cell death, 
whereas depletion of the cytosolic GSH pool did not elicit these deleterious effects 
(Wüllner et al., 1999). In a similar manner, specific depletion of mitochondrial GSH in 
astrocytes rendered these glial cells more vulnerable to both oxidative and nitrosative 
stress (Muyderman et al., 2007). Based on these previous studies, mitochondrial GSH 
appears to be a critical antioxidant that supports both glial and neuronal cell viability. 
Several factors indicate that GSH transport into mitochondria occurs via a facilitated 
process. These factors include a lack of the enzymes necessary for GSH synthesis within 
mitochondria, the negative potential of the inner mitochondrial membrane, the net 
negative charge of GSH at physiological pH, and the approximately equal concentrations 
of GSH in the cytosolic and mitochondrial compartments (Griffith and Meister, 1985; 
Lash, 2006). Previous studies have shown that two inner mitochondrial membrane anion 
transporters, the dicarboxylate carrier (DIC, Slc25a10) and the 2-oxoglutarate carrier 
(OGC, Slc25a11), are capable of transporting GSH into renal and hepatic mitochondria 
(Chen and Lash, 1998; Chen et al., 2000; Lash, 2006). Mechanisms of mitochondrial 
GSH transport in the brain have only recently been investigated. Using isolated 
mitochondria from whole brain, one study determined that mitochondrial GSH transport 
may depend on the function of the tricarboxylate carrier (Wadey et al., 2009). A second 
study showed that cortical neurons and astrocytes express both DIC and OGC. However, 
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in isolated mitochondria from whole cortical tissue, only the activity of DIC appeared to 
influence mitochondrial GSH content (Kamga et al., 2010). To date, the mechanism of 
mitochondrial GSH transport utilized by neurons specifically has not been examined. 
Furthermore, the effects of inhibiting either DIC- or OGC-dependent mitochondrial GSH 
transport on neuronal susceptibility to oxidative or nitrosative stress are unknown. Here, 
we demonstrate a key role for DIC-dependent mitochondrial GSH transport in the 
maintenance of the mitochondrial GSH pool and protection of CGNs from oxidative and 
nitrosative stress. 
3.3 Materials and Methods 
3.3.1 Materials 
Butylmalonic acid, phenylsuccinic acid, primary antibody against β-tubulin, poly-
L-lysine, GSH monoethylester,L-malate, and Hoechst stain were purchased from Sigma-
Aldrich. HA14-1 was acquired from Alexis Biochemicals (Enzo Life Sciences, Plymouth 
Meeting, PA). The GSH assay kit was purchased from Oxford Biomedical (Rochester 
Hills, MI). Anti-MAP2 was purchased from Santa Cruz Biotechnology, Inc.(Santa Cruz, 
CA). The mitochondrial/cytosolic fractionation kit was from Biovision (Mountain View, 
CA). Antibody against Cox-IV was obtained from Cell Signaling (Beverly, MA). Primary 
rat astrocyte cultures were purchased from ScienCell (Carlsbad, CA). Anti-GFAP, anti-
GAPDH, anti-DIC (Slc25a10), and anti-OGC (Slc25a11) antibodies were purchased from 
Abcam (Cambridge, MA). Sodium nitroprusside (SNP) was received from Calbiochem. 
Horseradish peroxidase conjugated secondary antibodies and reagents for enhanced 
chemiluminescence detection were purchased from Amersham Biosciences. The 
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ViraBind
®
 adenovirus miniprep kit and QuickTiterTM adenovirus titer immunoassay kit 
were purchased from Cell Biolabs (San Diego, CA). Adenoviral siRNA1 and siRNA2 
against DIC and the scrambled adenoviral control were constructed as described 
previously (Huypens et al., 2011). siRNA1 targets DIC from bp 119GCU UCG AAU 
GAC UGG AAU G, and siRNA2 targets DIC from bp 354GCA GAU UUG GUC AAU 
GUC A, whereas the scrambled siRNA sequence (GAG ACC CTA TCC GTG ATT A) 
has no known gene homology (Huypens et al., 2011). 
3.3.2 CGN Cell Culture 
CGNs were isolated and cultured from P7 Sprague-Dawley rat pups based on the 
methods described previously (Zimmermann et al., 2007). CGNs were maintained in 
basal modified Eagle’s medium, containing 10% heat inactivated fetal bovine serum, 25 
mM potassium chloride, 2 mM L-glutamine and 100 units/ml/100 μg/ml 
penicillin/streptomycin at 37 °C in 10% CO2. 
3.3.3 Primary Rat Cerebellar Astrocyte Cell Culture 
Primary rat cerebellar astrocyte cultures were grown on poly-L-lysine coated 
flasks in basal modified Eagle’s medium containing 10% heat-inactivated fetal bovine 
serum, 2mML-glutamine, and 100 units/ml/100 μg/ml penicillin/streptomycin. Cells were 
plated on poly-L-lysine-coated 6-well plates and grown to ~80% confluence at 37 °C in 
10% CO2, at which time cells were utilized for the described experiments.  
3.3.4 Immunofluorescence Staining 
CGNs and/or astrocytes were treated as described under “3.4 Results” and fixed with 4% 
paraformaldehyde. Cells stained for β-tubulin were blocked and permeabilized in 5% 
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BSA, 0.2% Triton X-100 in PBS for 1 h. Cells were then incubated with primary 
antibody overnight at 4 °C, at a dilution of 1:500 in 2% BSA, 0.2% Triton X-100 in PBS. 
Cells were then washed five times in PBS and incubated in secondary antibody for 1 h at 
room temperature at a dilution of 1:250 in 2% BSA, 0.2% Triton X-100 in PBS. Cells 
were then washed five times and placed in anti-quench solution. For cells with only 
nuclei stained, cells were fixed as above and incubated with Hoechst dye (8 μg/ml) in 
PBS for 1 h at room temperature. Cells were then washed five times with PBS and placed 
in antiquench. Images were captured using a Zeiss Axiovert-zoom inverted 
epifluorescence microscope. 
3.3.5 Mitochondrial/Cytosolic Fractionation 
Cells were treated as indicated under “3.4 Results” or in the figure legends, after 
which the medium was aspirated, and cells were washed once in ice-cold PBS, pH 7.4. 
200 μl of cytosolic buffer (provided in the kit, diluted 1:5 in double-distilled H2O, with 
added protease inhibitor mixture and 1 mM DTT as per the manufacturer’s 
recommendations) was added to the cells and allowed to incubate on ice for 20 min. Cells 
were scraped and harvested and then homogenized with 40 passes of a Dounce 
homogenizer. Samples were spun down at 720 relative centrifugal force for 10 min at 4 
°C. The supernatant from each sample was transferred to a new tube labeled 
“mitochondrial fraction” and spun at 10,000 relative centrifugal force for 30 min at 4 °C. 
The supernatant was then transferred to a new tube labeled “cytosolic fraction,” and the 
pellet in the mitochondrial fraction tube was resuspended in 150 μl of mitochondrial 
buffer (provided in the kit, with added protease inhibitor mixture and 1 mM DTT as per 
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the manufacturer’s recommendations). Samples were measured immediately for GSH 
content as described below.  
3.3.6 GSH Assay 
GSH was measured using an assay kit (DTNB) from Oxford Biomedical 
Research, following the manufacturer’s protocol. All GSH measurements were 
normalized to protein concentration. GSH concentrations were determined using a GSH 
standard in the DTNB assay and reported as nmol of GSH/mg of protein. The percentage 
of mitochondrial GSH and percentage of cytosolic GSH was calculated using the slope of 
the kinetic assay and the appropriate dilution factor. 
 
3.3.7 Cell Lysis 
CGNs were infected with the indicated adenoviral construct (shown under “3.4 
Results”) as described below, after which CGNs were washed in 1 mL PBS over ice and 
incubated with 1% Triton X-100 in Wahl buffer (20 mM HEPES, pH 7.4, 50  mM NaCl, 
1 mM EGTA, 5 mM β-glycerophosphate, 30 mM sodium pyrophosphate, 100 μM 
sodium orthovanadate, 10 μg/ml leupeptin, and 10 μg/ml aprotinin) for 10 min. Cells 
were harvested by scraping and spun down at 10,000 rpm for 2 min, and the cell 
supernatant was removed. 
3.3.8 Immunoblot Analysis 
Following mitochondrial/cytosolic fractionation or cell lysis, a BCA protein assay 
(Pierce) was used to determine protein concentration. Equal concentrations of protein 
were resolved by SDS-PAGE and immunoblotted as described previously (Zimmermann 
et al., 2007). 
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3.3.9 Purification and Titering of Adenoviral Constructs 
Adenoviral constructs were amplified in a HEK 293 AD cell line by adding 10 μl 
of the respective adenovirus to 4 ml of medium for 1.5 h, after which 16 ml of medium 
was added to the flask, and cells were incubated at 5% CO2 and 37 °C for 48 h or until 
the beginning signs of cytotoxicity were observed. Cells were harvested, and the 
adenoviral constructs were purified as per the manufacturer’s recommendations in the 
ViraBind® adenovirus miniprep kit. Adenoviral constructs were titered as per the 
manufacturer’s recommendations in the QuickTiterTM adenovirus titer immunoassay kit. 
3.3.10 Adenoviral Knockdown of DIC 
CGNs were infected with adenoviral constructs at a multiplicity of infection of 100 for 48 
h, after which experiments were completed.  
3.3.11 Statistical Analysis 
One-way analysis of variance tests followed by post hoc Tukey’s tests were 
performed to determine statistical significance between data sets.A p value of less than 
0.05 was considered statistically significant. A minimum of three independent 
experiments were completed for each figure. 
 
3.4 Results 
3.4.1 Differential Expression of the Mitochondrial GSH Transporters,OGCand DIC, 
within CGNs and Cerebellar Astrocytes 
To determine the specific cellular expression of the previously identified 
mitochondrial GSH transporters within the cerebellum, we employed primary rat CGN 
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and primary rat cerebellar astrocyte cultures (Fig. 3.1.A). We first completed 
immunoblots against DIC and OGC on mitochondrial fractions of these primary cultures. 
Here, we show that CGNs express DIC but no detectable OGC. In contrast, cerebellar 
astrocytes express both DIC and OGC (Fig. 3.1.B). 
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Figure 3.1 Differential expression of the mitochondrial GSH transporters, OGC and 
DIC, within CGNs and cerebellar astrocytes A. primary rat CGN cultures were fixed and 
stained for β-tubulin (red),MAP2(green), and Hoechst (blue). Primary rat astrocyte 
cultures were fixed and stained for GFAP (green) and Hoechst (blue). B. CGN and 
cerebellar astrocyte cultures were subfractionated into mitochondrial and cytoplasmic 
fractions using differential centrifugation as described under “Experimental Procedures.” 
Protein lysates from the mitochondrial and cytosolic fractions were resolved using 
SDSPAGE and immunoblotted for DIC and OGC. Immunoblotting for β-tubulin was 
used as a measure of fraction purity. 
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3.4.2 Inhibition of DIC but Not OGC Specifically Reduces the Mitochondrial GSH Pool 
in CGNs 
We next examined the effects of butylmalonate and phenylsuccinate, DIC and 
OGC inhibitors, respectively, on mitochondrial GSH levels within CGNs. Dose responses 
were initially completed in order to establish a maximal non-cytotoxic level of each of 
these inhibitors (data not shown). Accordingly, CGNs were treated with 5 mM 
butylmalonate or 5 mM phenylsuccinate overnight. After subfractionation of CGNs into 
mitochondrial and cytoplasmic fractions, GSH was quantified using a DTNB colorimetric 
assay. CGNs showed a significant reduction of the mitochondrial GSH pool when treated 
with butylmalonate, but they displayed no decrement in the cytosolic pool (Fig. 3.2). 
Interestingly, phenylsuccinate had no discernible effect on either the mitochondrial or 
cytosolic pools of GSH within CGNs (Fig. 3.2). These results are consistent with the 
immunoblot analysis, which demonstrated that the CGNs expressed DIC but not OGC 
(Fig. 3.1.B). Immunoblot analysis of the subcellular fractions for cytochrome c oxidase 
IV and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) verified the purity of the 
mitochondrial and cytosolic fractions, respectively (Fig. 3.2). Furthermore, mitochondrial 
GSH comprised 14.3 +/- 2.7% of total cellular GSH at a concentration of 6.9 +/- 1.10 
nmol/mg, consistent with previous studies (mean  +/- S.E., n = 6) (Ravindranath et al., 
1989; Sagara et al., 1993; Huang and Philbert, 1995; Wilkins et al., 2012). 
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Figure 3.2 Inhibition of DIC but not OGC specifically reduces the mitochondrial GSH 
pool in CGNs CGN cultures were treated with vehicle (DMSO;Con),5 mM butylmalonate 
(BM), or 5 mM phenylsuccinate (PS) overnight. Cells were then subfractionated into 
mitochondrial and cytoplasmic fractions using differential centrifugation. Mitochondrial 
and cytosolic fractions were measured for total GSH content using a DTNB assay. Data 
are represented as a percentage of control GSH. **, p <0.01 compared with control; NS, 
not significant; n =4 experiments with each treatment performed in duplicate. Protein 
lysates were resolved using SDS-PAGE and immunoblotted for cytochrome c oxidase IV 
(Cox-IV) and GAPDH to indicate pure fractionations. Error bars, S.E. 
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3.4.3 Inhibition of DIC or OGC Function Specifically Decreases the Mitochondrial GSH 
Pool in Cerebellar Astrocytes 
In order to resolve the mitochondrial GSH transporters utilized in cerebellar 
astrocytes, these cultures were incubated overnight with 5 mM butylmalonate or 5 mM 
phenylsuccinate, after which the cerebellar astrocytes were subfractionated, and GSH was 
quantified as described above. Cerebellar astrocytes displayed a significant level of 
mitochondrial GSH depletion with phenylsuccinate but no effect of this inhibitor on the 
cytosolic pool of GSH (Fig. 3.3). Although the results for butylmalonate did not reach 
statistical significance, the trend toward mitochondrial GSH depletion with this inhibitor 
is in agreement with the previous immunoblot analysis showing that these astrocytes 
express both DIC and OGC (Fig. 3.1.B). Furthermore, mitochondrial GSH comprised 
13.4 +/- 3.9% of total cellular GSH at a concentration of 2.0 +/- 0.78 nmol/mg, consistent 
with previous studies (mean +/- S.E., n=4) (Ravindranath et al., 1989; Sagara et al., 1993; 
Huang and Philbert, 1995). Cytochrome c oxidase IV blots showed consistent 
mitochondrial fractions. Although immunoblotting indicated that the mitochondrial 
phenylsuccinate sample contains GAPDH, this finding alone does not definitively 
demonstrate cytosolic contamination of this fraction. For instance, a previous study 
showed that GAPDH can localize to the mitochondria under conditions of mitochondrial 
permeability transition pore activation (Tarze et al., 2007). Given the significant 
depletion of mitochondrial GSH observed with phenylsuccinate, this mitochondrial 
perturbation may be occurring in astrocytes. Second, if the phenylsuccinate mitochondrial 
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samples did indeed contain significant cytosolic contamination, then we would expect to 
see a marked increase in mitochondrial GSH compared with controls because the 
cytosolic GSH pool is much larger than the mitochondrial GSH pool. Instead, we observe 
the opposite effect, where phenylsuccinate significantly reduces the mitochondrial GSH 
pool in cerebellar astrocytes (Fig. 3.3). 
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Figure 3.3 Inhibition of DIC or OGC function specifically decreases the mitochondrial 
GSH pool in cerebellar astrocytes Cerebellar astrocyte cultures were treated with vehicle 
(DMSO; Con), 5 mM butylmalonate (BM), or 5 mM phenylsuccinate (PS) overnight. 
Cells were then subfractionated into mitochondrial and cytoplasmic fractions using 
differential centrifugation. Mitochondrial and cytosolic fractions were measured for total 
GSH content using a DTNB assay. Data are represented as a percentage of control GSH. 
**, p < 0.01 compared with control; NS, not significant; n= 3 experiments with each 
treatment performed in duplicate. Protein lysates were resolved using SDS-PAGE and 
immunoblotted for cytochrome c oxidase IV (Cox-IV) and GAPDH to indicate pure 
fractions. Error bars, S.E. 
 
 
 
 
 
 
 
 
 88 
 
3.4.4 Inhibition of DIC-dependent Mitochondrial GSH Transport Renders CGNs More 
Susceptible to Oxidative Stress Induced by HA14-1 
The unique dependence of CGNs on DIC-dependent transport provided a valuable 
model for examining the effects of specific inhibition of mitochondrial GSH transport on 
neuronal sensitivity to oxidative stress. To this end, CGNs were preincubated overnight 
with either 5 mM phenylsuccinate or 5 mM butylmalonate. Incubation with these doses 
of inhibitors are not cytotoxic on their own (Fig. 3.4.A (BM panels) and B 
(quantification)). Next, CGNs were treated for an additional 4 h with 12.5 μM HA14-1, 
alone or in combination with butylmalonate or phenylsuccinate. We have previously 
shown that HA14-1 causes GSH-sensitive intrinsic apoptosis and mitochondrial oxidative 
stress, through the inhibition of Bcl-2 in CGNs (Zimmermann et al., 2007). Therefore, we 
utilized this Bcl-2 homology-3 domain (BH3) mimetic, HA14-1, as a model of oxidative 
stress. Incubation with 12.5 μM HA14-1 alone for 4 h had no significant effect on CGN 
survival (Fig. 3.4.A (HA14 panels) and B (quantification)). However, inhibition of 
mitochondrial GSH transport through the DIC using butylmalonate rendered the CGNs 
significantly more sensitive to this oxidative stressor (Fig. 3.4.A (BM + HA14 panels) 
and B (quantification)). In contrast, preincubation with the OGC inhibitor, 
phenylsuccinate, did not significantly impact the susceptibility of CGNs to oxidative 
stress induced by HA14-1, again consistent with our data showing that CGNs do not 
express OGC (Fig. 3.4.B, quantification). 
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Figure 3.4 Inhibition of DIC-dependent mitochondrial GSH transport renders CGNs 
more susceptible to oxidative stress induced by HA14-1 A. CGN cultures were treated 
with vehicle (Con) or 5 mM butylmalonate (BM) overnight. The following day, cells 
were either left untreated (BM or Con) or treated with 12.5 μM HA14-1 (HA14 or 
BM_HA14) for 4 h. After treatment, cells were fixed, and β-tubulin (FITC; green) and 
nuclei (Hoechst; blue) were stained (top four panels). The bottom panels show 
decolorized nuclei from separate fields. Scale bar,10 μm. B. Cells were treated as in A, 
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with the addition of a 5mM phenylsuccinate pretreatment and HA14-1 (PS+HA14) or no 
treatment (PS) the following day. Cells were fixed, and nuclei were stained with Hoechst. 
Apoptosis was quantified by determining the percentage of cells with condensed and/or 
fragmented nuclei. **p<0.01 versus butylmalonate alone; n = 4 experiments with each 
treatment performed in duplicate. Error bars, S.E. I acknowledge Danielle Kirchhof for 
assistance in generating the data for this figure. 
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3.4.5 Inhibition of DIC-dependent Mitochondrial GSH Transport Renders CGNs More 
Susceptible to Nitrosative Stress Induced by the Nitric Oxide Donor, SNP 
We next examined the effects of selective mitochondrial GSH depletion, through 
the inhibition of mitochondrial GSH transport, on the vulnerability of CGNs to 
nitrosative stress. As described above, CGNs were preincubated overnight with either 5 
mM phenylsuccinate or 5 mM butylmalonate. Incubations with these doses of inhibitors 
were not cytotoxic to CGNs on their own (Fig. 3.5.A, BM panel and PS panel). Next, 
CGNs were treated for an additional 6 h with the nitric oxide donor SNP, at a 
concentration (25 μM) that was also not cytotoxic on its own (Fig. 3.5.A, SNP panel). 
Some CGNs were also treated with SNP in combination with butylmalonate or 
phenylsuccinate. Consistent with the results described above for HA14-1, preincubation 
with butylmalonate but not phenylsuccinate rendered CGNs more susceptible to 
nitrosative stress-induced apoptosis (Fig. 3.5.A, compare BM + SNP and PS + SNP 
panels). Quantification of these data showed a statistically significant increase in CGN 
apoptosis induced by SNP in cells preincubated with butylmalonate versus cells 
incubated with butylamalonate alone (Fig. 3.5.B). 
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Figure 3.5 Inhibition of DIC-dependent mitochondrial GSH transport renders CGNs 
more susceptible to nitrosative stress induced by the nitric oxide donor, SNP A. CGN 
cultures were treated with vehicle (Con), 5 mM phenylsuccinate (PS), or 5 mM 
butylmalonate (BM) overnight. The following day cells were either left untreated (Con, 
PS, or BM) or treated with 25 μM SNP (SNP, PS +SNP, or BM +SNP) for 6 h. Cells 
were then fixed and stained with Hoechst dye. Scale bar, 10 μm. B. cells were treated as 
in A, and apoptosis was quantified by determining the percentage of condensed and/or 
fragmented nuclei. **p<0.01 versus butylmalonate alone; n=4 experiments with each 
treatment performed in duplicate. Error bars, S.E. I acknowledge Danielle Kirchhof for 
assistance in generating the data for this figure. 
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3.4.6 Inhibition of DIC-dependent Mitochondrial GSH Transport Does Not Render CGNs 
More Susceptible to Apoptosis Induced by Deprivation of Depolarizing Potassium 
Previous studies have shown that removing depolarizing potassium (5K; 5 mM 
potassium) induces CGN apoptosis and that this insult is insensitive to the addition of 
GSH-MEE(D’Mello et al., 1993; Zimmermann et al., 2005). Therefore, to determine if 
incubation of CGNs with the DIC inhibitor, butylmalonate, nonspecifically enhances the 
sensitivity of CGNs to any toxic insult, we examined the effects of 5K within this system. 
Incubation with 5K alone for 10 h had a significant deleterious effect on CGN survival 
(Fig. 3.6.A(5K panel) and B (quantification)). However, inhibition of mitochondrial GSH 
transport through the DIC, using butylmalonate, did not render the CGNs more sensitive 
to 5K (Fig. 3.6.A (BM+5K panel) and B (quantification)). Therefore, inhibition of GSH 
transport through the DIC does not indiscriminately render CGNs more susceptible to 
GSH-insensitive insults. 
 
 
 
 
 
 
 
 
 94 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Inhibition of DIC-dependent mitochondrial GSH transport does not render 
CGNs more susceptible to apoptosis induced by deprivation of depolarizing potassium A. 
CGN cultures were treated with vehicle (Con) or 5 mM butylmalonate (BM) overnight. 
The following day, medium was either changed to 25mM potassium minus serum (Con 
orBM) or changed to 5 mM potassium minus serum (5K or BM+5K). Cells were then 
fixed, and nuclei (Hoechst; blue) were stained. Panels show decolorized nuclei from 
representative fields. Scale bar, 10 μm. B. cells were treated as in A, after which cells 
were fixed, and nuclei were stained with Hoechst. Apoptosis was quantified by 
determining the percentage of cells with condensed and/or fragmented nuclei. ## p < 0.01 
versus butylmalonate alone; ** p <0.01 versus control; NS, not significant; n = 3 
experiments with each treatment performed in duplicate. Error bars, S.E. 
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3.4.7 Effects Induced by Inhibition of DIC-dependent Mitochondrial GSH Transport 
Next, we used a cell-permeable form of GSH, GSH monoethylester, to determine 
if the sensitization of CGNs to oxidative and nitrosative stress induced by the inhibition 
of DIC-dependent mitochondrial GSH transport was indeed due to the observed reduction 
in mitochondrial GSH (see Fig. 3.2). CGNs were preincubated with 5mM butylmalonate 
overnight, after which they were treated with either 12.5 μM HA14-1 (for 4 h) or 25 μM 
SNP (for 6 h) in the absence or presence of 2mM GSH monoethylester. Again, incubation 
with butylmalonate, SNP, and HA14-1 individually did not induce significant levels of 
apoptosis compared with control conditions (Fig. 3.7.B). However, as shown previously, 
preincubation with butylmalonate induced significant susceptibility to both oxidative and 
nitrosative stress caused by these insults (Fig. 3.7.A (BM+HA14 panels) and B 
(quantification)). Moreover, the cell-permeable form of GSH significantly protected 
CGNs from the sensitizing effects induced by inhibition of DIC-dependent 
mitochondrial GSH transport (Fig. 3.7.A BM + HA14 + GSHMEE panels). 
Quantification of these data showed statistically significant protection upon the addition 
of GSH monoethylester, when compared with the sensitizing conditions of pretreatment 
with butylmalonate and the subsequent addition of HA14-1 or SNP (Fig. 3.7.B). 
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Figure 3.7 A cell-permeable form of GSH protects CGNs from the sensitizing effects 
induced by inhibition of DIC-dependent mitochondrial GSH transport A. CGN cultures 
were treated with vehicle (Con) or 5 mM butylmalonate (BM) overnight. The following 
day, cells were either left untreated (Con orBM) or treated with 12.5 μM HA14-1 in the 
presence or absence of  2mM GSH monoethylester (GSHMEE) for 4 h, after which cells 
were fixed, and nuclei (Hoechst; blue) were stained. The left panels show decolorized 
nuclei from representative fields. The right panels show corresponding bright field 
images. Scale bar, 10 μm. B. Cells were treated as in A; in addition, some cells were 
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incubated with 25 μM SNP in the presence or absence of 2 mM GSH monoethylester. 
Cells were fixed, and nuclei were stained with Hoechst. Apoptosis was quantified by 
determining the percentage of cells with condensed and/or fragmented nuclei. **p< 0.01 
versus butylmalonate alone; + p < 0.05 versus butylmalonate + SNP; ## p < 0.01 versus 
butylmalonate + HA14-1; n = 3 experiments with each treatment performed in duplicate. 
Error bars, S.E. I acknowledge Danielle Kirchhof for assistance in generating the data for 
this figure. 
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3.4.8 The Addition of Malate Fails to Protect CGNs from the Sensitizing Effects Induced 
by Inhibition of DIC-dependent Mitochondrial GSH Transport 
Mitochondrial anion transporters work in concert with one another in order to 
transport critical molecules into and out of the mitochondria for energy production. 
Previous studies have shown that the DIC has the ability to transport malate 
bidirectionally in exchange for phosphate (Mizuarai et al., 2005). However, the 
tricarboxylate carrier transports malate into the mitochondria in exchange for citrate. 
Therefore, the DIC and the tricarboxylate carrier work in tandem, where DIC transports 
malate out of the mitochondria and the tricarboxylate carrier transports malate into the 
mitochondria (Kajimoto et al., 2005). These transport processes are critical for cell 
survival because citrate is a crucial component of fatty acid synthesis within the 
cytosol,whereas malate is required for the citric acid cycle in the mitochondrial matrix. 
Therefore, an important control experiment when inhibiting DIC-dependent transport 
function is to examine if malate is capable of protecting CGNs from the sensitizing 
effects of butylmalonate. This experiment is necessary to demonstrate that the sensitizing 
effects induced by inhibiting DIC-dependent transport function are not due to disruption 
of the malate transport capacity of the DIC. Here, we preincubated CGNs with 5mM 
butylmalonate in the absence or presence of 5 mM malate. Following these 
preincubations, CGNs were then treated for 6 h with 25 μM SNP. In the presence of 
malate, preincubation with butylmalonate and subsequent SNP treatment induced an even 
greater amount of CGN apoptosis as compared with butylmalonate in the presence of 
SNP alone (Fig. 3.8.A, compare BM+ SNP panel with BM +MA + SNP panel). 
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However, preincubation with malate alone followed by SNP treatment did not increase 
apoptosis beyond control levels (Fig. 3.8.A, MA +SNP panel). Quantification of these 
data showed a statistically significant increase in vulnerability to nitrosative stress after 
CGNs were preincubated with both malate and butylmalonate compared with 
butylmalonate preincubation alone (Fig. 3.8.B). 
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Figure 3.8 The addition of malate fails to protect CGNs from the sensitizing effects 
induced by inhibition of DIC-dependent mitochondrial GSH transport A. CGN cultures 
were treated with vehicle (Con), 5 mM butylmalonate (BM), or 5 mM malate (MA) 
overnight. The following day, cells were either left untreated or were treated with 25 _M 
SNP (SNP, BM+SNP, MA+SNP, or BM+MA+SNP) for 6 h, after which cells were 
fixed, and nuclei (Hoechst; blue) were stained. Scale bar, 10 μm. B. cells were treated as 
in A. Apoptosis was quantified by determining the percentage of cells with condensed 
and/or fragmented nuclei. **p<0.01 versus SNP alone; ## p<0.01 versus butylmalonate+ 
SNP; n =5 experiments with each treatment performed in duplicate. Error bars, S.E. 
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3.4.9 Adenoviral siRNA-mediated Knockdown of DIC Renders CGNs More Susceptible 
to Oxidative Stress 
Finally, we utilized two distinct adenoviral constructs encoding siRNA against rat 
DIC and a scrambled control construct to examine their effects on neuronal vulnerability 
to oxidative stress. After 48 h of infection with the adenoviral constructs, CGNs were 
treated with 12.5 μM HA14-1 for 4 h. In addition, a parallel group of cells from each 
adenoviral infection was lysed and analyzed for DIC protein levels. As expected, the 
siRNA DIC adenoviral constructs consistently induced a significant knockdown of DIC 
expression compared with CGNs infected with the scrambled control (Fig. 3.9.A, 
siRNA1, 33.6+/-16%, n=3; siRNA2, 48+/-11%, n =9; mean +/-S.E., reduction in DIC 
protein level normalized to β-tubulin). Neither of the adenoviral constructs caused any 
significant apoptosis on their own (Fig.3.9.B, Scram, siRNA1, and siRNA2 panels). 
However, CGNs infected with either the DIC siRNA1 or DIC siRNA2 adenovirus and 
subsequently treated with HA14-1 showed a significant increase in apoptosis compared 
with CGNs infected with the scrambled control virus and then incubated with HA14-1 
(Fig. 3.9.B, compare Scram +HA14 with siRNA1 + HA14 and siRNA2 +HA14 panels). 
Quantification of these data showed that knockdown of DIC with either of two distinct 
adenoviral siRNA constructs significantly sensitized CGNs to oxidative stress-induced 
apoptosis when compared with infection with the scrambled control construct (Fig. 
3.9.C). 
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Figure 3.9 Adenoviral siRNA-mediated knockdown of DIC renders CGNs more 
susceptible to oxidative stress A. CGNs were infected for 48 h with a scrambled (Scram) 
or two distinct DIC-specific siRNA (siRNA1 or siRNA2) adenoviruses. Cells were lysed; 
proteins were resolved by SDS-PAGE and immunoblotted for DIC (upper blots) and β-
tubulin (lower blots). B. CGNs were infected as described in A, after which cells were 
then either left untreated (Scram, siRNA1, or siRNA2) or treated with 12.5 μM HA14-1 
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(Scram+HA14, siRNA1+HA14, or siRNA2 +HA14) for 4 h. Cells were fixed, and nuclei 
were stained with Hoechst. The panels show representative fields of decolorized nuclei. 
Arrowheads indicate apoptotic nuclei. Scale bar, 10 μm. C. cells wereinfected/treated as 
in B, and apoptosis was quantified as the percentage of cells with condensed and/or 
fragmented nuclei. *p<0.05 versus scrambled+HA14; ** p<0.01 versus 
scrambled+HA14; n=3 experiments with each treatment performed in triplicate. Error 
bars, S.E. 
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3.5 Discussion 
Given that previous studies have demonstrated enhanced sensitivity of both 
neurons and astrocytes to specific depletion of mitochondrial GSH it is perhaps not 
surprising that inhibition of mitochondrial GSH transport would produce similar effects 
(Wüllner et al., 1999; Muyderman et al., 2007). However, it is striking that the discrete 
inhibition of a single inner membrane transport protein, DIC, is sufficient to significantly 
sensitize neurons to both oxidative and nitrosative stress. We chose to use CGNs as a 
model for inhibition of mitochondrial GSH transport based on their apparent dependence 
on DIC-mediated GSH transport. Interestingly, a mere ~32% reduction in mitochondrial 
GSH through specific inhibition of DIC leads to a dramatic increase in the susceptibility 
of CGNs to both oxidative and nitrosative stress-induced apoptosis. We used both 
chemical inhibition of DIC (butylmalonate) and molecular knockdown of DIC 
(adenoviral siRNA) in order to show that discrete inhibition of this single transporter 
could render CGNs more susceptible to apoptosis. As discussed previously, the 
mitochondrial GSH pool is an indispensable reservoir of this critical antioxidant. Several 
studies have shown that specific depletion of mitochondrial GSH versus depletion of the 
cytosolic GSH pool leads to neuronal degeneration as well as increased vulnerability of 
astrocytes to both oxidative and nitrosative stress (Wüllner et al., 1999; Muyderman et 
al., 2007). Furthermore, depletion of mitochondrial GSH may occur upstream of 
mitochondrial dysfunction and oxidative stress, suggesting that reductions in 
mitochondrial GSH may act as a trigger for these pathological mechanisms (Merad-
Boudia et al., 1998). Based on our data, it becomes an interesting possibility that 
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dysfunction of one or more mitochondrial GSH transport proteins could lead to the 
enhanced susceptibility of neurons in the CNS to oxidative and nitrosative stress. This 
may be particularly relevant within chronic neurodegenerative diseases (e.g. PD or ALS), 
which have been hypothesized tooccur via multiple “hits” involving gene-environment 
interactions as underlying pathological mechanisms (Sulzer, 2007). To date, a role for 
DIC or OGC dysfunction in neurodegeneration has not been examined. 
In the context of neurodegenerative diseases, the devastating triad of GSH 
depletion, mitochondrial dysfunction, and oxidative stress has been implicated in the 
underlying pathology of a large number of disorders, such as Alzheimer disease, PD, and 
ALS (Castellani et al., 2002; Mattiazzi et al., 2002; Eckert et al., 2003; Lin and Beal, 
2006; Henchcliffe and Beal, 2008; Murata et al., 2008). Specifically, GSH has been 
shown to be depleted within the substantia nigra of PD patients (Perry et al., 1986). 
Moreover, depletion of nigral GSH was detected in a mouse model of PD before the 
onset of complex I deficiency and neurodegeneration (Chinta et al., 2007). Similarly, in a 
familial mouse model of ALS, the G93A mutant hSOD1 mouse, GSH depletion in the 
spinal cord was positively correlated with disease onset and progression (Chi et al., 
2007). Forced reduction of GSH levels in the G93A mutant hSOD1 mouse model, 
through the knockdown of γ-glutamyl cysteine ligase modifier subunit (the rate-limiting 
enzyme in GSHsynthesis) led to a decrease in life span, increased oxidative stress, and 
accelerated motor dysfunction (Vargas et al., 2011). Furthermore, in sporadic ALS 
patients, erythrocyte GSH levels were found to be diminished, whereas lipid peroxidation 
levels were significantly increased compared with healthy age-matched controls (Babu et 
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al., 2008). Despite this abundant and compelling evidence for a key role of GSH 
depletion within neurodegenerative diseases, neither mitochondrial GSH nor 
mitochondrial GSH transport mechanisms explicitly have been studied within models of 
these diseases.  
To further support the role of DIC-dependent mitochondrial GSH transport as a 
protective mechanism in neurons, while excluding the contribution of interference with 
the malate transport function of DIC, we examined whether malate would protect CGNs 
from the sensitizing effects of DIC inhibition to nitrosative stress. Our results show that 
the addition of malate in the presence of the DIC inhibitor butylmalonate caused CGNs to 
become more susceptible to nitrosative stress than in the presence of butylmalonate 
alone. This result can be attributed to the competitive inhibition produced by 
butylmalonate and malate together on DIC-dependent mitochondrial GSH transport. 
Butylmalonate inhibits DIC through competitive inhibition by binding to the transport 
site, and because it is an analog, it does not become transported or metabolized (Lash, 
2006; Palmieri et al., 1971). Therefore, the addition of malate with butylmalonate at the 
same concentration would allow malate to outcompete butylmalonate for transport. 
However, by adding both of these chemicals together, GSH would have to compete with 
both malate and butylmalonate, therefore causing an even more significant reduction in 
mitochondrial GSH transport and a greater vulnerability to nitrosative stress. In contrast 
to malate addition, the sensitizing effects induced by DIC inhibition with butylmalonate 
could be rescued by adding back GSH as a cellpermeable esterified form. Therefore, 
because malate was unable to protect CGNs from the enhanced susceptibility induced by 
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DIC inhibition, whereas adding back GSH did prevent these effects, we are able to rule 
out deficits in fatty acid synthesis and the citric acid cycle as the mechanism by which 
CGNs become vulnerable to apoptosis, leaving mitochondrial GSH transport as the most 
probable mechanism. Depletion of mitochondrial GSH and increased susceptibility to 
oxidative and nitrosative stress did not occur in CGNs exposed to phenylsuccinate, ruling 
out the possibility that chemical analogs of commonly transported anions are capable of 
non-specifically inducing neuronal susceptibility to these insults. Furthermore, 
butylmalonate did not render the CGNs more vulnerable to a GSH-insensitive insult, 5K-
induced apoptosis. The specificity of the sensitizing effects of butylmalonate is also 
supported through the use of two distinct adenoviral siRNAs to knock down DIC, which 
similarly induced increased susceptibility to oxidative stress compared with a scrambled 
control virus.  
Previous studies have shown that whole brain mitochondria utilize the 
tricarboxylate carrier (Slc25a1) as a mitochondrial GSH transport protein, whereas 
mitochondria isolated specifically from cerebral cortex, which express both DIC and 
OGC, use primarily DIC as a mitochondrial GSH transport protein (Wadey et al., 2009; 
Kamga et al., 2010). Our study shows that CGNs are dependent on DIC, whereas 
cerebellar astrocytes use both DIC and OGC as mitochondrial GSH transport proteins. 
CGNs appear to be unique because they are insensitive to phenylsuccinate; however, 
based on the relatively small decrease in mitochondrial GSH (~32%) observed with 
butylmalonate, it cannot be ruled out that a second inner membrane transporter, such as 
the tricarboxylate carrier, is also being used to transport GSH into CGN mitochondria. 
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Overall, more studies are necessary to determine the identity of a second transport protein 
that contributes significantly to mitochondrial GSH transport within CGNs.  
Several studies have shown that mitochondrial oxidative stress plays a key role 
within neurodegenerative diseases, such as PD and ALS. In one such study, a partial 
knockdown of the mitochondrial specific manganese-superoxide dismutase (SOD2) led 
to a significant decrease in survival and a greater decline in motor function within the 
G93A mutant hSOD1 mouse model (Andreassen et al., 2000). In addition, 
overexpression of SOD2 in a differentiated human neuroblastoma cell line protected from 
cell death induced by the overexpression of several different mutant SOD1 proteins 
(Flanagan et al., 2002). These studies indicate the importance of maintaining the 
mitochondrial redox status for neuronal viability. Mitochondrial SOD2 and mitochondrial 
GSH (via the activity of GSH peroxidase) work in concert to abolish the free radicals 
generated by leakage from the electron transport chain, and these antioxidants are equally 
important in maintaining the redox balance within mitochondria. Therefore, the prior 
mentioned studies focused on SOD2, in combination with our data, indicate that the 
antioxidant repertoire of mitochondria is critical in protecting neurons from pathological 
mechanisms common to many neurodegenerative diseases.  
In addition to defining the specific transport proteins involved in mitochondrial 
GSH transport in the CNS, the regulation of mitochondrial GSH transport is also an area 
that is not well understood. We have previously shown that Bcl-2 plays a central role in 
maintaining the mitochondrial GSH pool in CGNs and is also capable of directly binding 
GSH(Zimmermann et al., 2007). Furthermore, Bcl-2 is an interacting partner of OGC, 
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and co-overexpression of these proteins leads to a significant increase in mitochondrial 
GSH (Wilkins et al., 2012). Finally, BH3-only proteins (e.g. Bim) and BH3 mimetics 
antagonize the Bcl-2/GSH interaction and inhibit GSH transport into isolated rat brain 
mitochondria (Zimmermann et al., 2007; Wilkins et al., 2012). Therefore, Bcl-2 appears 
to play a crucial role in regulating mitochondrial GSH transport. This point becomes 
particularly relevant when considering that Bcl-2 function is often compromised within 
neurodegenerative diseases. For instance, Bcl-2 expression has been shown to be 
significantly decreased within the spinal cord of ALS patients (Mu et al., 1996). In the 
G93A mutant hSOD1 mouse model of familial ALS, the mutant SOD1 protein was found 
to interact with Bcl-2 and form dysfunctional aggregates with Bcl-2 at mitochondria 
(Pasinelli et al., 2004). This interaction between G93A mutant SOD1 and Bcl-2 was also 
shown to induce a toxic conformational change in Bcl-2, which prevents it from 
performing its anti-apoptotic function (Pedrini et al., 2010). Therefore, it would be of 
interest to determine if these deficits in Bcl-2 protein expression or its interaction with 
G93A mutant SOD1 lead to consequential decreases in mitochondrial GSH transport in 
the context of specific neurodegenerative diseases like ALS.  
In summary, we have shown that by modulating mitochondrial GSH transport 
through the specific inhibition of a discrete inner membrane transporter, DIC, neurons 
become more vulnerable to apoptosis induced by oxidative or nitrosative stress. This 
study provides novel insights into the importance of mitochondrial GSH transport in 
maintaining neuronal survival and suggests that understanding the mechanisms involved 
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in the regulation of mitochondrial GSH transport in neurons may reveal novel therapeutic 
targets for neurodegenerative disorders. 
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CHAPTER FOUR: STABLE OVEREXPRESSION OF THE 2-OXOGLUTARATE 
CARRIER ENHANCES NEURONAL CELL RESISTANCE TO OXIDATIVE 
STRESS VIA BCL-2-DEPENDENT MITOCHONDRIAL GSH TRANSPORT 
4.1 Abstract 
 
4.1.1 Aims 
Mitochondrial glutathione (GSH) is a key endogenous antioxidant pool and its 
maintenance is critical for cell survival. Here, we generated stable NSC34 motor neuron-
like cell lines overexpressing the mitochondrial GSH transporter, the 2-oxoglutarate 
carrier (OGC), to further elucidate the importance of mitochondrial GSH transport in 
determining neuronal resistance to oxidative stress.  
4.1.2 Results 
Two stable OGC cell lines displayed specific increases in mitochondrial GSH 
content and resistance to oxidative and nitrosative stressors, but not staurosporine. 
Inhibition of transport through OGC and reduced levels of mitochondrial GSH re-
sensitized the stable cell lines to oxidative stress. The stable OGC cell lines displayed sig-
nificant upregulation of the anti-apoptotic protein, Bcl-2. This result was reproduced in 
parental NSC34 cells by chronic treatment with GSH monoethylester, which specifically 
increased mitochondrial GSH levels. Knockdown of Bcl-2 expression with siRNA 
decreased mitochondrial GSH and re-sensitized the stable OGC cells to oxidative stress. 
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Finally, endogenous OGC was co-immunoprecipitated with Bcl-2 from rat brain lysates 
in a GSH dependent manner.  
4.1.3 Innovation 
These data are the first to show that increased mitochondrial GSH transport is 
sufficient to enhance neuronal resistance to oxidative stress. Moreover, sustained and 
specific enhancement of mitochondrial GSH leads to increased Bcl-2 expression, a 
required mechanism for the maintenance of increased mitochondrial GSH levels.   
4.1.4 Conclusion 
Modulation of mitochondrial GSH transport renders neuronal cells resistant to 
oxidative stress, in a manner dependent on Bcl-2. These findings suggest that mito-
chondrial GSH transport may be deficient in neurodegenerative diseases where Bcl-2 
expression and function have been shown to be compromised. 
 
4.2 Introduction 
Mitochondrial dysfunction and oxidative stress, particularly at the level of the 
mitochondria, play key roles in the pathogenesis underlying several neurodegenerative 
diseases (Lin and Beal, 2006). While the central nervous system (CNS) accounts for a 
mere two percent of total body weight, it generates approximately twenty percent of the 
resting metabolic rate (Silver and Erecinska, 1998). Furthermore, neurons require high 
amounts of ATP production, most of which is generated from oxidative phosphorylation 
at the level of the mitochondrial electron transport chain (ETC), and are thus particularly 
vulnerable to reactive oxygen species (ROS) generated by electron leakage from the ETC 
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(Kann and Kovács, 2007). If ROS production is not balanced by free radical scavenging 
systems, such as GSH or thioredoxin, then mitochondrial oxidative stress (MOS) occurs 
triggering damage to DNA, lipids and proteins, ultimately leading to apoptotic or necrotic 
degeneration of neurons (Lin and Beal, 2006).  
Glutathione (GSH), an endogenous tripeptide antioxidant, is the most prominent 
cellular thiol present at concentrations which are 500-1000 times greater than other free 
radical scavenging systems (Schafer and Buettner, 2001; Filomeni et al., 2002). There are 
several reservoirs of GSH throughout the cell, but in particular the mitochondrial GSH 
pool has been shown to be critical for cell survival in several different systems (Meredith 
and Reed 1982; Meredith and Reed 1983; Muyderman et al., 2007; Wilkins et al., 2013).  
GSH is compartmentalized into mitochondria via a facilitated transport process involving 
inner mitochondrial anion transporters such as the dicarboxylate (Slc25a10; DIC), 2-
oxoglutarate (Slc25a11; OGC), and tricarboxylate (Slc25a1; TCC) carriers (Lash, 2006; 
Wadey et al., 2009; Kamga et al., 2010). We have previously shown that mitochondrial 
GSH transport is critical for cell survival in primary cerebellar granule neurons (CGNs);  
discrete inhibition or molecular knockdown of a single mitochondrial GSH transporter 
(DIC) significantly sensitized these neurons to both oxidative and nitrosative stress 
(Wilkins et al., 2013). These previous findings indicate that not only is the mitochondrial 
GSH pool critical, but that mitochondrial GSH transport is a major determinant of 
neuronal susceptibility to oxidative stress.  
To further elucidate the importance of mitochondrial GSH transport on neuronal 
viability, we derived NSC34 motor neuron-like cell lines that stably overexpress V5- 
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tagged OGC. Here, we show that the stable OGC cell lines display a specific increase in 
mitochondrial GSH levels. In addition, these OGC stable cell lines are significantly 
resistant to oxidative and nitrosative stress, as well as to a GSH depleting agent, 
ethacrynic acid, but not to a classically Bax- dependent apoptotic inducer, staurosporine. 
Furthermore, the stable OGC cell lines showed a significant upregulation of Bcl-2 protein 
expression, an effect that is dependent on enhanced mitochondrial GSH levels. Finally, 
either chemical inhibition of OGC transport function or knockdown of Bcl-2 using 
siRNA, led to a decrease in mitochondrial GSH levels and re-sensitization of the stable 
OGC cell lines to oxidative stress. It has been previously shown in several systems using 
either recombinant proteins or transient transfection that Bcl-2 and OGC can interact in a 
GSH-dependent manner (Gallo et al., 2011; Wilkins et al., 2012). However, here we 
provide the first evidence that endogenous Bcl-2 and OGC interact in a GSH-dependent 
manner in lysates derived from rat brain. Overall, these findings suggest a synergistic 
mechanism between Bcl-2 and OGC in facilitating mitochondrial GSH transport and 
further establish the importance of mitochondrial GSH transport in sustaining neuronal 
viability under conditions of increased oxidative and nitrosative stress.     
 
4.3 Materials and Methods 
 
4.3.1 Reagents 
 
Phenylsuccinic acid, L-reduced glutathione, ethacrynic acid, staurosporine, 
primary antibody against α-tubulin, and GSH monoethylester were purchased from 
Sigma-Aldrich (St.Louis, MO). The MTT cell viability assay, Geneticin (G418) and 
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Lipofectamine were obtained from Invitrogen (Carlsbad, CA). The GSH assay was 
purchased from Oxford Biomedical (Rochester Hills, MI). The mitochondrial/cytosolic 
fractionation kit was from Biovision (Mountain View, CA). Antibody against cytochrome 
c oxidase IV (Cox-IV) was purchased from Cell Signaling (Beverly, MA). Anti-
glyceraldehyde 3-phosphate dehydrogenase (Anti-GAPDH), anti-Bcl-2, anti-OGC, non-
immune IgG, anti- neuron specific β3 tubulin and anti-V5 antibodies were purchased 
from Abcam (Cambridge, MA). Sodium nitroprusside was purchased from Calbiochem 
(Billerica, MA).  Secondary antibodies for immunoblotting and reagents for enhanced 
chemiluminescence were obtained from GE Life Sciences (Piscataway, NJ). 
DharmaFECT Transfection Kit, Smart pool siRNA against mouse Bcl-2, and Non-target 
siRNA were purchased from Thermoscientific Pierce Biotechnology (Rockford, IL). 
Optimem and Dulbecco’s Modified Eagle’s Medium (DMEM) were obtained from Gibco 
(Carlsbad, CA).  V5-OGC plasmid was a generous gift from Dr. Larry Lash (Wayne 
State University). NSC34 cells were kindly provided by Dr. Neil Cashman (University of 
British Columbia).  
4.3.2 Establishment of stable OGC NSC34 cell lines  
NSC34 cells were plated at 80% confluence in 10 cm cell culture dishes, and 
transfected with 40 μg of V5-OGC plasmid DNA using a standard Lipofectamine 2000 
protocol. At 24 h post transfection cells were split into two cell culture dishes and the 
following day 500 μg/mL of G418 was added to the media to allow for the selection of 
transfected cells.  Media was changed every three days with the addition of 500 μg/mL of 
G418. Clones were then selected and grown in a 24-well plate in duplicate, grown to 
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confluence and immunoblotted for V5 expression. High expressing clones were 
propagated for further experiments.    
4.3.3 Cell culture of parental (wild-type, WT) and stable OGC NSC34 cell lines 
NSC34 WT cultures were grown in DMEM high glucose medium containing 10% 
heat-inactivated fetal bovine serum, 2 mM L-glutamine, and 100 units/ml/100 μg/ml 
penicillin/streptomycin. NSC34 stable OGC cell lines were grown in identical media 
containing 500 μg/mL of G418. Cells were plated on 6-well plates and grown to ∼80% 
confluence at 37 °C in 10% CO2, at which time cells were utilized for the described 
experiments. 
4.3.4 Mitochondrial/ Cytosolic Fractionation 
Cells were treated as indicated in the 4.4 Results section.  Media was aspirated 
and cells were washed once with 1X ice-cold phosphate buffered saline (PBS), pH 7.4. 
One ml of cytosolic buffer, provided in the kit was diluted 1:5 in ddH2O, with added 
protease inhibitor cocktail and 1 mM DTT as per the manufacturer’s recommendations. A 
100 μL aliquot of the cytosolic buffer was added per well and incubated on ice for 20 
min, at which point cells were harvested and homogenized with 40 passes of a Dounce 
homogenizer. Samples were then spun down at 720 rcf for 10 min at 4º C. The 
supernatant was transferred to a new tube which was labeled “mitochondrial fraction” 
and the supernatant was spun down at 10,000 rcf for 30 min at 4ºC. The supernatant was 
transferred to a new tube which was labeled the “cytosolic fraction” and the pellet in the 
mitochondrial fraction tube was re-suspended  in 100 μL of mitochondrial buffer 
(provided in the kit) with protease inhibitor cocktail and 1 mM DTT as per the 
 117 
 
manufacturer’s recommendations. Samples were immediately used for further 
experiments. 
4.3.5 Glutathione Assay 
Total glutathione (reduced GSH+oxidized glutathione (GSSG)) was measured 
using an assay kit (DTNB) from Oxford Biomedical, following the manufacturer's 
protocol. All glutathione measurements were normalized to protein concentration. 
4.3.6 Immunoblot Analysis 
Protein concentrations of samples were determined by a BCA protein assay. 
Equal protein concentrations were subjected to SDS-PAGE, transferred and 
immunoblotted as previously described (Linseman et al., 2001). Briefly, PVDF 
membranes were incubated in blocking solution (10% BSA and 0.01% sodium azide 
diluted in PBS with 0.1% Tween 20; PBS-T) for 1 h at room temperature (RT). The 
primary antibodies were diluted in blocking solution at the manufacturer’s recommended 
dilution and membranes were either incubated with primary antibody for 1 h at RT or 
overnight at 4°C, as per manufacturer’s recommendations. Membranes were then washed 
5x over 30 min with PBS-T. Next, membranes were incubated for 1 h at RT with 
horseradish peroxidase-conjugated secondary antibodies that were diluted to appropriate 
concentrations with PBS-T. Membranes were then washed 5x over 30 min with PBS-T. 
Proteins were detected by enhanced chemiluminescence. 
4.3.7 MTT Viability Assay 
After treatment as indicated in the Figure Legends or Results, cell were incubated 
with 100 μL of 12 mM MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
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bromide) reagent for 4 h at 37°C, 10% CO2.  Next, 2 ml of dimethyl sulfoxide was added 
to solubilize the formazan and the plate was read at 570 nm in a spectrophotometer.      
4.3.8 SMARTPOOL 
®
  siRNA mediated knockdown of Bcl-2 
Stable NSC34 OGC cells were transfected with either the SMARTPOOL
®
 siRNA 
against mouse Bcl-2 or non-target siRNA pool using the DharamaFECT transfection 
protocol. Briefly, 25 nM of appropriate siRNA per well was incubated with 5 µL of 
DharmaFECT transfection reagent separately with serum free medium for 5 min at RT. 
siRNA and DharmaFECT in serum free medium were mixed and incubated at RT for 20 
min. The mixture of siRNA/DharamaFECT was then added to the cells and incubated for 
48 h at 37ºC and at 10% CO2  before subsequent experiments were completed.   
4.3.9 Immunoprecipitation 
Whole rat brain was obtained from two  P7 rats and homogenized with 8 passes of 
the loose pestle and 4 passes of the tight pestle from a dounce homogenizer in 0.1% 
Triton X-100 in lysis buffer containing protease inhibitors and 10 mM reduced GSH.  
The immunoprecipitation reaction consisted of 200 µg of protein lysate with 4 µg 
antibody to Bcl-2, OGC, or non-immune IgG; reactions were incubated overnight at 4°C 
with mixing by inversion. Next, 100 µL of protein A/G agarose beads were incubated 
with the immunoprecipitation reactions for 4 h, 4°C, mixing by inversion. Samples were 
spun down and washed 3x with 0.1% Triton X-100 in lysis buffer, before being resolved 
by SDS-PAGE and immunoblotted. Total lysate was loaded at 100 µg of protein.  All 
animal procedures were performed according to a protocol approved by the University 
of Denver Institutional Animal Care and Use Committee.  
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4.3.10 Statistical Analysis 
One-way analysis of variance (ANOVA) followed by a post hoc Tukey’s test or 
an unpaired Student’s T test was performed to determine statistical significance between 
data sets. A  p value of  < 0.05 was considered to be statistically significant.  
 
4.4 Results 
 
4.4.1 Stable overexpression of OGC specifically increases the mitochondrial GSH pool 
To establish the successful overexpression of V5-tagged OGC we used a parental 
(un-transfected) NSC34 cell line to compare with two separate NSC34 cell lines which 
showed resistance to geneticin. We immunoblotted all cell lines for both the V5 epitope 
tag and OGC protein levels. Both stable OGC cell lines displayed abundant expression of 
V5 and OGC compared to parental NSC34 cells (indicated as wild-type (WT) in Figure 
4.1.A). Lysates were also blotted against β3 tubulin, a neuron specific loading control, 
thus indicating that the overexpression of OGC did not appear to change the neuronal 
phenotype of the NSC34 cells (Figure 4.1.A). Stable OGC cell lines were continually 
monitored for maintenance of high V5-OGC expression throughout the course of the 
experiments.  
In order to examine the effects of stable OGC expression on mitochondrial GSH 
levels, stable cell lines and WT NSC34 cells were fractionated into mitochondrial and 
cytosolic fractions and GSH levels were measured. Both stable OGC cell lines displayed 
a significant and specific approximate two-fold increase in mitochondrial GSH levels 
compared to WT NSC34 cells (Figure 4.1.B). Mitochondrial GSH concentrations 
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calculated as nmoles/mg of protein were as follows, for WT, 24.4 +/-3.4; OGC 3, 50.3 +/- 
8.1; OGC 6, 57.6 +/- 14.7 (mean +/- SEM, n=6).The percentage of mitochondrial GSH 
compared to cytosolic GSH was in a range consistent with previous studies, where the 
mitochondrial GSH pool is between 5% and 30% of total cellular GSH (Lash, 2006). For 
WT NSC34 cells, mitochondrial GSH comprised 4.6% +/- 1.1%, while for OGC 3 
mitochondrial GSH was 7.2% +/- 3.1%,  and for OGC 6 mitochondrial GSH was 12.2% 
+/- 5.6%, of total cellular GSH (mean +/- SEM, n=7). These data further support the 
purity of the cellular fractionations, along with the immunoblots against cytochrome c 
oxidase IV (Cox-IV), a mitochondrial specific protein, and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), a cytosolic marker (Figure 4.1.B).   
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Figure 4.1 Stable overexpression of OGC specifically increases the mitochondrial GSH 
pool A. Whole cell lysates were resolved by SDS-PAGE and immunoblotted against V5, 
OGC and neuron specific β3 tubulin. OGC stable cell lines are indicated as OGC 3 and 
OGC 6; parental NSC34 cells are indicated as wild-type (WT). B. Cells were fractionated 
by differential centrifugation and total GSH content was then measured using a DTNB 
colorimetric assay. Data are represented as a percentage of WT GSH measurements. * 
p<0.05 versus WT mitochondrial GSH; **p<0.01 versus WT mitochondrial GSH in an 
unpaired student’s T-test, n=7, error bars indicate standard error. Cellular fractions were 
resolved using SDS-PAGE and immunoblotted against Cox-IV and GAPDH.  
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4.4.2 The stable OGC NSC34 cell lines are resistant to oxidative stress induced by 
hydrogen peroxide 
To determine if the stable OGC cell lines were more resistant than WT NSC34 
cells to oxidative stress, the reactive intermediate hydrogen peroxide (H2O2) was used. 
Here, we employed two doses of H2O2, 500 μM or 1 mM, for a period of 24 h. In Figure 
4.2.A, brightfield images indicate the distinct cell death induced at both doses of H2O2 in 
the WT NSC34 cell line, and the striking resistance of both OGC stable cell lines to this 
oxidative stressor.  In order to quantify the differences in cell viability between the WT 
and stable OGC cell lines, an MTT assay was employed.  The WT cells displayed a 
significant loss of cell viability compared to the untreated controls at both 500 μM and 1 
mM H2O2 (Figure 4.2.B). However, neither stable OGC cell line showed any significant 
decrease in cell viability at either dose of H2O2 (Figure 4.2.B). Upon completion of these 
experiments, it became clear that both OGC stable cell lines proliferated at a much higher 
frequency compared to the WT NSC34 cells. While all cell lines were plated at one 
million cells per well, increased proliferation of the stable OGC cell lines induced a 
greater cell density compared to WT NSC34 cells. This is important, because we have 
previously shown that increased cell density can lead to increased expression of pro-
survival proteins, such as Bcl-2 and Bcl-XL (Zimmermann et al., 2005). This led us to 
question the effect of the high proliferation frequency of the stable OGC NSC34 cell lines 
on their resistance to oxidative stress.   
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Figure 4.2 The stable OGC NSC34 cell lines are resistant to oxidative stress induced by 
hydrogen peroxide A. After plating cells at one million cells per well, cells were treated 
the following day with either vehicle control (Con); 500 μM H2O2 or 1 mM H2O2 
overnight. Brightfield images were captured following treatment. B. Cells were plated 
and treated as in A, after which an MTT cell viability assay was completed. Data are 
represented as percent of Con for each cell line.  * p<0.05 versus Con; ** p<0.01, 
compared to Con WT; NS, not significant via a one-way ANOVA with posthoc Tukey’s 
test, n=6, error bars indicate standard error.  I acknowledge Samantha Brock for 
assistance in generating the data for this figure. 
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4.4.3 Resistance of OGC overexpressing cell lines to oxidative stress is not dependent on 
cell density 
To address the above possibility, we employed three different cell plating 
densities to discern the dependence on cell density for resistance to oxidative stress. 
Brightfield images are shown to indicate the relative difference in each of the cell 
densities used (Figure 4.3.A). The WT NSC34 cell line showed significant loss of cell 
viability with treatment of H2O2 at each cell density tested (Figure 4.3.B).  In contrast, 
neither stable OGC cell line showed any statistically significant decrement in cell 
viability in response to H2O2 treatment at any of the aforementioned densities (Figure 
4.3.C and 4.3.D). However, there was a trend towards loss of cell viability with H2O2 in 
cells plated at 100,000 cells per well, although it did not reach statistical significance 
(Figure 4.3.C and 4.3.D).  As indicated by the brightfield images in Figure 4.3.A, 
100,000 cells per well is a very sparse density, thus some sensitivity to H2O2 of all three 
cell lines at this cell plating density should perhaps be anticipated. Furthermore, at the 
250,000 and 500,000 cells per well densities this decline was not observed in either of the 
stable OGC cell lines (Figure 4.3.C and 4.3.D). These results indicate that the observed 
resistance of the OGC cell lines to H2O2 is not due to enhanced proliferation or higher 
cell density.  
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Figure 4.3 Resistance of OGC overexpressing cell lines to oxidative stress is not 
dependent on cell density A. Cells were plated at the indicated densities and brightfield 
images were captured the following day. B. After plating of WT NSC34 cells at the 
indicated densities, cells were treated with vehicle control (Con); or the indicated 
concentrations of H2O2 for 24 h. An MTT cell viability assay was completed and data are 
represented as a percent of Con for each cell line. * p<0.05 versus WT Con at 100,000 
cells/well; + p<0.05 versus WT Con at 250,000 cells/well ; ## p<0.01 versus WT Con at 
500,000 cells/well. C. OGC 3 cells were plated and treated as in B with an MTT cell 
viability assay being completed. NS, not significant. D. OGC 6 cells were plated and 
treated as in B with an MTT cell viability assay being completed. NS, not significant. For 
B-D all statistical comparisons were analyzed by one-way ANOVA with posthoc tukey 
test, n=3, error bars indicate standard error. I acknowledge Samantha Brock for assistance 
in generating the data for this figure. 
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4.4.4 Stable overexpression of OGC prevents loss of cell viability in the presence of 
ethacrynic acid 
Ethacrynic acid has previously been shown to non-preferentially deplete both 
mitochondrial and cytosolic pools of GSH, and thus induce cell death. Therefore, to 
determine if enhanced mitochondrial GSH transport affords protection from this GSH 
depleting agent, we examined the toxic effects of ethacrynic acid. Brightfield images are 
shown of representative fields for each cell line at both doses of ethacrynic acid used 
(Figure 4.4.A). The WT NSC34 cell line displayed significantly reduced cell viability 
following exposure to two doses of ethacrynic acid (Figure 4.4.B). In contrast, stable 
OGC overexpression prevented this loss of cell viability induced by ethacrynic acid 
(Figure 4.4.B). Therefore, enhanced mitochondrial GSH transport prevents cell death 
induced by the depletion of total cellular GSH levels, illustrating the key role of the 
mitochondrial GSH pool in maintaining neuronal survival.   
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Figure 4.4 Stable overexpression of OGC prevents loss of cell viability in the presence of 
ethacrynic acid A. Cells were plated at one million cells per well, following which cells 
were treated with vehicle control (Con); 50 μM or 70 μM  ethacrynic acid (EA) for 24 h. 
Brightfield images were captured following treatment. B. Cells were treated as in A, 
following which an MTT cell viability assay was completed, Data are represented as a 
percent of Con for each cell line. ** p<0.01 compared to WT Con; NS, not significant via 
a one-way ANOVA with posthoc Tukey’s test, n=4, error bars indicate standard error. I 
acknowledge Josie Gray for assistance in generating the data for this figure. 
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4.4.5 Overexpression of OGC renders NSC34 cells resistant to nitrosative stress 
The nitric oxide donor, sodium nitroprusside (SNP), was used to induce 
nitrosative stress and determine if enhanced mitochondrial GSH transport would protect 
from this insult. Brightfield images taken after SNP treatment indicated that the WT 
NSC34 cells were sensitive to both doses of SNP used, but no toxic effect was observed 
in either of the OGC stable cell lines (Figure 4.5.A). The WT cells displayed a significant 
loss of cell viability as measured by an MTT assay at both SNP doses (Figure 4.5.B). 
However, neither OGC cell line showed any significant decrement in cell viability in 
response to SNP (Figure 4.5.B). Therefore, overexpression of the mitochondrial GSH 
transporter, OGC, and thus enhancement of mitochondrial GSH transport, reduces 
neuronal sensitivity to nitrosative stress conditions.   
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Figure 4.5 Overexpression of OGC renders NSC34 cells resistant to nitrosative stress A. 
Cells were plated at one million cells per well, following which cells were treated with 
vehicle control (Con), 200 μM or 250 μM  sodium nitroprusside (SNP) for 24 h. 
Brightfield images were captured following treatment. B. Cells were treated as in A, 
following which an MTT cell viability assay was completed, Data are represented as a 
percent of Con for each cell line. ** p<0.01 compared to WT Con; NS, not significant via 
a one-way ANOVA with posthoc Tukey’s test, n=4, error bars indicate standard error. I 
acknowledge Samantha Brock for assistance in generating the data for this figure. 
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4.4.6 Stable overexpression of OGC does not protect NSC34 motor neuron-like 
cells from staurosporine-induced apoptosis 
We next examined the ability of enhanced mitochondrial GSH transport, and thus 
increased mitochondrial GSH content, to protect from a non-oxidative cell death 
mechanism. Stable OGC cell lines and WT NSC34 cells were treated with two doses of 
staurosporine (STS), a classically Bax-dependent method of inducing intrinsic apoptosis. 
WT and OGC 3 NSC34 cells both displayed the caspase-generated cleavage product of 
PARP in response to STS treatment, indicating an apoptotic mode of cell death (Figure 
4.6.A). Furthermore, WT NSC34 cells and both stable OGC cell lines displayed similar 
significant decreases in cell viability at both doses of STS (Figure 4.6.B). Therefore, 
stable overexpression of the mitochondrial GSH transporter, OGC, did not afford 
protection from this classical (non-oxidative) apoptotic insult. These data demonstrate the 
specificity of increased mitochondrial GSH transport for enhancing the resistance of 
neuronal cells to oxidative damage.  
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Figure 4.6 Stable overexpression of OGC does not protect NSC34 motor neuron-like 
cells from staurosporine-induced apoptosis A. Cells were plated at one million cells per 
well, following which cells were treated with vehicle control (Con); 100 nM or 500 nM 
staurosporine (STS) for 24 h. Cells were lysed and proteins were resolved by SDS-
PAGE, immunoblot against PARP was completed. FlPARP-full length PARP, Clvg-
PARP-cleavage of PARP. B. Cells were treated as in A, following which an MTT cell 
viability assay was completed, Data are represented as a percent of Con for each cell line. 
** p<0.01 compared to WT Con; *p<0.05 compared to OGC 3 or OGC 6 Con via a one-
way ANOVA with posthoc Tukey’s test, n=4, error bars indicate standard error.  
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4.4.7 Chemical inhibition of OGC transport function specifically reduces mitochondrial 
GSH and re-sensitizes OGC stable cell lines to oxidative stress induced by hydrogen 
peroxide. 
Phenylsuccinate is a chemical analog of 2-oxoglutarate that specifically blocks 
transport through the OGC. In order to show that enhanced mitochondrial GSH transport 
was responsible for conferring resistance of both stable OGC cell lines to oxidative stress, 
phenylsuccinate was used to inhibit OGC-dependent transport. First, we examined the 
effects of phenylsuccinate on mitochondrial GSH levels. Both OGC stable cell lines 
showed significant and specific decreases in mitochondrial GSH suggesting that 
phenylsuccinate successfully reduced the transport of GSH into the mitochondria (Figure 
4.7.A). Following phenylsuccinate treatment, the mitochondrial GSH concentrations 
calculated as nmoles/mg were 29.8 +/- 5.3 for OGC 3 and 20.9 +/- 5.5 for OGC 6 (mean 
+/- SEM, n=3). Therefore, phenylsuccinate lowered the mitochondrial GSH 
concentrations in both OGC 3 and OGC 6 to approximately WT levels (24.4 +/- 3.4 as 
discussed in Figure 4.1). Cox-IV and GAPDH immunoblots indicate the purity of the 
mitochondrial fractions (Figure 4.7.A). Next, OGC stable cell lines were co-incubated 
with phenylsuccinate and H2O2, phenylsuccinate alone, or H2O2 alone and cell viability 
was measured. Following incubation with phenylsuccinate or H2O2 alone, neither OGC 
cell line showed any significant decrease in cell viability (Figure 4.7.B and 4.7.C). 
However, both cell lines showed significant reductions in cell viability at both doses of 
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H2O2 when OGC was simultaneously inhibited with phenylsuccinate, as compared to 
cells that were treated with H2O2  alone (Figure 4.7.B and 4.7.C).  
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Figure 4.7 Chemical inhibition of OGC transport function specifically reduces 
mitochondrial GSH and re-sensitizes OGC stable cell lines to oxidative stress induced by 
hydrogen peroxide A. Stable OGC NSC34 cells were treated with 10 mM 
phenylsuccinate (PS) overnight. Cells were then fractionated using differential 
centrifugation. Cell fractions were measured for total GSH using a DTNB colorimetric 
assay. Data are represented as a percent of untreated control (Con) GSH. *p<0.05 
compared to OGC 3 Con** p<0.01 versus OGC 6 Con; NS, not significant via a 
Student’s T-test. n=4, error bars indicated standard error. Cell fractions were resolved by 
SDS-PAGE and immunoblotted against Cox-IV and GAPDH.  B. Stable OGC 3 NSC34 
cells were treated with 10 mM PS alone or in combination with 500 µM or 1 mM H2O2. 
At 24 h after treatment an MTT assay was completed and data are represented as percent 
of the representative   Con. * p<0.05, **p<0.01 versus Con, NS, not significant; via a 
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one-way ANOVA with posthoc Tukey’s test n=3, error bars indicate standard error. C. 
Stable OGC 6 NSC34 cells were treated with 10 mM PS alone or in combination with 
500 µM or 1 mM H2O2. At 24 h after treatment an MTT assay was completed and data 
are represented as percent of the representative control (Con). * p<0.05, ** p<0.01 versus 
Con, NS, not significant; via a one-way ANOVA with posthoc Tukey’s test n=5, error 
bars indicate standard error. 
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4.4.8 Specific increases in mitochondrial GSH induce an increase of the anti-apoptotic 
protein Bcl-2 
Previous studies using recombinant proteins or transient overexpression 
constructs have shown that Bcl-2 and OGC are interacting partners (Gallo et al., 2011; 
Wilkins et al., 2012). Thus, Bcl-2 protein levels were examined in the OGC stable cell 
lines and interestingly, both lines displayed increased Bcl-2 expression, compared to WT 
NSC34 cells (Figure 4.8.A) (approximate 5 fold increase). In order to determine if the 
increased Bcl-2 expression was generally due to stable OGC overexpression or more 
specifically, to increased mitochondrial GSH, WT NSC34 cells were chronically treated 
(for 48 h) with the cell-permeable GSH monoethylester (GSH-MEE). In Figure 4.8.B, we 
show that chronic exposure to GSH-MEE specifically increased mitochondrial GSH 
levels, with no significant effect on the cytosolic pool. Cox-IV and GAPDH immunoblots 
indicate the purity of the mitochondrial and cytosolic fractions (Figure 4.8.B).  Next, WT 
NSC34 cells chronically pre-treated with GSH-MEE were immunoblotted for Bcl-2 
protein levels, which were significantly increased compared to untreated WT NSC34 
cells (Figure 4.8.C) (approximate 2 fold increase). Overall, these data show that an 
upregulation of Bcl-2 protein expression occurs as a result of specifically increased 
mitochondrial GSH levels.    
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Figure 4.8 Specific increases in mitochondrial GSH induces an increase of the anti-
apoptotic protein Bcl-2 A. Lysates were resolved by SDS-PAGE and immunoblotted 
against Bcl-2 and α-tubulin. Densitometry was completed for Bcl-2 and was normalized 
to α-tubulin. Data are represented as percent of WT Bcl-2 levels. *p<0.05 versus WT via 
a one way ANOVA with post-hoc Tukey’s test, n=3, error bars indicate standard error. B. 
WT NSC34 cells were treated for 48 h with 2 mM GSH-MEE, fractionated by 
differential centrifugation and total GSH was measured using a DTNB colorimetric 
assay. Data are represented as a percent of Con GSH. **p<0.01 versus Con via an 
unpaired student’s T-test n=7, error bar indicate standard error. Samples were resolved by 
SDS-PAGE and immunoblotted against Cox-IV and GAPDH. C. WT NSC34 cells 
treated as in B were lysed and proteins were resolved by SDS-PAGE. Immunblots against 
Bcl-2 and α-tubulin were completed. Densitometry was completed for Bcl-2 and 
normalized to α-tubulin. Data are represented as a percent of the Con Bcl-2 expression. * 
p<0.05 versus Con via an unpaired student’s T-test; n=3, error bar indicate standard error.   
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4.4.9 The siRNA mediated knockdown of Bcl-2 specifically decreases mitochondrial 
GSH and re-sensitizes OGC overexpressing NSC34 cells to oxidative stress. 
We have previously shown that inhibition of OGC-dependent GSH transport 
prevents the ability of Bcl-2 overexpression to protect CHO cells from H2O2-induced 
oxidative stress (Wilkins et al., 2012). Therefore, we hypothesized that Bcl-2 induction 
may be reciprocally necessary for OGC-dependent protection of NSC34 cells from 
oxidative stress. To determine if the increased expression of Bcl-2 was instrumental in 
rendering the OGC stable cell lines resistant to oxidative stress, we used a 
SMARTPOOL
®
 siRNA to specifically knockdown Bcl-2 in the stable OGC 6 cell line. 
OGC 6 cells were transfected with either non-target or Bcl-2 siRNA for 48 h and Bcl-2 
protein levels were examined. As shown in Figure 4.9.A, the Bcl-2 siRNA markedly 
reduced Bcl-2 protein levels compared to the non-target control (an average of 47.3% +/- 
8.1 % reduction in Bcl-2 protein levels, mean +/-SEM, n=5). Next, we examined the 
effects of reduced Bcl-2 levels on mitochondrial GSH content. Knockdown of Bcl-2 
protein levels induced a specific 35% reduction in mitochondrial GSH content compared 
to non-target transfected cells (Figure 4.9.B). Cox-IV and GAPDH blots indicate pure 
cellular fractionations (Figure 4.9.B). Based on the specific reduction in mitochondrial 
GSH with siRNA-mediated knockdown of Bcl-2 protein levels, we hypothesized that 
these cells would be re-sensitized to oxidative stress. Indeed, OGC 6 cells transfected 
with siRNA against Bcl-2 displayed a statistically significant reduction in cell viability 
with both concentrations of H2O2, whereas no decrease in cell viability was observed 
with the non-target control (Figure 4. 9.C). Experiments were also completed comparing 
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the non-target siRNA against a no transfection control and no significant differences in 
Bcl-2 protein levels, mitochondrial GSH content, or cell viability were observed (data not 
shown).  
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Figure 4.9 The siRNA mediated knockdown of Bcl-2 specifically decreases mitochondrial 
GSH and re-sensitizes OGC overexpressing NSC34 cells to oxidative stress A. Stable 
OGC 6 NSC34 cells were transfected with either non-target or Bcl-2 siRNA at 25 nM for 
48 h. Cells were lysed, proteins were resolved by SDS-PAGE and immunoblotted against 
Bcl-2 and β3-tubulin. Densitometry of Bcl-2 normalized to β3 tubulin showed a 43.3% 
+/- 8.1% (mean +/- SEM, n=5) reduction in Bcl-2 levels in siRNA Bcl-2 transfected cells 
compared to non-target transfection. B.  Cells transfected as in A, then fractionated by 
differential centrifugation and total GSH content was measured using a colorimetric 
DTNB  assay. Data are represented as a percent of the Non-target control. *p<0.05 
compared to non-target via an unpaired student’s T-test, n=6, error bars indicate standard 
error.  C. Cells were transfected as in A, treated with vehicle control (Con); 500 μM or 1 
mM H2O2. Cell viability was assed via an MTT assay.  *p<0.05 versus Con siRNA; **, 
p<0.01 versus con siRNA; NS, not significant via a one-way ANOVA with posthoc 
Tukey’s test. n=5, error bars indicate standard error. 
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4.4.10 Bcl-2 and OGC co-immunoprecipitate from rat brain lysates in a GSH-dependent 
manner 
As stated previously, Bcl-2 and OGC have been demonstrated to be interacting partners. 
However, past studies have used recombinant and protein overexpression systems to 
show the association between these two proteins (Wilkins et al., 2012). Therefore, we 
aimed to determine if the Bcl-2 and OGC interaction could be observed in a system with 
endogenous levels of protein expression. Here, we used whole rat brain lysates in the 
presence of high (10 mM) GSH to perform co-immunoprecipitation reactions. As shown 
in Figure 4.10.A, Bcl-2 co-immunoprecipitated with OGC and OGC co-
immunoprecipitated with Bcl-2 in a GSH-dependent manner.  The co-
immunoprecipitation did not occur without the addition of high GSH (Figure 4.10.B). 
Finally, an IgG immunoprecipitation is shown as a control for non-specific binding 
(Figure 4.10.A).   
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Figure 4.10 Bcl-2 and OGC co-immunoprecipitate from rat brain lysates in a GSH-
dependent manner A. Whole rat brain was homogenized in 0.1% Triton X-100 in lysis 
buffer with protease inhibitors and 10 mM GSH-MEE. Immunoprecipitation reactions 
were completed using either an IgG, Bcl-2, or OGC antibody. Samples were resolved by 
SDS-PAGE and immunoblotted against Bcl-2 and OGC. Tot=total lysate. B. Samples 
were prepared as in A except without GSH-MEE. Immunoprecipitation reactions were 
completed using either an IgG or OGC antibody. Samples were resolved by SDS-PAGE 
and immunoblotted against Bcl-2 and OGC. Tot=total lysate. 
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4.5 Discussion 
Previous studies have shown that the overexpression of mitochondrial GSH 
transporters (OGC and DIC) renders kidney and liver derived cell lines resistant to 
apoptotic stimuli (Xu et al., 2006; Zhong et al., 2008). However, very limited information 
is available on the role of these mitochondrial GSH transporters in neuronal systems. 
Here, we generated stable V5-tagged OGC cell lines using immortalized mouse NSC34 
motor neuron-like cells. NSC34 motor neuron-like cells afforded ease of transfection, 
however, because NSC34 cells are an immortalized cell line, they only approximate the 
phenotypic characteristics of motor neurons. NSC34 cells differ from primary motor 
neurons because they lack synaptic transmission; however they do share some similarities 
with motor neurons such as, sensitivity to insults that block voltage-gated ion channels 
and axonal transmission (Durham et al., 1993). Furthermore, the stable NSC34 OGC cell 
lines appeared to retain their neuronal phenotype, as shown through the continued 
expression of neuron-specific β3 tubulin, despite showing enhanced proliferation 
compared to parental NSC34 cells. Stable overexpression of OGC in the NSC34 cells led 
to a significant and specific increase in mitochondrial GSH levels and a corresponding 
increase in resistance of these cells to oxidative stress. These data suggest an interesting 
question of whether OGC might play a role in mitochondrial GSH transport within 
primary motor neurons.  Indeed, OGC is abundantly expressed in mouse spinal cord 
(Wilkins and Linseman, unpublished data). Thus, further studies are warranted in primary 
motor neurons, especially given the profound resistance observed with enhanced 
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mitochondrial GSH transport against both oxidative and nitrosative stress, major 
pathogenic factors in neurodegenerative motor diseases like ALS.  
While it may be anticipated that overexpression of a mitochondrial GSH 
transporter would lead to an increase in mitochondrial GSH and enhanced neuronal cell 
resistance to oxidative and nitrosative stress, it is quite novel that stable OGC cells also 
displayed a marked increase in Bcl-2 protein levels. Furthermore, the upregulation of 
Bcl-2 could be recapitulated by chronic exposure of parental NSC34 cells to a cell-
permeable form of GSH, which similarly produced a specific increase in mitochondrial 
GSH levels. Our data are consistent with previous studies which showed that modulation 
of total cellular GSH levels results in the alteration of Bcl-2 protein levels (Ho et al., 
1997; Celli et al., 1998). However, these prior studies only examined the relationship 
between manipulating total cellular GSH content and Bcl-2 protein expression. To our 
knowledge, this is the first study to demonstrate that Bcl-2 protein expression is explicitly 
regulated by mitochondrial GSH levels.  
Several mechanisms could lead to an increase in Bcl-2 protein levels, including 
decreased proteasome-dependent degradation, de-repression of Bcl-2 transcription or 
translation (such as through microRNAs), or upregulation of Bcl-2 transcription. Celli et 
al. (1998) showed that Bcl-2 protein levels were down-regulated in response to depletion 
of total cellular GSH levels in a liver cell line due to increased Bcl-2 protein degradation 
by the proteasome. MicroRNA involvement has also been implicated in the regulation of 
Bcl-2 expression. Two microRNAs, miR-15 and miR-16, have been shown to down-
regulate Bcl-2 expression, a process that is deficient in chronic lymphocytic leukemia 
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lymphocytes (Cimmino et al., 2005). Whether microRNAs are relevant to the 
upregulation of Bcl-2, demonstrated here in our model is unknown, however it is 
interesting to note that chronic lymphocytic leukemia lymphocytes have been shown to 
have an approximate two-fold increase in GSH, a common observation in most cancerous 
cells which overexpress Bcl-2 (Ferraris et al., 1994).  
While the above mechanisms may contribute to increased Bcl-2 protein levels in 
response to changes in total cellular GSH, mitochondrial redox alterations specifically, 
have been shown to modulate protein kinase A (PKA) and downstream cyclic AMP  
response element binding protein (CREB) transcriptional activities (Lee et al., 2005; Ryu 
et al. 2005). Importantly, CREB has been shown to contribute significantly to Bcl-2 
transcriptional regulation and is known as a redox sensitive transcription factor (Wilson 
et al., 1996).  PKA is activated through an auto-phosphorylation event induced by cyclic 
AMP (cAMP), and a discrete pool of PKA appears to localize to the outer mitochondrial 
membrane where it is associated with A kinase anchoring protein (AKAP121) (Affaitati 
et al., 2003; Ginsberg et al., 2003). It has been previously shown that cAMP generated 
through a mitochondrial soluble adenylyl cyclase which is sensitive to ATP production, 
allows for the phosphorylation and activation of mitochondrial localized PKA (Acin-
Perez et al., 2009). Furthermore, antioxidants such as the iron chelator deferoxamine, can 
increase the activity of mitochondrial PKA/CREB, while inhibition of PKA prevented the 
protective action of deferoxamine against GSH depletion (Ryu et al., 2005). Finally, the 
association of PKA with AKAP121 has been shown to promote the translocation of 
mRNA of nuclear encoded mitochondrial proteins from the cytosol to the outer 
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mitochondrial membrane, thus allowing their translation to occur locally at that site 
(Ginsberg et al., 2003). While, we have not yet elucidated the mechanism allowing for 
the upregulation of Bcl-2 protein levels in response to chronically elevated mitochondrial 
GSH, an increase in Bcl-2 transcription through the PKA/CREB axis, specifically at the 
level of the mitochondria, is most supported by previous studies. Overall, our data 
indicate a novel mitochondria-to-nucleus redox sensitive signaling mechanism in the 
regulation of Bcl-2 protein expression.  
We have previously shown that Bcl-2 interacts with OGC in a GSH-dependent 
manner using both recombinant and protein overexpression systems (Wilkins et al., 
2012). The Bcl-2 homolog, CED9, was also shown to be an interacting partner for the 
OGC homolog, MISC-1, in C. elegans, suggesting this interaction is evolutionarily 
conserved (Gallo et al., 2011).  Here, we show that Bcl-2 and OGC interact in a GSH-
dependent manner in rat brain lysates, thus verifying this interaction within an 
endogenous expression system. We have previously demonstrated the dependence of the 
protective effects of Bcl-2 on the transport function of OGC; treatment of CHO cells 
overexpressing both Bcl-2 and OGC with the OGC inhibitor, phenylsuccinate, prevented 
the ability of Bcl-2 to protect from oxidative stress (Wilkins et al., 2012). Our current 
data show that the knockdown of Bcl-2 through siRNA prevents the ability of 
overexpressed OGC to protect NSC34 cells from oxidative stress. The knockdown of 
Bcl-2 also led to a significant and specific decrease in mitochondrial GSH levels in the 
stable OGC overexpressing cell lines. Therefore, we have provided compelling evidence 
that OGC and Bcl-2 are interacting partners that work in conjunction to modulate 
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mitochondrial GSH transport and sensitivity to oxidative and nitrosative stress 
conditions. Moreover, the protection against oxidative stress afforded by Bcl-2 or OGC 
overexpression are reciprocally dependent upon one another.   
Overall, we show that enhancing mitochondrial GSH transport through the 
overexpression of OGC provides two main cytoprotective mechanisms. First, 
overexpression of OGC specifically increased mitochondrial GSH content and rendered 
NSC34 cells resistant to oxidative and nitrosative stress conditions. Second, the specific 
increase in mitochondrial GSH induced by the overexpression of OGC produced a 
corresponding increase in Bcl-2 protein levels. These findings are important to the field 
of neurodegeneration especially, because Bcl-2 expression is often decreased in these 
diseases. For example, Bcl-2 expression is diminished in spinal cord tissue from both 
ALS patients and in a mutant SOD1 mouse model of familial ALS (Mu et al., 1996; 
Vukosavic et al., 1999). Furthermore, it has been shown that the ratio of GSH/GSSG is 
also decreased in mitochondria isolated from spinal cord of mutant SOD1 mouse models 
of familial ALS, and we have recently found that total mitochondrial GSH content is 
significantly decreased in lumbar spinal cord from end-stage G93A mutant SOD1 mice 
(Ferri et al., 2006; Pesaresi et al., 2011; Wilkins and Linseman, unpublished data). 
Therefore, modulating mitochondrial GSH transport could prove to be a significant 
therapeutic target in neurodegenerative diseases like ALS in which Bcl-2 expression is 
diminished.   
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4.6 Innovation 
Increased expression of Bcl-2 has previously been shown to enhance cellular 
GSH content. Here, we show that specifically increasing mitochondrial GSH content 
through OGC-dependent transport reciprocally induces Bcl-2 expression. Moreover, this 
increased Bcl-2 expression is necessary for the enhanced resistance of neuronal cells to 
oxidative stress provided by overexpression of OGC.  These data suggest a novel redox 
sensitive mitochondria-to-nucleus signaling mechanism for the regulation of Bcl-2 
expression and identifies mitochondrial GSH transport as a new therapeutic target in 
neurodegenerative diseases in which Bcl-2 expression is diminished.  
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CHAPTER FIVE: DISCUSSION 
 
Emerging evidence suggests that the discrete pool of mitochondrial GSH is 
critical for cell survival. Despite this, the role mitochondrial GSH transport contributes in 
determining cell resistance to apoptosis has not been elucidated, particularly in neurons. 
Mechanisms of mitochondrial GSH transport within the CNS are not well understood and 
this includes both the carriers responsible and their regulation. The pro-survival protein, 
Bcl-2, which acts as a suppressor of pro-apoptotic proteins, also functions in an 
antioxidant-like mechanism. However, studies indicating a significant correlation 
between Bcl-2 and cellular GSH trafficking had not been furthered, until recently. 
Zimmermann et al. described a novel role for Bcl-2 as a GSH binding protein and 
depicted that inhibition of Bcl-2 led to mitochondrial GSH efflux (Zimmermann et al., 
2007). Thus, the major goals of this thesis were to provide insight into the role Bcl-2 may 
contribute in maintaining the mitochondrial GSH pool, the carriers responsible for 
mitochondrial GSH transport in neurons and astrocytes, and the significance of 
mitochondrial GSH transport in neuronal survival.    
5.1 Summary of Major Findings 
Chapter 2 of this thesis provided evidence for a direct role of Bcl-2 in 
mitochondrial GSH transport. Inhibition of Bcl-2 led to a specific and significant 
reduction in mitochondrial GSH levels, induced MOS, prevented the interaction between 
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Bcl-2 and GSH, and inhibited mitochondrial GSH transport. After these observations, a 
mechanism in which Bcl-2 contributes to mitochondrial GSH transport was shown 
through a novel GSH-dependent Bcl-2/OGC interaction. In addition,  the observation that 
Bcl-2 and OGC work in a concerted manner to enhance mitochondrial GSH transport and 
that Bcl-2 is dependent on the transport function of OGC to  protect against oxidative 
stress, further demonstrates the importance of these proteins in regulating  mitochondrial 
redox status through GSH.  
The main goals of Chapters 3 and 4 of this thesis were to examine the importance 
of mitochondrial GSH transport in neuronal systems. Chapter 3 elucidated that 
mitochondrial GSH transport mechanisms are variable between primary cerebellar 
astrocytes and CGNs. In addition, discrete inhibition or molecular knockdown of a single 
mitochondrial GSH transporter, in CGNs, rendered these primary neurons more 
susceptible to oxidative and nitrosative stress conditions. Chapter 4 focused on the 
protective ability of enhanced mitochondrial GSH transport. In order to examine this a 
stable cell line overexpressing OGC  was developed in the motor neuron-like cell, NSC34 
(mouse neuroblastoma fusion with mouse motor neuron cultures). The stable OGC cell 
lines were significantly resistant to oxidative and nitrosative stress, as well as the GSH 
depleting agent, ethacrynic acid. The major finding in Chapter 4 was the ability of 
enhanced mitochondrial GSH content to induce an upregulation of Bcl-2 protein levels. 
Similar to the finding of Chapter 2, the ability of OGC to protect from oxidative stress 
was dependent on enhanced Bcl-2 expression. Finally, Bcl-2 and OGC were shown to 
interact endogenously from rat brain lysates in a GSH-dependent manner. The work 
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completed in this thesis provides substantial evidence for a role of Bcl-2 in mitochondrial 
GSH transport and the significant importance of mitochondrial GSH transport in 
determining neuronal viability. However, what contribution does enhancing the 
bioavailability of GSH, within the context of neurodegenerative diseases, provide in 
regards to providing an efficacious treatment option? This question and the role of 
mitochondrial GSH transport within ALS disease pathology are discussed below. 
5.2 Enhancing Glutathione synthesis as a therapeutic approach for ALS 
It is not surprising that antioxidant therapies have been examined in 
neurodegenerative diseases, given the role oxidative and nitrosative stress contribute to 
disease pathogenesis; however all of the various antioxidants attempted (including 
enhancing GSH synthesis by providing GSH precursors) have failed in clinical trials 
especially for ALS. The efficacy of modulating GSH levels within the context of ALS 
has been previously studied through the use of GSH precursors, such as N-acetylcysteine 
(NAC) and N-acetylmethionine (NAM). In the G93A mutant SOD1 mouse model of 
ALS, NAC significantly delayed disease progression and prolonged survival (Andreassen 
et al., 2000). However, in clinical trials NAC failed to show any discernible effect on 
disease progression or survival in a randomized, double blind, placebo controlled study 
(Louwerse et al., 1995). In a separate clinical trial, a combination therapy which included 
NAC and NAM (among other antioxidants), reported no significant effect on survival for 
ALS patients (Vyth et al., 1996).  To further elucidate the efficacy of GSH precursors as 
a therapeutic intervention for ALS, a whey protein supplement which has a high content 
of double bonded cysteine (cystine), known as Immunocal®, was tested in the G93A 
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mutant SOD1 mouse model. Immunocal® preserved GSH levels and the GSH/GSSG 
ratio in blood and lumbar spinal cord from end-stage G93A mutant SOD1 mice, 
compared to non-treated mutant mice (Figure 5.1). Immunocal® treatment led to a 
significant delay in disease onset and slowed the rate of motor decline, as shown through 
grip strength measurements (Figure 5.2). However, no effect was observed on survival 
with Immunocal® in the G93A mutant SOD1 mouse model (Figure 5.2). Overall, these 
data indicate two possible hypotheses, first being that antioxidant therapy particularly at 
the level of increasing GSH synthesis is not an efficacious ALS therapy. The second 
hypothesis, is that while providing precursors for GSH synthesis appears to delay disease 
onset in animal models of ALS (this is not an effect that could be observed in human 
patients), it is unable to provide an effect on disease survival because the available GSH 
pool is unable to be transported into mitochondria. As discussed earlier, mitochondrial 
GSH has been shown in diverse models to be the most critical reservoir of this 
antioxidant for cell survival (Meredith and Reed, 1982; Meredith and Reed, 
1983;Wüllner et al., 1999; Muyderman et al., 2007).  Indeed, upon examination of 
mitochondrial GSH levels in lumbar spinal cord of end-stage G93A mutant SOD1 mice, 
it was found that Immunocal® failed to preserve this critical pool of GSH (Figure 5.3). 
These findings suggest the interesting possibility that the failure of GSH synthesis 
precursors within ALS clinical trials may stem from a failure of the newly synthesized 
GSH to be efficiently transported into mitochondria.   
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Figure 5.1 HPLC-EC detection reveals whole blood and lumbar spinal cord GSH is 
depleted in the hSOD1G93A mouse model of ALS and is preserved at NonTG levels in 
hSOD1G93A  mice receiving Immunocal
®
 A. Mean GSH concentrations from the whole 
blood of end stage trial animals, ** p<.01, * p<.05, n=13. B. GSH/GSSG ratios from the 
whole blood of end stage trial animals, ** p<.01, n=13. C. Mean GSH concentrations 
from the lumbar spinal cord of end stage trial animals. * p<.05, n=17.  D. GSH/GSSG 
ratios from the lumbar spinal cord of end stage trial animals. * p<.05, n=17. I 
acknowledge Erika Ross for assistance in generating the data for this figure. 
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Figure 5.2 Immunocal® delays clinical onset and diminishes the rate of decline in grip 
strength in the hSOD1G93A mouse model of ALS A. Median survival is not significantly 
different between hSOD1
G93A
 mice receiving Immunocal® ad libitum beginning at 60 
days of age and untreated mutant mice (n= 13). B. hSOD1
G93A
 mice receiving 
Immunocal® ad libitum  beginning at 60 days of age displayed a delay in disease onset 
and clinical decline compared to untreated mutant mice (n=13). Onset curves are 
significantly different (p<.001) determined by Gehan-Breslow-Wilcoxon Test. C. PaGE 
hanging wire test represented as (mean ± SEM) latency to fall at indicated ages (n=13). 
*** indicates p<.001 compared to NonTG, ** indicates p<.01 compared to NonTG, † 
indicates p<.05 compared to hSOD1
G93A
 mice (one-way ANOVA with a post-hoc 
Tukey’s test). I acknowledge Erika Ross for assistance in generating the data for this 
figure. 
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Figure 5.3 Immunocal® fails to preserve mitochondrial GSH levels from lumbar spinal 
cord of end-stage G93A SOD1 mice Mitochondria were isolated from lumbar spinal cord 
using a Percoll gradient and differential centrifugation. Total GSH was measured using a 
DTNB colorimetric assay. All measurements of total GSH are normalized to protein and 
represented as nmols/mg. *p<0.05, **p<0.01, NS=not significant via a One-way 
ANOVA with post hoc Tukey’s test, n=4, error bars indicated SEM.    
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Mitochondrial GSH levels in this disease model were further examined at disease 
onset (~90 days) and end-stage (~120 days) time points in lumbar spinal cord and cortex. 
Mitochondrial GSH did not show a significant reduction in either lumbar spinal cord or 
cortex at disease onset in the G93A mutant SOD1 mouse model (Figure 5.4). However, 
end-stage animals displayed a significant decrease in mitochondrial GSH in lumbar 
spinal cord. This effect was not significant in mitochondria isolated from cortex, but did 
display a trend towards significant depletion (Figure 5.4). These data are consistent with 
prior studies showing that G93A mutant SOD1, both in vitro (overexpression in NSC34 
cells) and in vivo (mouse model) causes a disruption in mitochondrial GSH/GSSG ratios 
(Ferri et al., 2006; Pesaresi et al., 2011). Next, the ability of mitochondria from this 
mouse model to transport GSH was assessed. While mitochondria isolated from both 
wild-type (NonTg) and G93A mutant SOD1 lumbar spinal cord displayed a large 
increase in GSH content during the incubation period, there was an ~50% reduction in 
the ability to take up GSH in mitochondria isolated from G93A mutant SOD mice (Figure 
5.4). The effect observed was specific to isolated mitochondria from lumbar spinal cord 
of G93A mutant SOD1 mice, as mitochondria isolated from mutant cortex did not show a 
deficit in mitochondrial GSH uptake compared to NonTg controls (Figure 5.4).  Overall, 
these data strongly support the notion that mitochondrial GSH transport is compromised 
in the G93A mutant SOD1 mouse model of ALS.  
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Figure 5.4 Mitochondrial GSH levels and transport in the G93A mutant SOD1 mouse 
model A. Mitochondria were isolated from WT (NonTg) G93A mutant SOD1 
(hSOD1
G93A
) mice at onset (~90 days old) and end-stage (~120 days old) from lumbar 
spinal cord and whole cortex as described in Figure 5.3. Total GSH was measured using a 
DTNB colorimetric assay. All measurements were normalized to protein and represented 
as a percent of NonTg. ***p<0.001, NS=not significant via an unpaired student’s T-test, 
n=4, error bars indicated SEM. B. Mitochondria were isolated from lumbar spinal cord 
and cortex of end-stage (~120 days old) G93A mutant SOD1 (hSOD1
G93A
) and age-
matched WT (NonTg) mice as described in Figure 5.3. Isolated mitochondria were 
incubated with 2 mM GSH at 37 °C, 300 rpm for 4 h. After which, mitochondria were 
washed 3x and total GSH was measured using a DTNB colorimetric assay. All 
measurements were normalized to protein and represented as μmoles/mg of GSH loaded 
per hour. *p<0.05, NS=not significant, via a paired student’s T-test, n=7, error bars 
indicated SEM.   
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5.3 Mechanisms of decreased mitochondrial glutathione transport in ALS 
 There are several mechanisms by which mitochondrial GSH transport could be 
compromised within the context of ALS disease pathology. First, Bcl-2 expression and 
function are compromised in ALS and as this thesis has depicted, Bcl-2 contributes a 
significant role in mitochondrial GSH transport. Second, the expression levels of other 
mitochondrial GSH carriers could be down-regulated in the lumbar spinal cord, such as 
DIC and OGC. Finally, post-translational modifications that occur with increased 
oxidative and nitrosative stress (such as S-nitrosylation, thiol oxidation, or 
carbonylation), may compromise function of Bcl-2 or the previously identified 
mitochondrial GSH transporters. All of these hypotheses are discussed below.  
5.3.1 Aberrant changes in Bcl-2 function and expression as a mechanism of 
decreased mitochondrial glutathione transport in ALS 
The compromise of Bcl-2 function and expression in ALS could lead to a 
profound impact on the ability of mitochondria to transport GSH.  In the G93A mutant 
SOD1 mouse model of ALS, Bcl-2 adopts a “toxic” conformation induced through its 
interaction with mutant SOD1 (Pasinelli et al., 2004; Pedrini et al., 2010).  This “toxic” 
conformation exposes the pro-apoptotic BH3- domain of Bcl-2, potentially transforming 
it into a death inducing protein (Pedrini et al., 2010). Bcl-2 also interacts with WT SOD1 
however; Bcl-2 associates more strongly with high molecular weight aggregates of 
mutant SOD1, particularly at mitochondria (Pasinelli et al., 2004). WT SOD1 does not 
induce the same “toxic” conformational change in Bcl-2 as that observed with mutant 
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SOD1 (both G93A and G37R) (Pedrini et al., 2010). Moreover, the interaction between 
Bcl-2 and high molecular weight aggregates of  mutant SOD1 was specific to lumbar 
spinal cord in both mice and ALS patients (harboring A4V SOD1 mutation specifically), 
as the same observation was not found in liver (Pasinelli et al., 2004). It was shown in 
Chapter 2 of this thesis, that a BH3-mimetic (HA14-1) prevented the interaction between 
Bcl-2 and GSH, while also specifically depleting mitochondrial GSH. Combined with the 
data presented above showing that G93A mutant SOD1 mice have compromised 
mitochondrial GSH tranpsort, the ability of G93A mutant SOD1 to disrupt the interaction 
between GSH and Bcl-2 was investigated. As shown in Figure 5.5, upon incubation of 
recombinant Bcl-2 with recombinant mutant G93A SOD1, GSH-agarose beads failed to 
pull Bcl-2 out of solution, while incubation with WT SOD1 had no effect on this Bcl-
2/GSH interaction. Incubation of isolated rat brain mitochondria with G93A mutant 
SOD1 also led to an inhibition of GSH uptake when compared to WT SOD1 (Figure 5.5). 
While more experiments are necessary, the aberrant interaction between mutant SOD1 
and Bcl-2 could contribute to deficits of mitochondrial GSH transport within this ALS 
mouse model.  
In addition to altered function of Bcl-2 through an interaction with mutant SOD1, 
previous studies have shown that Bcl-2 levels are decreased in patients and mouse 
models of ALS. Decreased Bcl-2 levels were not observed pre-symptomatically, but were 
apparent post-symptomatically in the G93A mutant SOD1 mouse model and this effect 
was specific to spinal cord (Vukosavic et al., 1999).  In addition, Bcl-2 mRNA levels are 
decreased in lumbar spinal cord tissues isolated post-mortem from sporadic ALS patients 
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(Mu et al., 1996). Therefore, while inhibition of Bcl-2 function may contribute to 
decreased mitochondrial GSH transport, diminished Bcl-2 expression levels may also 
play a role in this deficit.  
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Figure 5.5 Effects of G93A mutant SOD1 on the ability of Bcl-2 to bind GSH and 
mitochondrial GSH transport A. Recombinant Bcl-2 was incubated with GSH-agarose 
beads (GSHAg), Agarose beads (Ag), GSH-agarose beads with 25 ng of recombinant 
G93A mutant SOD1 (25ng G93A SOD1) all in the presence of 1 mM DTT in lysis 
buffer, for 1 h at 4°C, mixing by inversion. Samples were spun down and washed 3x 
(with lysis buffer) and proteins were resolved by SDS-PAGE. Immunoblots were 
completed against Bcl-2, n=2. B. Samples were prepared as in A, except using 25 ng WT 
SOD1 (25 ng WT SOD1), n=2. C. Mitochondria were isolated from rat brain using a 
Percoll gradient and incubated for 4 h at 37°C, 300 rpm in the presence of either 25 ng 
WT SOD1 (25 ng WT) or 25 ng G93A SOD1 (25 ng G93A) and 2 mM GSH. 
Mitochondria samples were washed 3x and total GSH was measured using a DTNB 
colorimetric assay. Data are indicated as percent of Control (Con), n=2.   
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5.3.2 Alterations in protein levels of mitochondrial glutathione transporters as a 
mechanism of decreased mitochondrial glutathione transport in ALS 
While alterations in Bcl-2 function and expression are a likely contributor to 
decreased mitochondrial GSH transport, decreased expression of mitochondrial GSH 
carriers could also lead to similar deficits. A previous study compared mitochondrial 
protein composition from lumbar spinal cord, between WT and G93A mutant SOD1 
mice, and found a subset of proteins were either upregulated or down-regulated in the 
G93A mutant SOD1 mouse model (Li et al., 2010).  Two carriers from the SLC family 
(Slc25a4 and Slc25a5; ADP/ATP translocase ANT 1 and 2) were down-regulated, 
however the study did not find any previously identified mitochondrial GSH carriers to 
have altered expression levels (Li et al., 2010). This study is in agreement with 
immunoblotting completed from lumbar spinal cord in the G93A mutant SOD1 mouse 
model, examining OGC and DIC protein levels, which did not show a difference 
compared to WT mice in expression levels (data not shown). While it appears a down-
regulation in mitochondrial GSH transporter protein levels has not yet been observed, 
two caveats need to be discussed. First, it is impossible to distinguish between cell types 
with immunoblotting, therefore, immunohistochemical studies are needed to determine if 
mitochondrial GSH transporter protein level alterations are possibly cell type specific. 
However, given the data showing mitochondrial GSH and transport are decreased from 
mitochondria isolated from whole lumbar spinal cord, this may not be the case. Finally, 
the specific carriers responsible for mitochondrial GSH transport in lumbar spinal cord 
motor neurons versus astrocytes needs to be distinguished so those specific proteins can 
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be examined. However, current observations do not support a role for decreased protein 
expression of known mitochondrial GSH carriers in mitochondrial GSH transport deficits 
within the G93A mutant SOD1 mouse model of ALS.  
5.3.3 Protein modifications of mitochondrial glutathione transporters or Bcl-2, as a 
mechanism of decreased mitochondrial glutathione transport in ALS 
Protein function can be significantly altered by modifications of key residues, 
particularly in environments of enhanced oxidative and nitrosative stress, such as that 
observed in ALS. Therefore, the last hypothesis for the mechanism of reduced 
mitochondrial GSH transport within the G93A mutant SOD1 mouse is oxidative or 
nitrosative modification of amino acid residues within mitochondrial GSH transporters or 
Bcl-2, leading to disrupted function of these proteins.  
Cysteine residues are often cited as critical for protein function and this is based 
on their role in active sites as well as intra- and inter-molecular disulfide bridge 
formation. In particular, OGC contains three cysteine residues (C184, C221, and C224), 
two of which form an intramolecular disulfide bridge (C221 and C224). Mutagenesis of 
C221 and C224 into serine residues significantly reduces the transport ability of OGC 
(Xu et al., 2006).  In comparison, DIC has five cysteine residues, and when mutated to 
serine or alanine, no effect on DIC transport function was observed (Lash, 2006). 
However, isolated recombinant DIC is very susceptible to thiol oxidation, which leads to 
its subsequent inactivation. Bcl-2 contains two cysteine residues and mutagenesis of both 
leads to a reduced capacity in its anti-apoptotic function while retaining its ability to 
interact with the pro-apoptotic protein, Bax (Maser et al., 2000).  Evidence of alterations 
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in cysteine residues has been found in the plasma of ALS patients, which have a 
significant reduction in free thiol content compared to control subjects (Baillet et al., 
2010). Therefore, oxidative or nitrosative modifications to key cysteine residues within 
OGC, DIC, or Bcl-2 may lead to decreased mitochondrial GSH transport as discussed 
below.  
There are several oxidative modifications of protein thiols which can affect 
function, including thiyl radicals (-RS
-
), sulfenate (-SO
-
), sulfinate (-SO2
-
), and sulfonate 
(SO3
-
) formation. Thiyl radical formation is extremely transient, resulting in disulfide 
bond formation; sulfenic acid is a reversible modification, while sulfinate and sulfonate 
are thought to be irreversible within mammalian systems (Jones, 2008). It has been 
hypothesized that thiol containing proteins involved in redox signaling are susceptible to 
oxidative modifications, especially by non-radical oxidants (i.e. H2O2) (Jones, 2008). In 
particular, sulfenic acid formation through the oxidation of thiols has been proposed to 
alter the biological function of proteins through the modification of allosteric cysteines 
(Jones, 2008). This may be particularly relevant in regards to the hypothesis presented in 
Chapter 2 of this thesis, where the interaction between Bcl-2 and GSH, possibly induces a 
conformational change (allosteric) in Bcl-2 which increases its affinity for OGC. 
Furthermore, the formation of sulfenic acid through the oxidation of the cysteine residues 
of Bcl-2, by H2O2, has been shown to induce a down-regulation of Bcl-2 protein levels 
and apoptosis (Luanpitpong et al., 2013). However, no evidence for sulfenic acid 
modification has been observed currently for the mitochondrial GSH transporters, OGC 
and DIC.  
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Nitric oxide-induced modifications to cysteine residues, or S-nitrosylation, can 
also induce an inhibitory effect on protein function. While no evidence has yet been 
observed regarding S-nitrosylation of DIC, a previous study identified C184 of OGC as 
an S-nitrosylation site within the myocardium (Kohr et al., 2011).  C184 is not a part of 
the intramolecular disulfide bridge of OGC, but is hypothesized to act as a redox sensor 
for OGC function (Lash, 2006). Bcl-2 has been shown to be s-nitrosylated; however this 
modification prevented the ubiquitination and subsequent degradation of Bcl-2; thus was 
a protective mechanism from apoptosis (Azad et al., 2006). Overall, the literature 
supports different consequences of s-nitrosylation for Bcl-2 and OGC functions.  
 While there are many other forms of oxidative and nitrosative modifications to 
amino acids, protein carbonylation (oxidative) and 3-nitrotyrosine (3-NT; induced by 
peroxynitrite) modifications are increased in ALS patients and the G93A mutant SOD1 
mouse model (Beal et al., 1997; Ferrante et al., 1997; Siciliano et al., 2007; Andrus et al., 
1998). In addition, a recent study elucidated that depletion of GSH induced a significant 
increase in protein carbonylation, an effect that was required for apoptosis, in a neuron-
like PC12 cell line (Dasgupta et al., 2012). While it is not surprising that no evidence has 
been published regarding carbonylation of OGC and DIC thus far, Bcl-2 has previously 
been shown to be carbonylated prior to apoptotic cell death in the insulin-secreting 
RINm5F cell line in response to nitric oxide (Cahuana et al., 2004). Currently, no 
observations are published regarding 3-NT modifications of Bcl-2, OGC, or DIC.  
 Overall, the possible effects of oxidative or nitrosative modifications to Bcl-2 and 
previously identified mitochondrial GSH transporters warrants investigation in the G93A 
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mutant SOD1 mouse model of ALS. Based on current literature, evidence depicts that 
oxidative modifications can inhibit the ability of Bcl-2 to prevent apoptosis; however no 
current literature has examined the effect of oxidative modifications on OGC or DIC 
function. Furthermore, the effects that these potential oxidative modifications induce on 
the mitochondrial GSH transport functions of these proteins necessitate examination.  
5.4 The role of decreased mitochondrial glutathione transport in the mechanism of 
ALS disease pathology 
While this thesis has provided evidence of decreased mitochondrial GSH 
transport in the G93A mutant SOD1 mouse model of ALS, the relevance of this finding 
to disease mechanism and pathology requires discussion.  Reactive gliosis imparts a large 
role on ALS disease onset and progression, as shown through the effect of targeted 
overexpression of Nrf2 (Nuclear factor (erythroid-derived 2)-like 2); a transcription 
factor which upregulates antioxidant defense proteins; such as GSH synthesis enzymes) 
in astrocytes of mutant SOD1 mouse models. Vargas and colleagues showed that 
overexpression of Nrf2 within astrocytes increased GSH content and secretion.  
Astrocytes overexpressing Nrf2 protected co-cultured motor neurons from G93A mutant 
SOD1 toxicity, an effect that was dependent on GSH secretion (Vargas et al., 2008). In 
vivo, targeted Nrf2 overexpression in astrocytes significantly delayed disease onset and 
extended survival in two distinct mutant SOD1 mouse models (Vargas et al., 2008). 
Finally, exposure of astrocytes to peroxynitrite induces a neuroinflammatory phenotype, 
apoptosis of co-cultured motor neurons, and an increase in nitrotyrosine levels (Cassina 
et al., 2002).Therefore, the oxidative balance in astrocytes appears to greatly influence 
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the induction of a neuroinflammatory phenotype and more importantly, disease 
progression in mutant SOD1 mouse models. 
In additional studies, the role of GSH in the ability of astrocytes to protect co-
cultured neurons has been extensively studied. Total cellular GSH depletion within 
astrocytes prevented the protection of co-cultured neurons from nitrosative stress and 
H2O2 (Drukarch et al., 1997; Chen et al., 2001).  Furthermore, astrocytes depleted of 
GSH and co-cultured with neurons, induced a loss in neuronal survival and dopamine 
transport (Drukarch et al., 1997). GSH depletion of astrocytes has also been shown to 
affect neuronal mitochondrial function. Specifically, GSH depleted astrocytes secreted 
significantly less GSH and induced a decrease in co-cultured neuronal complex II, III, 
and IV activities (Gegg et al., 2005). Finally, studies have elucidated that neurons are 
more sensitive to GSH depletion when compared to astrocytes (Byrd et al., 2004). 
Overall, the GSH status of both neurons and astrocytes greatly influences cell survival 
and the susceptibility to oxidative and nitrosative stress in vitro.  
A more recent study deciphered that astrocytes isolated from the G93A mutant 
SOD1 mouse model induce cell death of WT co-cultured motor neurons(Cassina et al., 
2008).This effect could be recapitulated through the inhibition of the electron transport 
chain within WT astrocytes (Cassina et al., 2008). More striking, is the result depicting 
that treatment of G93A mutant SOD1 astrocytes with mitochondrial targeted antioxidants 
prevents the death of co-cultured motor neurons (Cassina et al., 2008). These are the first 
observations showing that mitochondrial oxidative stress within astrocytes is required for 
the induction of cell death in co-cultured neurons.  
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In addition to studies showing that MOS and GSH play an important role in the 
ability of astrocytes to either be helpful or harmful neighbors to motor neurons, this thesis 
has found several novel observations relating to the role of mitochondrial GSH transport 
in neuronal viability. First, Bcl-2 and OGC work in a concerted manner in mitochondrial 
GSH transport and subsequent inhibition of apoptosis. Second, discrete inhibition of a 
single mitochondrial GSH transporter within neurons, is sufficient to increase 
vulnerability to oxidative and nitrosative stress. Third, mitochondrial GSH has a potential 
role in the regulation of Bcl-2 protein levels, possibly through a signaling mechanism to 
the nucleus. Finally, while these data were not shown within my thesis, mitochondrial 
GSH also appears to have a function in regulating mitochondrial dynamics (through 
enhanced mitochondrial fission and/or biogenesis). Therefore, deficits in mitochondrial 
GSH transport have the potential to affect many cellular processes either directly or 
indirectly.  
The observations presented within this thesis and discussed above have led to the 
following hypothesis. Underlying oxidative and nitrosative stress, within astrocytes, leads 
to deficits in mitochondrial GSH transport (this could be a consequence of any one of the 
factors discussed above). The underlying oxidative stress is postulated to be a result from 
either environmental exposures, genetic abnormalities, or both. Overall these events 
culminate through the induction of a reactive gliosis phenotype, a decrease in GSH 
secretion and an increase in the release of NO and ROS from the reactive astrocytes. 
These effects then induce an elevation in the underlying oxidative stress within motor 
neurons, increasing MOS and dysfunction, as mitochondrial GSH levels plummet.  
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Decreased mitochondrial GSH levels (due to inhibited transport and increased oxidative 
stress) will induce a reduction in Bcl-2 protein levels, increased production of ROS and 
altered cell signaling pathways. These events culminate in motor neuron axon retraction 
and degeneration, as depicted in Figure 5.6.  
In conclusion, the pathogenic mechanisms of ALS are complicated, but deficits in 
mitochondrial GSH transport, whether a cause or effect in the cascade of disease 
progression, offers a unifying hypothesis between neuronal and astrocyte interactions. 
While further evidence is necessary in order to determine more specific clinical trial 
targets, I hypothesize that targeting mitochondrial GSH transport as a therapy in ALS 
may provide efficacious treatment options for this devastating neurodegenerative disease.   
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Figure 5.6 Working model regarding the role decreased mitochondrial GSH transport 
may contribute to ALS disease pathogenesis Increased oxidative and nitrosative stress, 
within astrocytes, leads to deficits in mitochondrial GSH transport, induction of a reactive 
gliosis phenotype, decreased GSH secretion and increased release of NO and ROS. The 
orange arrow represents the induction of effects within motor neurons as a result of 
reactive gliosis onset within astrocytes. Where, an elevation in the underlying oxidative 
stress within motor neurons can induce a deficit in mitochondrial GSH transport, altered 
cell signaling pathways, axon retraction and motor neuron degeneration. I would like to 
acknowledge Aimee Winter for drawing the astrocyte and motor neuron.  
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APPENDIX A: ABBREVIATIONS 
[
3
H]GSH; tritiated glutathione  
32D; mouse immortalized myeloblast-like cell line 
3-NT; 3-nitrotyrosine 
5K; 5mM potassium 
8-OHdG; 8-hydroxydeoxyguanosine 
A4V mutant SOD1; alanine mutated to valine at amino acid position 4 in Cu/Zn 
superoxide dismutase 
ABT-737; BH3 mimetic 4-{4-[(4′-Chlorobiphenyl-2-yl)methyl]piperazin-1-yl}-N-{[4-
({(1R)-3-(dimethylamino)-1-[(phenylsulfanyl)methyl]propyl}amino)-3-
nitrophenyl]sulfonyl}benzamide 
ADP; adenine diphosphates 
AIF; apoptosis inducing factor 
AKAP121; A kinase anchoring protein 
ALS; amyotrophic lateral scelorosis 
AMPA; 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid 
ANT; Slc25a5 or Slc25a4 adenenine nucleotide transporter 
AP-1; activator protein 1 transcription factor 
AP-2; activator protein 2 transcription factor 
ARE/EpRE; antioxidant/electrophile response element  
ATP; adenine triphosphate 
Bcl-2; B cell lymphoma protein 2 
BH; Bcl-2 homology domain 
BM; butylmalonate 
BSO; buthionine sulfoxide 
Ca
2+;
 calcium  
CAD; caspase dependent DNAse 
Cas; caspase 
CGN; cerebellar granule neuron 
CGN; cerebellar granule neurons 
CHO; chinese hamster ovarian cell 
CNS; central nervous system 
Cox-IV; cytochrome c oxidase or complex IV  
CREB; cyclic AMP response element binding protein 
CSF; cerebral spinal fluid 
CSM14.1; immortalized mesencephalic progenitor cell line 
Cyt c; cytochrome c 
DIC; Slc25a10 dicarboxylate carrier 
DISC; death inducing signaling complex 
DMSO; dimethylsulfoxide  
DNA; deoxyribonucleic acid 
DSS; disuccinimidyl suberate  
DTNB; 5’-dithiobis(2-nitrobenzoic acid) 
 190 
 
DTT; dithiothreitol  
E2F1; E2F transcription factor 1 
E2F4; E2F transcription factor 4 
EA; ethacrynic acid  
EAAT-excitatory amino acid transporter 
ER; endoplasmic reticulum 
ETC; electron transport chain 
FasL; Fas ligand 
FDC-P1; mouse bone marrow lymphoblast cell line 
FL5.12; mouse pro-B-cell lymphoid cell line 
G37R mutant SOD1; glycine mutated to arginine at amino acid position 37 in Cu/Zn 
superoxide dismutase 
G6PD; glucose-6-phosphate dehydrogenase 
G93A mutant SOD1; glycine mutated to alanine at amino acid position 93 in Cu/Zn 
superoxide dismutase 
GAPDH; glyceraldehyde 3-phosphate dehydrogenase 
GCL; γ-glutamylcysteine ligase 
GCLC- γ-glutamylcysteine ligase catalytic subunit 
GCLM- γ-glutamylcysteine ligase modulatory subunit 
GPx; glutathione peroxidase 
GR; glutathione reductase 
GS; glutathione synthetase 
GSH; glutathione 
GSH-MEE; glutathione monoethylester  
GSNO; s-nitrosoglutahione  
GSSG; glutathione disulfide 
GST; glutathione S transferase 
GT1-7; mouse immortalized gonadotropin-releasing hormone neurons 
H2O; water  
H2O2; hydrogen peroxide  
H4IIE; rat hepatoma cell line 
HA14-1; 2-Amino-6-bromo-α-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid 
ethyl ester 
HeLa; human epitheloid cervix carcinoma 
HL-60; Human promyelocytic leukemia cell line 
HNE; hydroxyl noneal 
hSOD1
G93A
- human G93A SOD1 transgenic mice 
ID2; inhibitor of DNA binding 2 
IMM; inner mitochondrial membrane 
IP; immunoprecipitation 
IP3; Inositol trisphosphate 
L929; murine aneuploid fibrosarcoma cell line 
LY-ar; mouse lymphoma cells 
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MCF-7; Michigan cancer foundation 7 human breast adenocarcinoma cell line 
mM; millimolar 
MOMP; mitochondrial outer membrane permeabilization 
MOS; mitochondrial oxidative stress 
mPTP; mitochondrial permeability transition pore 
mRNA- messenger ribonucleic acid 
NAC; n-acetylcysteine 
NAD+; nicotinamide adenine dinucleotide  
NADPH/NADP+; nicotinamide adenine dinucleotide phosphate 
NAM; n-acetylmethionine  
NFκB; nuclear factor kappa-light-chain-enhancer of activated B cells transcription factor 
NMDA; N-methyl-D-aspartate 
NO; nitric oxide 
NonTg-non-transgenic 
Nrf1/2; nuclear respiratory factor 1 or 2 also known as nuclear factor (erythriod-derived)-
like transcription factors 
Nrk52E; rat renal proximal tubular cell line 
NSC; neocarzinostatin  
NSC34; mouse immortalized motor neuron cell line 
NT2/D1; pluripotent human testicular embryonic carcinoma cell line 
O2
-
; superoxide 
OGC; Slc25a11 2-oxoglutarate carrier 
PBS; phosphate buffered saline  
PC12; rat pheochromocytoma adrenal medulla cell line 
PD; parkinson’s disease 
PhS or PS; phenylsuccinate 
PKA; protein kinase A 
PM; plasma membrane 
Pro-cas; caspase 
PS; phenylsuccinate 
RNA-ribonucleic acid 
ROS; reactive oxygen species 
RS
-
; thyil radical 
Sin-1; Amino-3-morpholinyl-1,2,3-oxadiazolium NO donor 
Sk-N-MC; human neuronal epithelioma cell line 
SLC; solute carrier family 
SNAP; S-Nitroso-N-acetyl-DL-penicillamine NO donor 
SNP; sodium nitroprusside  
SO
-
; sulfenate 
SO2
-
; sulfinate 
SO3
-
; sulfonate 
SOD; superoxide dismutase 
SOD1; Cu/Zn superoxide dismutase 
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SOD2; manganese superoxide dismutase 
SP-1; specificity protein 1 transcription factor 
STS; starausporine 
TCC; Slc25a1 tricarboxylate carrier 
TM; transmembrane 
TNF; tumor necrosis factor 
VDAC; voltage dependent anion channel 
WT; wild-type 
XAG-;Slc1a1 glutamate transporter 
Xc-; Slc7a11 cysteine/glutamate transporter 
μM; micromolar 
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